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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Advanced Pediatric
Psychopharmacology
Complex Tics and Complex Management in a Case of Severe
Tourette’s Disorder (TD) in an Adolescent
Presenter: Gholson J. Lyon, M.D., Ph.D.1
Discussant: Barbara J. Coffey, M.D., M.S.2
Chief Complaint and Presenting Problem
S.is a 16-year-old adolescent boy with Tourette’s Dis-order (TD) referred to our clinic through family friends.
The parents reported that S. was currently hospitalized for
severe tics at a medical center. They were seeking additional
consultation and follow-up treatment.
History of Present Illness
The parents reported that S. had low-pitched vocalizations
since about age 3 or 4 years. The parents report that they
consulted their pediatrician who said that S. would ‘‘out-
grow’’ the sounds. S. subsequently went on to develop com-
plex finger movements and some intermittent throat clearing.
At no time did these sounds or movements cause distress or
interfere with S.’s functioning in any way. However, in the
summer when S. was 13 years old, he developed the onset of
forceful mouth opening movements. The parents report that
there were no unusual stresses, illnesses, or changes in S.’s life
at that time. The forcefulness of the mouth opening gradually
increased, and S. subsequently developed episodes in which
he would ‘‘space out.’’ The parents reported that there were
times when S. would not remember things that had hap-
pened. On occasion, S. would fall and then complain that he
did not know how he got from one place to the other. Ad-
ditionally, in the year prior to presentation, S. reportedly had
a seizure and fell off a gas scooter, losing consciousness and
fracturing an arm. S. had been wearing a helmet and did not
experience head trauma, but reported that he ‘‘blacked out’’
while riding the scooter, leading to the crash. S. was hospi-
talized and underwent a 72-hour video EEG, which showed
no seizure activity. He was also evaluated by a pediatric
neurologist who recommended an empiric trial of oxcarba-
zepine, even though there were no seizures observed during
the video EEG. A cardiac workup was normal, including
normal EKG and echocardiogram.
The parents reported that immediately after the oxcarba-
zepine was begun, S.’s tics increased significantly, including
much more forceful mouth opening, arm and shoulder
movements, and head and neck movements. He had a pri-
mary complex tic that comprised of a sequence of both motor
and vocal tics, beginning with a premonitory sensation of
general overall tension, leading to an urge to stretch his neck.
After stretching his neck and throwing his head backwards,
the tic included mouth opening, muscle stretching in his up-
per body, fist clenching, feet stretching, and rubbing his face.
During this time, the vocal component included cursing with
the ‘‘F’’ word followed by throat clearing, squeaking, and a
‘‘sh’’ sound. When asked about potential precipitants of the
tics, S. readily reported that stress was a trigger.
S. was taken off oxcarbazepine and switched to levetir-
acetam, which also did not seem helpful as the movements
continued to worsen. S. was evaluated by another neurologist
who reportedly recommended discontinuation of the leve-
tiracetam and another outpatient video EEG, which again
revealed no seizure activity. S. was subsequently treated with
clonidine, clonazepam, and guanfacine, all of which were not
helpful as per mother.
Through family friends, S. was referred to a movement
disorder specialist. At that time, S. was diagnosed with
Tourette’s Disorder (TD), and treatment was started with
risperidone and benztropine. For approximately five months,
S.’s tics essentially remitted. However, he gained a significant
amount of weight during this time. He also became de-
pressed, lethargic, and developed suicidal ideation, according
to his parents, but did not actually try to act on the suicidal
thoughts or harm himself.
During the several months prior to presentation to our
clinic, parents reported that S. had only occasional head and
neck thrusts and occasional coprolalia, but not nearly to the
degree that he had these symptoms in the previous six
months. During this time, S. was referred to a child and ad-
olescent psychiatrist who diagnosed anxiety. S. was started on
fluoxetine, which was gradually increased to his current dose
of 30mg. Parents report that this has been helpful for him.
S. asked to go off the risperidone two months prior to
presentation to our clinic because of mood problems and
weight gain. According to his parents, the medication was
tapered and discontinued, and S.’s tics gradually got worse in
one month prior to presentation. The head and neck thrusting
movements increased, and S. reportedly developed a rotatory
component. In an attempt to switch to a medication with less
weight-gain potential, ziprasidone was prescribed up to
80mg twice a day (bid) for about a month, with very little
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evaluated and found to have no sequelae. For the first con-
cussion, MRI or CAT scan was normal. For the second, S. was
hospitalized after his reported seizure and broken arm.
Otherwise, there has been no history of surgery or chronic
medical illnesses including thyroid, cardiac, asthma, or dia-
betes. S. has no allergies.
S. eats a typical adolescent diet and has recently started
an exercise program. He was described as having grown 12
inches and gained significant weight between ninth and tenth
grade, but gained much more weight in the past six months
when he was treated with risperidone.
S. is described as an adolescent who sleeps generally
soundly but has had some episodes of sleepwalking. He is
also described as a restless sleeper who kicks the blankets and
sheets off the bed at night.
Medication History
S. had been treated with numerous medications, although
for relatively brief durations, including oxcarbazepine, leve-
tiracetam, clonidine, clonazepam, guanfacine, haloperidol
and tetrabenazine. He reportedly became ‘‘stiff’’ on haloperi-
dol; a trial of tetrabenazine six months prior to presentation at
a maximum dose of 37.5mg bid resulted in severe depression
with suicidal ideation, although S. was not treated at the time
with an antidepressant. Risperidone treatment was effective
but complicated by lethargy, weight gain, elevated prolactin
(up to 65 ng=mL resulting in galactorrhea), and depression. S.
was treated for three to four days with olanzapine, and then
for one to two weeks with aripiprazole 10mg bid. with little
effect. Fluoxetine was added to the risperidone prior to pre-
sentation; this was reported to be beneficial for S.’s anxiety
and mood symptoms.
Medications on Presentation to the Clinic
Risperidone 5mg by mouth daily; fluoxetine 40mg daily;
benztropine 0.5mg bid; topiramate 50mg bid; fish oil 1000mg
bid.
Mental Status Examination on Presentation
to the Clinic
S. was evaluated with his mother and grandfather in the
room. He was a tall, muscular, casually but neatly dressed
adolescent with glasses who looked his appropriate age of 16.
S. was generally pleasant and cooperative. He appeared a bit
sedated with mild bradykinesia. The conversation was unin-
terrupted until S. had an episode of unresponsiveness when
the discussion centered on the phenomenon of tics. At this
point, S. stared off into space for approximately 1–2 minutes,
not responding to mother’s questions. After approximately
2 minutes, S. resumed the conversation but could not elabo-
rate on his experience during the interruption.
He denied current depressed mood, and his affect was re-
active. He denied suicidal or homicidal ideation and further
denied any perceptual disturbance, including no auditory or
visual hallucinations. His thought process was linear, and his
thought content was as described above with no obvious
delusions.
After about one hour, S. experienced one tic episode, lasting
for about 5minutes. The episodewas begun by interruption of
conversation, following by a backward dystonic type neck
arch. S. thrust his head backward, clenched his fists bilater-
ally, and stretched both of his legs out. He then began to open
his mouth forcefully, followed by forced vocalizations of the
‘‘F’’ word at a fairly loud pitch on a scale of 3–4þ . After the
‘‘F’’ word, he made other vocalizations that ended in a ‘‘sh’’
sound. At the end of the sequence, he squeezed both cheeks
with each hand rather intensely. There was no self-injurious
behavior during this tic episode. S. attempted to take deep
breaths during the episode upon advice to try to relax. S.
relaxed and resumed normal discussion after the 5 minute
episode. He did acknowledge having had the premonitory
experience of feeling tension build up within him before the
tic sequence.
Rating Scales
The Yale Global Tic Severity Scale (YGTSS) was adminis-
tered at the time of presentation. S.’s total tic score was 40,
with 20 on motor tics and 20 on vocal tics, with an overall
impairment rating of 50, given his home-schooling and recent
hospitalization due to the severity of his tics.
Brief Formulation
In summary, S. is a 16-year-old adolescent boy referred by
his parents for a history of severe TD requiring hospitalization
to manage his tics. By history, he also appeared to meet cri-
teria for obsessive-compulsive disorder (full or sub-threshold),
generalized anxiety disorder, and a major depressive episode
concurrent with risperidone. It also appeared possible, if not
likely, that S. experienced a depressive reaction or a major
depressive episode in the past during his transition to middle
school. Family history contributed a diathesis for TD, in that
there is a history of possible obsessive-compulsive symptoms
and affective disorder on the maternal pedigree. Medical his-
tory contributed a clinical diagnosis of seizure disorder, which
resulted in an arm fracture; there is also a significant history of
concussion twice in the past two years. It is possible, if not
likely, that either or both of these central nervous system dis-
orders were contributing to the severity of the current picture.
From a developmental perspective, S. was on a healthy tra-
jectory until the beginning of middle school and the transition
to early adolescence, during which he may have experienced
increased anxiety and possible mood difficulty. By history, he
has had extreme functional impairment secondary to tics in the
past year. On the positive side, S. has con iderable strengths
including excellent academic performance, capacity for warm
object relationships, and supportive and resourceful parents
who are seeking to optimize his care.
Multi-Axial Diagnoses
Axis I: Tourette’s Disorder, severe to marked.
Obsessive-compulsive disorder, sub-threshold.
Generalized anxiety disorder.
Major depressive episode, secondary
to risperidone and tetrabenazine, past.
Axis II: Deferred.
Axis III: Seizure disorder, not otherwise specified.
Concussion twice within the past two years.
Fractured arm, past.
Axis IV: Level of psychosocial stressors: Severe:
Hospitalized for tics and unable to attend
the school in the past year.
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Axis V: Current Global Assessment of Functioning
(GAF) Score: 40.
Most severe lifetime GAF: 40.
Follow Up Outpatient Treatment Course
This is a summary of approximately one year of outpatient
treatment since S.’s presentation to our clinic. Initial rec m-
mendations included behavioral, psychosocial, and pharma-
cologic interventions, each of hich will be summarized
below.
Behavioral treatment
The behavioral c mponent included a referral for habit
reversal training (HRT). S. attended several session of HRT
initially, and the therapy was effective for ide tification of his
premonitory urges and substitution of a competing response
for his simplemotor tics. How v r, it was not possible for S. to
extend these results to his complex tics that lasted 5–12 (or
longer) minutes in duration. S. discontinued HRT after four
sessions, as he and his parents were not convinced that it
would be helpful for his complex tics. Many months later, the
parents reported that his complex major tic could be stopped
at the outset with tickling of S. by one of them. However, S.’s
parents were concerned that tickling was only delaying and
then increasing the duration and intensity of what seemed to
be the inevitable major complex tic.
Psychosocial treatment
The major psychosocial intervention was to enroll S. in a
private school with very supportive staff and a small class-
room with other children with medical and=or neurologic
issues. After several years of enduring bullying and teasing in
public school, S. began to like school again, as evidenced by
his desire to go to school and an observable improvement in
his grades. Psychoeducation, including referral to the Tour-
ette Syndrome Association, and support for the family and S.
was also helpful.
Pharmacologic treatment
The family and S. were very concerned about weight gain
and galactorrhea, likely from risperidone. After extensive
discussions with S. and his parents, it was decided to attempt
to cross-taper S. from risperidone to fluphenazine in 1 milli-
gram increments, as S. had never had a trial with pimozide or
fluphenazine. This was initially successful, and S. tolerated
fluphenazine. The tics did not worsen as fluphenazine was
increased to 3mg total daily and risperidone decreased to
2mg total daily. However, upon decreasing the risperidone to
1mg and increasing fluphenazine to 4mg daily in the fourth
week of the cross-taper, S. had an exacerbation of tics. He had
been previously hospitalized when risperidone was reduced
below 2mg daily, and this was therefore the second exacer-
bation of his tics with a decrease in risperidone below a 2mg
threshold. Subsequently, risperidone was restored to 2mg
daily, and fluphenazine decreased back to 3mg daily, with
resolution of the tic exacerbation. S. remained stable on these
twomedications for approximately four months; his prolactin
levels were noted to decrease slightly from 65ng=mL to
45 ng=mL, although he continued to have mild galactorrhea
and weight gain. He had one spontaneous episode of de-
pression with tearfulness and hopeless feelings, with no sui-
cidal ideation, approximately five months after starting
treatment. This prompted an increase in his fluoxetine to
50mg daily with good effect. There was also one spontaneous
episode of urinary retention that resolved naturally but
prompted reducti n of his benztropi e to 0.5mg daily.
Weight gain was an ongoing problem during the course of
outpatient treatment, although lipid nd glucose profiles re-
mained in the normal range. Diet and exercise were encour-
aged at every visit, and the parents and S. tried various diets.
Exercise was usually difficult to do for S. as he was sedated on
medication a d ha to be ac ompanied byhi parents or school
staff at all times. About four months into outpatient treatment,
to iramate was increased for further appetite suppression.
This was helpful in terms of suppressing his appetite; how-
ever, S. had a tic exacerbation that the parents felt was associ-
ated with the increase of topiramate to 75mg bid. Topiramate
was discontinued, despite the treatment team’s opinion that
there was a favorable benefit risk ratio. Through the course of
outpatient treatment, S. experienced a total weight gain of 50
pounds. Other options are under consideration.
After approximately sevenmonths of outpatient treatment,
S. had a spontaneous worsening of tic symptoms with no
apparent precipitant and no change in his medications. S.’s
major complex tic increased to 6–14 minutes, and began to
occur 2–5 times daily. New self-injurious tics emerged, in-
volving hitting himself in the chest and head with his hands
bilaterally. Initially, this tic exacerbation was managed with
addition of clonazepam 0.5mg bid–tid, and with increase of
fluphenazine to 2mg AM and 3mg PM, and risperidone 1mg
bid. S. and his parents were reluctant to increase the risper-
idone because S.’s tics continued to worsen, and he continued
to gainweight. It was still theoretically possible to increase the
fluphenazine to even higher doses; however, the parents and
S. were very distraught about his tics. They began to inquire
about surgical options for the treatment of TD, including deep
brain stimulation, which is indicated only for adults with
treatment refractory illness (Larson 2008). It was felt that S.
was not treatment-refractory at that time, as he had not yet
had a trial of pimozide or some other medication interven-
tions.
A pimozide trial was begun cautiously in one mg incre-
ment titrations per week with weekly EKG monitoring, as S.
was concurrently taking fluoxetine 50mg daily. Pimozide is
metabolized primarily by CYP 450 3A4, so it was expected
that its concentration would be elevated, with potential in-
crease in QTc interval, due to inhibition of its hepatic
metabolism by fluoxetine. In the first twoweeks following the
addition of pimozide, there was no benefit and no QTc pro-
longation noted. However, S.’s tics were worsening, so it was
decided to hospitalize him due to his severe and self-injurious
tics and to more quickly increase the pimozide in a monitored
setting. Clonazepam was also increased to 0.5mg daily. On
admission, S.’s QTc was in the normal range, but after in-
creasing the pimozide to 3mg total daily (and decreasing the
fluphenazine to 1mg by mouth in the morning and 3mg by
mouth in the evening) S.’s QTc interval increased over two
days to 467 msec, beyond the upper limit of normal (450
msec). He was evaluated by cardiology, and it was re-
commended that the pimozide be discontinued, along with
discontinuation of the fluoxetine. The pimozide and fluoxe-
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tine were stopped, and the QTc interval normalized over the
next couple of days in the hospital. S’s tics also improved
somewhat, and he was discharged on fluphenazine 3mg
daily, risperidone 1mg bid, and benztropine 0.5mg daily. The
fish oil capsules were also resumed by the mother.
Given the QTc prolongation on pimozide, following addi-
tional discussion and consultation, it was decided to cau-
tiously rechallenge S. with tetrabenazine, concurrent with
antidepressant treatment. After QTc normalization, fluoxe-
tine was restarted at 40mg daily along with tetrabenazine
12.5mg daily. Tetrabenazine was increased a few days later to
12.5mg bid, which resulted in an improvement n tics.
However, at an increased total dose of 37.5mg daily, S. ex-
perienced a recurrent depressive episode. Fluoxetine was in-
creased to 50mg daily, and tetrabenazine was reduced to
12.5mg bid. The depression resolved, and S.’s tics improved.
Parents are also investigating the possibility of botulinum
injections to the neck to decrease the premonitory urge. Over
the last year, S.’s prolactin level decreased from 65ng=ml to
27 ng=ml, secondary to the reduction of risperidone. Current
medic tions include risperi one 1mg bid, fluph nazine 3mg
daily, tetrabenazine 12.5mg bid, fluoxetine 50mg daily, and
benztropine 0.5mg daily. The patient has also electively been
taking fish oil capsules 1000mg by mouth twice daily, at the
suggestion of his mother.
Discussion
This is a complex case of TD in an adolescent, requiring
behavioral, psychosocial, and pharmacologic interventions.
The severity of S.’s tics made it difficult to implement a suc-
cessful course of HRT, although there i growing evidence
that HRT i eff ctive in treatment of tics (Himle et al. 2006). At
some point in the future, this treatment might be more feasi-
ble. Placement in a more appropriate school setting and
pharmacologic interventions have provided significant ben-
efit. Whether S. will continue to experience significant tic ex-
acerbation in the future is not clear, although in th ajority of
patients, tics improve after adolescenc (Swain et al. 2007).
The waxing and waning course of TD can make it difficult
sometimes to judge whether clinical interventions are truly
helpful. Notably, despite the adverse effects including weight
gain and prolactin elevation, risperidone had been generally
beneficial; tics increased on three separate occasi ns when it
was lowered bel w 2 g daily (Correll 2008). Thus, in the
long term, other interventions such as tetrabenazine need to
be investigated so that risperidone can be more safely tapered
and discontinued. Topiramate, which has been reported to be
beneficial for tics, appeared to be helpful in reduction of S.’s
appetite on risperidone (Baptista et al. 2008), but his parents
did not want to rechallenge S. with topiramate. For the time
being, weight gain and risk for metabolic syndrome will be
managed by a trial of tetrabenazine (via a cross-taper off ris-
peridone) and=or trying other interventions beyond diet and
exercise to prevent further weight gain. This might includ
adding other pharmacologic agents, such as sibutramine
(Shin et al. 2008).
S. had become clinically depressed while taking risper-
idone on one occasion, responsive to fluoxetine, and he had
also become depressed while taking tetrabenazine the first
time. It has been known for many years that tetrabenazine can
induce severe epressive states (Adler 1964).
The QTc prolongation on pimozide and fluoxetine was
noteworthy, and hospitalization was indicated, since clear-
ance is slow for both agents, (Sallee et al. 1987). Fluoxetine is a
potent inhibitor of the hepatic enzyme 2D6 and a moderate
inhibitor of 3A4 (Caccia 1998). Pimozide is metabolized pri-
marily by 3A4, and plasma levels can be elevated due to in-
hibition of its hepatic metabolism by fluoxetine. There have
been three case reports of sudden death on pimozide when
clarithromycin was added, which is a potent inhibitor of 3A4
(Flockhart et al. 2000). There are no case reports of sudden
death with pimozide and fluoxetine co-administration; how-
ever, there are some reports of adverse cardiac effects with the
co-administration of the two drugs ( Ahmed et al. 1993;
Friedman 1994).
There is otherwise very little literature regarding the co-
administration of a selective serotonin reuptake inhibitor
(SSRI) with pimozide. One brief report describes 28 patients
with body dysmorphic disorder on a mean dose of
62.5mg=day of fluoxetine assigned to augmentation with
either placebo or pimozide (Phillips 2005). Eighteen patients
were assigned to take placebowith fluoxetine, and 11 patients
to pimozide, which was increased to a dose of 10mg=day if
tolerated (Phillips 2005). Therewere no reports of any adverse
events during the study, although no mention was made of
cardiac monitoring.
Given the documented cardiac effects of this combination
in outpatient settings (Ahmed et al. 1993; Friedman 1994) and
S.’s QTc prolongation observed in the hospital with the co-
administration of fluoxetine and pimozide, EKG monitoring
is indicated. Fluphenazine and risperidone are also inhibitors
at 2D6, but not at 3A4. Citalopram, a mild inhibitor of 2D6,
but not of 3A4, could be considered, whereas fluvoxamine,
paroxetine, and sertraline, moderate to potent inhibitors of
2D6 and 3A4, could potentially be more risky. British guide-
lines have a contraindication on the co-administration of 3A4
inhibitors (of any degree). Children should also be advised
that grapefruit juice, a moderate inhibitor of 3A4, should not
be consumed during treatment with pimozide.
Pimozide-fluoxetine interactions are further complicated
by the pharmacokinetics of both drugs. There is extremely
slow elimination of fluoxetine nd its active metabolite nor-
fluoxetine from the body, which distinguishes them from
most other antidepressants. With time, fluoxetine and nor-
fluoxetine inhibit their own metabolism, so fluoxetine elimi-
nation half-life changes from 1 to 3 days, after a single dose, to
4 to 6 days, after long-term use. Similarly, the half-life of
norfluoxetine is longer (16 days) after long-term use. In one
prior study, the mean elimination half-life of pimozide in
children was 66 hours compared with 111 hours in adults
with TD although there was significant inter-individual var-
iability of pimozide pharmacokinetics in both adults and
children with TD (Sallee et al. 1987).
To date, there are no published data on the efficacy of fish
oil in the treatment of TD, but a study has recently been
completed (Gabbay & Coffey, 2007; Gabbay et al. 2008). More
studies are needed.
In summary, S.’s tic symptom severity was profound, and
his clinical course and follow-up illustrate some of the chal-
lenges of treatment of severe tics in an adolescent. While
comprehensive biopsychosocial treatment approaches are
aspired to in all cases, it is not always feasible to combine
evidence-based treatme ts for each indi idual.
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Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	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  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	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through	  Qme,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctuaQons.	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Abstract
Background: Deep brain stimulation (DBS) remains an experimental but promising treatment for patients with severe refractory Gilles de la Tourette syndrome
(TS). Controversial issues include the selection of patients (age and clinical presentation), the choice of brain targets to obtain optimal patient-specific outcomes, and
the risk of surgery- and stimulation-related serious adverse events.
Methods: This report describes our open-label experience with eight patients with severe refractory malignant TS treated with DBS. The electrodes were placed in
the midline thalamic nuclei or globus pallidus, pars internus, or both. Tics were clinically assessed in all patients pre- and postoperatively using the Modified Rush
Video Protocol and the Yale Global Tic Severity Scale (YGTSS).
Results: Although three patients had marked postoperative improvement in their tics (.50% improvement on the YGTSS), the majority did not reach this level of
clinical improvement. Two patients had to have their DBS leads removed (one because of postoperative infection and another because of lack of benefit).
Discussion: Our clinical experience supports the urgent need for more data and refinements in interventions and outcome measurements for severe, malignant,
and medication-refractory TS. Because TS is not an etiologically homogenous clinical entity, the inclusion criteria for DBS patients and the choice of brain targets
will require more refinement.
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Introduction
Tourette syndrome (TS) is a childhood-onset neuropsychiatric
disorder characterized by multiple motor and vocal tics lasting a
minimum of 1 year. Tic disorders are frequently chronic, if not lifelong
conditions. Usual clinical practice focuses initially on educational and
supportive interventions. In addition, a recent multisite randomized
clinical trial demonstrated the efficacy of comprehensive behavioral
intervention for tics in a subset of pediatric and adult patients.1,2
Nevertheless, most controlled treatments have focused on pharmaco-
logic interventions. Although valuable in the management of
individuals with TS, pharmacotherapy rarely eradicates tics comple-
tely, and many individuals have residual and clinically impairing
symptoms.3,4 Furthermore, some of the most effective medications for
reducing tics can be associated with a range of adverse effects, and
there is a small subset of patients who will not respond to either
behavioral or pharmacologic approaches.3
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Table 2. Continued
Patient Location Identification of the Anatomic Target DBS Settings
6 Thalamus Leksell frame, MRI/CT fusion, procedure
performed under local anesthesia with
dexmedetomidine used for sedation
R 1-C+, 3.0 V, 90 ms,
130 Hz
X (mm lateral AC-PC) 55 L 1-C+, 3.2 V, 90 ms,
130 Hz
Y (mm posterior AC-PC) 5 4
Z (mm beneath AC-PC) 5 0
Physiologic confirmation with
microelectrode recording and
macrostimulation
7 GPi, anterior mesial (limbic) Leksell frame, MRI intraoperative guidance,
sedation with dexmedetomidine/propofol,
physiologic confirmation with
microelectrodes recording only
*R 1-C+, 3.0 V, 150
ms, 90 Hz
X (mm lateral to intercommissural)514 *L 1-C+, 2.5 V, 180
ms, 120 Hz
Y (mm anterior to mid-commissural)518
Z (mm deep to mid-commissural)55
Thalamus *R 11-C+, 2.0 V, 60
ms, 120 Hz
X (mm lateral AC-PC)56 *L 9-10-C+, 3.0 V, 60
ms, 120 Hz
Y (mm posterior AC-PC)53
Z (mm beneath AC-PC)50
GPi (posteroventral/sensori otor) R 8-C+, 2.5 V, 90 ms,
185 Hz
X (mm lateral to intercommissural)517 *L 8-C+, 2.5 V, 90 ms,
180 Hz
Y (mm anterior to mid-commissural)54
Z (mm deep to mid-commissural)55
8 Thalamus Leksell frame, MRI/CT fusion, procedure
performed under general anesthesia with
propofol and remifentanil
R C+1-, 2.1 V, 90 ms,
130 Hz
X (mm lateral AC-PC)55 L C+1-, 1.9 V, 90 ms,
130 Hz
Y (mm posterior AC-PC)54
Z (mm beneath AC-PC)50
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Table 3. Continued
Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
8 M 17 13 Atypical long
bouts of
severe tics
(20 minutes
to 1 hour)
interspaced
with long tic-
free periods,
tics include
opening
mouth wide,
arm and
shoulder
movements,
head and
neck jerks,
rapidly
shaking head
from side to
side, gyrating
head, arching
back, flexion
and
extension of
arms one
side at a time
No Yes,
pounding
of chest,
punching
forehead
OCD, mild
depression,
some
symptoms
of general
anxiety
disorder
Yes for
OCD
Unmarried,
student
Pimozide,
risperidone,
ziprasidone,
aripiprazole,
fluphenazine,
clonidine,
guanfacine,
fluoxetine,
clonazepam,
topiramate
None
Abbreviations: ADHD, Attention-Deficit Hyperactivity Disorder; M, Male; OCD, Obsessive–Compulsive Disorder.
Positive family history: a first-degree (parent, sibling, child) or second-degree (grandparent, aunt, uncle, nephew, niece, half-sibling or a grandchild) relative with a chronic tic disorder. For additional
clinical details, see Supplementary Materials.
aThe electrodes removed due to side effect of infection.
bThe electrodes removed due to a lack of therapeutic benefit.
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Subject	  8	  underwent	  bilateral	  midline	  thalamic	  (VOI)	  implantaQon	  under	  
general	  anesthesia	  due	  to	  the	  intensity	  of	  his	  Qcs.	  He	  experienced	  a	  dramaQc	  
micro-­‐lesion	  eﬀect	  with	  almost	  complete	  resoluQon	  of	  his	  Qcs	  in	  the	  
immediate	  post-­‐operaQve	  period.	  His	  Qcs	  remained	  dramaQcally	  improved	  at	  
the	  Qme	  of	  iniQal	  programming.	  	  
	  
	  
Similar	  to	  our	  TS	  DBS	  subject	  #6,	  he	  also	  reported	  a	  sensaQon	  with	  the	  
greatest	  ventral	  contact	  but	  generally	  had	  good	  tolerability	  with	  PW	  90	  and	  
frequency	  of	  130.	  	  IniQal	  sekngs	  were	  set	  low	  given	  the	  near	  absence	  of	  Qcs	  
(Lel	  and	  Right	  IPGs:	  C+1-­‐	  1.0/90/130)	  and	  were	  subsequently	  mildly	  
increased	  over	  the	  next	  six	  months	  following	  a	  mild	  return	  of	  his	  Qcs.	  At	  last	  
programming,	  six	  months	  post-­‐operaQvely,	  voltages	  had	  been	  increased	  to	  
2.1	  on	  the	  lel	  and	  1.9	  on	  the	  right	  with	  good	  tolerability.	  	  
LocaQon	  of	  the	  thalamus	  in	  the	  brain,	  anterior	  view.	  The	  thalamus	  is	  the	  
main	  part	  of	  the	  diencephalon,	  and	  is	  involved	  in	  integraQng	  informaQon	  
from	  prethalamic	  inputs	  to	  the	  cerebral	  cortex.	  Purple	  lines	  denote	  the	  
thalamus	  midline.	  
evidence that reductions in caudate hyper-
metabolism follow treatments that reduce
OCD symptoms (43). Below, we discuss ev-
idence for CTSC involvement in OCD.
Movement disorders and psychiatric ill-
ness share several common features and
neural substrates. The role of neuronal ar-
eas subserving motor function in OCD
pathogenesis has been suspected since
early observations of the illness. Support-
ing the idea that a single neural substrate
can produce bothmotor and psychiatric ill-
ness, Tourette disorder is associated with
both motor tics and OCD-like symptoms.
Tourette and OCD exhibit significant co-
morbidity and genetic associations that
suggest the etiological importance of the
basal ganglia in OCD symptoms (22, 24,
128).Dysregulationof basal ganglia circuits
has been implicated in the generation of
motor and OCD symptoms in Tourette syn-
drome (33, 106). These circuits and some
clinical features of OCD are also related to
those of Parkinson disease, and patients
with either illness frequently have comor-
bid depression (85).
The efficacy of pharmacotherapies such
as selective serotonin reuptake inhibitors
(SSRIs) also supports a role for CSTC loops
in OCD pathogenesis (109). The striatum
has high levels of 5-HT2A and 5-HT2C ex-
pression, offering a mechanism by which
serotonergic agents could influence the
function of CTSC circuits (112).
Other neurotransmitters involved in
these CTSC circuits are also likely to play a
role in OCD susceptibility, chronicity, se-
verity, and treatment response. Several lines
of evidence have also implicated dopami-
nergic dysfunction (38). For example, the
serotonergic tricyclic, clomipramine that
suggested the importance of serotonin in
OCD, may be effective partly due to dopa-
mine antagonism (8, 116). Furthermore, a
substantial number of OCD patients who
fail to respond to treatment with SSRIs re-
spond to augmentation with dopaminergic
atypical antipsychotics (80, 81). Preclinical
data support this model; chronic dopami-
nergic stimulation in mice results in com-
pulsive behaviors (19, 27, 113). Humans
with OCD have higher dopamine trans-
porter binding ratios in the basal ganglia
(119). Also, OCD patients display decreased
Figure 9. Schematic of cortico-striato-thalamocortical loops. An illustration of
pathways in motor, associative, and limbic circuitry. (A) Motor circuit.
Neurons from the sensorimotor cortex project to the posterolateral
putamen (Put). The putamen sends two main projections onto the
posterolateral region of the target nuclei: (i) the direct circuit to the globus
pallidus pars interna (GPi) and (ii) the indirect circuit connecting the
posterior putamen to the globus pallidus pars externa (GPe), the
subthalamic nucleus (STN) and the GPi. The GPi is the primary output
nucleus of the basal ganglia to the cortex via the ventrolateral thalamus.
(B) Associative circuit. This circuit originates in the dorsolateral prefrontal
and lateral orbitofrontal cortices, which project to the striatal caudate
nucleus (Cn) and anteromedial portion of the putamen. From there, it
projects to the dorsomedial region of the GPi and anteromedial portions of
the GPe and STN. These in turn project onto the GPi and back to the
cortex via the ventral anterior nuclei of the thalamus. (C) Limbic circuit.
Here, the hippocampus, amygdala, paralimbic, and limbic cortices project
to the ventral striatum (ventral portion of the caudate and putamen,
including the nucleus accumbens [NAc]). The ventral striatum projects to
the limbic portion of the GPe, medioventral STN, ventral GPi, and to the
cortex via the mediodorsal nucleus of the thalamus. (Reproduced with
permission from Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA: Deep
brain stimulation: from neurology to psychiatry? Trends Neurosci 33:474-
484, 2010.)
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ABSTRACT
Background. In recent years, there has been an explosion in the number of technical
and medical diagnostic platforms being developed. This has greatly improved our
ability to more accurately, and more comprehensively, explore and characterize
human biological systems on the individual level. Large quantities of biomedical
data are now being generated and archived in many separate research and clinical
activities, but there exists a paucity of studies that integrate the areas of clinical
neuropsychiatry, personal genomics and brain-machine interfaces.
Methods. A single person with severe mental illness was implanted with the
Medtronic Reclaim® Deep Brain Stimulation (DBS) Therapy device for Obsessive
Compulsive Disorder (OCD), targeting his nucleus accumbens/anterior limb of the
internal capsule. Programming of the device and psychiatric assessments occurred
in an outpatient setting for over two years. His genome was sequenced and vari-
ants were detected in the Illumina Whole Genome Sequencing Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory.
Results. We report here the detailed phenotypic characterization, clinical-grade
whole genome sequencing (WGS), and two-year outcome of a man with severe
OCD treated with DBS. Since implantation, this man has reported steady improve-
ment, highlighted by a steady decline in his Yale-Brown Obsessive Compulsive Scale
(YBOCS) score from⇠38 to a score of⇠25. A rechargeable Activa RC neurostimula-
tor battery has been of major benefit in terms of facilitating a degree of stability and
control over the stimulation. His psychiatric symptoms reliably worsen within hours
of the battery becoming depleted, thus providing confirmatory evidence for the
eYcacy of DBS for OCD in this person.WGS revealed that he is a heterozygote for the
p.Val66Met variant in BDNF, encoding a member of the nerve growth factor family,
and which has been found to predispose carriers to various psychiatric illnesses.
He carries the p.Glu429Ala allele in methylenetetrahydrofolate reductase (MTHFR)
and the p.Asp7Asn allele in ChAT, encoding choline O-acetyltransferase, with both
alleles having been shown to confer an elevated susceptibility to psychoses. We have
found thousands of other variants in his genome, including pharmacogenetic and
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimul tion surg ry for his treatment refractory OCD. Two deep brain
stimulator probes can be see to be in place from a bifr ntal approach (B), with tips of the probes located
in t e region f the hypothalamus. L ads traverse through the left scalp soft tissues. Streak artifact from
the leads somewh t obscures visualization of the adjac nt bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift r extra-axial fluid collection. Brain
parenchyma was n rmal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and pro inent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
Severe	  Mental	  Illness	  (and	  other	  severe	  
illness)	  in	  current	  system	  
Current	  Standard	  of	  
Care	  
	  
HospitalizaQon	  
Therapy-­‐	  counseling	  
MedicaQon	  
A	  family	  in	  Utah,	  with	  a	  40	  year	  old	  Caucasian	  man	  
with	  
very	  severe	  obsessive	  compulsive	  disorder,	  severe	  
depression	  and	  intermiPent	  psychoses,	  with	  symptoms	  
that	  started	  around	  age	  5.	  
	  
MulQple	  medicaQon	  trials	  failed	  over	  many	  years.	  	  
Considered	  treatment	  refractory.	  
	  
GeneQc	  architecture	  of	  mental	  illness?	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Abstract
Deep brain stimulation (DBS) has virtually replaced ablative neuro-
surgery for use in medication-refractory movement disorders. DBS is
now being studied in severe psychiatric conditions, such as treatment-
resistant depression (TRD) and intractable obsessive-compulsive disor-
der (OCD). Effects of DBS have been reported in ∼100 cases of OCD
and ∼50 cases of TRD for seven (five common) anatomic targets. Al-
though these published reports differ with respect to study design and
methodology, the overall response rate appears to exceed 50% in OCD
for some DBS targets. In TRD, >50% of patients responded during
acute and long-term bilateral electrical stimulation in a different target.
DBS was generally well tolerated in both OCD and TRD, but some
unique, target- and stimulation-specific adverse effects were observed
(e.g., hypomania). Further research is needed to test the efficacy and
safety of DBS in psychiatric disorders, compare targets, and identify
predictors of response.
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History of Psychosurgery: A Psychiatrist’s Perspective
Kyle A. B. Lapidus1, Brian H. Kopell1,2, Sharona Ben-Haim2, Ali R. Rezai3, Wayne K. Goodman1
THE LEGACY OF “PSYCHOSURGERY”
Interest in and evidence for neurosurgical
approaches to psychiatric disorders is rap-
idly increasing, largely because of the allure
and success of novel neuromodulation ap-
proaches, including deep brain stimulation
(DBS).DBShasbecomewidelyused inmove-
mentdisorderssuchasParkinsondiseaseand
is beginning to receive approval for psychiat-
ric indications. The possibility of developing
new treatments with more specific anatomi-
cal andmolecular targets is exciting,but there
are varied viewsonwhen surgical approaches
are indicated. These discrepant views among
psychiatrists stem from differing thoughts
about the specific etiologies of illness, con-
cerns about the ability to localize function
based on current knowledge, and a desire to
avoid pastmistakes.
Investigators who are developing neuro-
surgical approaches to psychiatric disor-
dersmust remain cautious and cognizant of
historical uses of related techniques such as
frontal leucotomy and lobotomy. Based on
primate research by Fulton and Jacobsen,
Moniz, with assistance from Lima, per-
formed the first modern neurosurgical pro-
cedure for psychiatric illness in humans in
1936.Moniz went on to win the Nobel Prize
for his work on frontal leucotomy. Mean-
while, Freeman initially with, and subse-
quently without, Watts brought the tech-
nique to America where over 20,000
lobotomies were performed by 1951 (14)
(Figure 1). Thiswork suffered not only from
poor technique, but particularly from the
lack of evidence in the form of adequately
controlled trials (Figure 2). Also, Freeman’s
showmanship and callousness promul-
gated a negative reputation, while enabling
widespread application. Ultimately, it was
the advent of a new treatment, chlorproma-
zine, rather than efficacy concerns or public
outrage, that led to the demise of this lobot-
omy technique. Despite reservations stem-
ming from this early use, interest in the po-
tential for psychiatric surgery persisted.
THE STEREOTACTIC LESION COMES OF
AGE
Technological advancements,particularly the
development and application of stereotaxis,
enabled the refinement of psychiatric neuro-
surgery. Previous experience with frontal lo-
botomy suggested that interrupting white
matter tracts while minimizing cortical dam-
agecouldmaintainefficacywhileminimizing
side effects. Attempts to create increasingly
discrete, subcortical lesions ultimately led to
Interest in using neuromodulation to treat psychiatric disorders is rapidly increasing.
The development of novel tools and techniques, such as deep brain stimulation
(DBS), increases precision and minimizes risk. This article reviews the history of
psychosurgical interventions and recent developments of DBS to provide a frame-
work for understanding current options and future goals. We begin by discussing
early approaches to psychosurgery, focusing on the widespread use of lobotomy and
the subsequent backlash from the public and professionals in the field. Next, we
discuss the development of stereotaxis. This technique allows for more targeted,
precise interventions that produce discrete subcortical lesions. We focus on four
stereotactic procedures that were developed using this technique: cingulotomy,
capsulotomy, subcaudate tractotomy, and limbic leucotomy. We subsequently
review contemporary theory and approaches with relevance to psychosurgery. We
discuss the systems and neurocircuitry that are thought to be involved in psychiatric
illness and provide targets for intervention. This discussion includes presentation of
basal ganglia thalamocortical pathophysiology including cortico-striato-thalamo-
cortical loops. We focus the discussion on two psychiatric disorders that have been
targets of neurosurgical interventions: obsessive-compulsive disorder and mood
disorders such as major depressive disorder. Evidence from studies of DBS in
psychiatric disorders, including efficacy and tolerability, is reviewed. Finally, we
look to the future, exploring the possibilities for these approaches to increase
understanding, transform societal views of mental illness, and improve treatment.
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the application of stereotaxis for psychiatric
neurosurgical procedures.
In 1947, Wycis and Spiegel introduced
the dorsomedial (DM) thalamotomy, the
first subcortical stereotactic neurosurgical
procedure performed on humans, and the
model on which all modern psychiatric
neurosurgical procedures ar bas d (110).
For stereotactic procedures, the brain is ref-
erenced to a specific coordinate system, de-
fined in a Cartesian three-dimensional
space. Use of stereotactic technique facili-
tated precisely and accurately reaching sub-
cortical structures with minimal disruption
of brain tissue. Subsequently, stereotactic
techniques have incorporated develop-
ments of computer-based data manage-
ment, functional imaging, and physiologic
recording technology.
Four psychiatric neurosurgical proce-
dures were developed using stereotactic
techniques: cingulotomy, capsulotomy,
subcaudate tractotomy, and limbic leucot-
omy (Figure 3). Only cingulotomy, capsu-
lotomy, and limbic leucotomy remain in
current use for severe, treatment-refractory
psychiatric patients. Many of the following
studies of psychiatric neurosurgical treat-
ments suffer from significant flaws. Most
importantly, ethical concerns often pre-
clude sham controls, requiring studies to
include the inherent bias of unrandomized,
unblinded designs. Although this bias and
the frequent lack of confirmation with ob-
jective functional imaging techniques limit
the conclusions that can be drawn fromFigure 1. Lobotomy. (A) Axial T2-weighted and (B) sagittal T2-weighted images of lobotomy lesion.
Figure 2. Transorbital or “ic pick” l botomy
technique. This procedure was developed by
Freeman after severi g ties with Watts.
Here, frontal white matter is cut by a metal
spike inserted thr ugh the thin bony orbit
above the eye. (Reproduced with permission
from Lerner BH: Last-ditch medical therapy—
revisting lobotomy. N Engl J Med 353;119-
121, 2005.)
Figure 3. Illustration of stereotactic lesions. Illustration of anatomic locations of psychiatric
neurosurgical procedures: anterior cingulotomy, anterior capsulotomy, subcaudate tractotomy.
Stereotactic limbic leucotomy combines cingulotomy and subcaudate tractotomy. (Reproduced with
permission from Lipsman N, Neimat JS, Lozano AM: Deep brain stimulation for treatment-refractory
obsessive-compulsive disorder: the s arch for a valid target. Neurosurgery 61:1-13, 2007.)
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these studies, they do suggest a viable
means of treatment for a subset of patients
whomay have no other options. These pro-
cedures described below are best under-
stood in context of the underlying physio-
logical systems. Ultimately, all of these
procedures seek to modulate activity in the
dorsolateral frontal, orbitofrontal, and cin-
gulate cortices as well as their interactions
with the basal ganglia and thalamus.
Cingulotomy
Striving for a more anatomically precise
treatment thatmaintained efficacywhile re-
ducing side effects, Whitty et al. developed
cingulectomy, bilateral removal of a 4 cm!
1 cm! 1 cm section of the anterior cingular
gyrus (124). In 1962, Ballantine introduced
the modern stereotactic procedure; a bilat-
eral lesion in the anterior cingulate, local-
ized by air ventriculography, and made us-
ing thermocoagulation (9). Since 1991,
magnetic resonance imaging (MRI) guid-
ancehas beenused tomake approximately 1
cm3 lesions (Figure 4). Typically, lesions are
made 2–2.5 cm from the tip of the frontal
horns, 7mm lateral from themidline, and 1
mmabove the roof of the ventricles, bilater-
ally. These lesions are expected to interrupt
reciprocal activity from the dorsal anterior
cingulate cortex (ACC) to the orbitofrontal
cortex (OFC), amygdala, and hippocampus
via the cingulum bundle, thereby affecting
the cortico-striato-thalamo-cortical (CSTC)
loop (102). Stereotactic cingulotomy is the
most widely performed neurosurgical pro-
cedure for psychiatric illness in the United
States and Canada (Figure 5).
Response rates for patients with obses-
sive-compulsive disorder (OCD) symptoms
receiving cingulotomy were initially re-
ported to be as high as 56% (41). A prospec-
tive study of 44 OCD patients who received
cingulotomy was published in 2002 (30).
Using rigorous screening and assessment,
this study found that 32%met conservative
response criteria whereas an additional
14%were partial responders after amean of
32months following single ormultiple cin-
gulotomies. Subsequent smaller studies of
OCD patients reported response rates of
43% and 47% (52, 60). Studies of patients
with affective disorders have reported even
higher response rates. The largest, includ-
ing more than 100 patients, found that over
60% showedmeaningful improvement and
over 40%were functionally normal (9). In a
more recent study, 33 patients received cin-
gulotomy for intractable major depression
and those who failed to respond received
either additional cingulotomy procedures
or subcaudate tractotomy (105). This study
corroborated the earlier findings, reporting
41% response and 35% partial response in
the group who only received cingulotomy
and 33% response and 42% partial re-
sponse in the entire sample at 30-month
follow-up.
No deaths were reported in more than
1000 anterior cingulotomies performed at
Massachusetts General Hospital, and since
the advent of MRI guidance only one stroke
occurred (99). Other adverse events, sei-
zures and hydrocephalus, occur with low
rates similar to other stereotactic proce-
dures. No permanent behavioral or cogni-
tive deficits have been reported in psychiat-
ric cingulotomy patients (41).
Capsulotomy
Anterior capsulotomy, developed inparallel
by Leksell and Talairach, has been used for
refractory psychiatric illness since 1949.
Two stereotactic techniques can be used to
perform this procedure: radiofrequency or
gamma radiation. The target lies between
the anterior andmiddle third of the anterior
limb of the internal capsule at approxi-
mately the level of the foramen of Monro
(Figure 6). The approximately 15- to 18-
mm-long, 4- to 5-mm-wide lesion is most
commonly made 17 mm from the midline,
10 mm rostral to the anterior commissure,
and 8 mm above the intercommissural line
(59). MRI examination of 11 patients sug-
gested that reducing the lateral extension of
the lesions may increase efficacy, while re-
ducing the medial and posterior extent of
the lesions may limit side effects (98).
Anterior capsulotomy is thought to ame-
liorate psychiatric symptoms by interrupt-
ing the ventral fibers traversing the anterior
internal capsule en route from the OFC and
subgenual ACC tomedial, DM, and anterior
thalamic nuclei.
Historically, response rates following
capsulotomy have ranged from 48% to 78%
(41). A recent prospective study of 35 pa-
tients using modern assessment tools
found 57% symptom free and another 29%
significantly improved 3 years after bilateral
capsulotomy (70). Another recent prospec-
tive trial using strict response measures
(35% decrease in Yale-Brown Obsessive
Compulsive Scale [Y-BOCS] scores) re-
ported a 60% response rate 2 years after
bilateral lesions of the ventral portion of the
anterior limb of the internal capsule.
In general, capsulotomy has been well tol-
erated and no deaths have been directly asso-
ciated with the procedure. However, at-
tempted suicides have been reported in this
populationbothpre-andpostoperatively,and
one patient completed suicide after receiving
this treatment (98). Generally transient head-
aches, confusion, disinhibition, urinary in-
continence, weight gain, and lethargy have
also been reported. A group of 21 thermoco-
agulative capsulotomy patients showed no
significantcognitiveorbehavioraldifferences
from a similarly symptomatic group that did
not receive this treatment (91). Of nine pa-
tients treatedwith radiosurgeryby this group,
one case of radiation necrosis was reported,
with symptomsof apathy,memory, andexec-
utive dysfunction, whereas another patient
developed edema with ensuing apathy and
urinary incontinence.Weight gain and sexual
disinhibition were also reported (98). Cere-
bral edema and headache (in 6 [20%]), small
asymptomaticcaudal infarctions(in3[10%]),
and apathy (in 1 [3%]) were noted in 31 pa-
tients who underwent capsulotomy (41).
Subcaudate Tractotomy
Subcaudate tractotomy or innominatomy
also aims to interrupt fibers from the cortex
to the thalamus via the striatum (Figure 7).
This procedure was first performed by
Knight in London in 1961, and was initially
Figure 4. Cingulotomy pathology. Gross
pathology of brain with cingulotomy lesion.
The lesion is more complete on the right
than the left side. (Reproduced with
permission from Laitinen L, Livingston K:
Surgical approaches in psychiatry.
Proceedings of the 3rd International
Congress of Psychosurgery. Baltimore:
University Park Press; 1973.)
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Table 1 Partial list of brain stimulation devices for treatment of psychiatric disorders
Device Description of procedure
Uses: established or
investigational FDA regulatory status
Safety/tolerability of
procedure References
Electroconvulsive
therapy (ECT)
Induction of generalized
seizure with application of
electricity to scalp
Performed during anesthesia
with cardiopulmonary support
and use of muscle relaxants
Typically 3 sessions per week
for 2–4 weeks
MDD that is severe,
accompanied by
psychosis or suicidality,
or refractory to other
treatments
Other indications include
catatonia and
schizophrenia
Currently categorized as a Class
III device. FDA is reviewing
whether ECT devices should
remain in Class III (highest
risk) or be downgraded to
Class II (intermediate risk)
devices for certain uses
Risks associated with general
anesthesia
Possible persistent
autobiographical memory
loss
(43, 68)
Repetitive
transcranial
magnetic
stimulation
(rTMS)
Fluctuating magnetic field from
electromagnetic coil placed
outside the skull induces an
electrical current in the
underlying cerebral cortex
Typical course of treatment is
five 40-min sessions per week
for 4–6 weeks
Treatment-resistant
depression
Used off-label in clinical
practice for other
psychiatric disorders
Approved for narrow use in
MDD patients who failed
exactly one antidepressant
medication in the current
episode
Noninvasive and safe
Minor scalp discomfort and
headaches possible; very
rarely seizures
(69, 70)
Vagus nerve
stimulation
(VNS)
Helical electrode is wrapped
around left vagus nerve in the
neck
Connected to pulse generator
under skin of chest that
delivers ∼30 s of stimulation
every 5 min
Refractory epilepsy
Treatment-resistant
depression; benefit seen
only after prolonged (up
to 12 months) use
Approved as adjunctive therapy
for refractory epilepsy
Approved as adjunctive therapy
for treatment-resistant
depression (defined as ≥4 failed
antidepressant treatments)
Invasive: requires surgery to
attach electrode in neck and
device under skin of chest
Risks of general anesthesia;
rarely infection or injury to
recurrent laryngeal nerve
causing hoarseness
(71, 72)
Deep brain
stimulation
(DBS)
Lead(s) implanted in brain
anatomic target through burr
hole(s) in cranium and locked
in place
Extension wires tunneled under
skin and connected to pulse
generator(s) implanted under
skin of chest
Programming of device settings
performed wirelessly
Movement disorders
Psychiatric disorders:
Intractable OCD
Treatment-resistant
depression
Tourette syndrome
Approved for essential tremor
Approved for refractory
Parkinson’s disease
Limited approval under HDE
for dystonia and intractable
OCD
Most invasive, highest risk:
requires craniotomy and
implantation of electrodes
directly in brain
parenchyma
Risk of serious adverse events
including intracerebral
hemorrhage (∼2%) and
infection (∼10%)
More than 75,000 operations
performed worldwide for
movement disorders
See text
Abbreviations: MDD, major depressive disorder; OCD, obsessive-compulsive disorder; FDA, U.S. Food & Drug Administration; HDE, humanitarian device exemption.
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Abstract
Deep brain stimulation (DBS) has virtually replaced ablative neuro-
surgery for use in medication-refractory movement disorders. DBS is
now being studied in severe psychiatric conditions, such as treatment-
resistant depression (TRD) and intractable obsessive-compulsive disor-
der (OCD). Effects of DBS have been reported in ∼100 cases of OCD
and ∼50 cases of TRD for seven (five common) anatomic targets. Al-
though these published reports differ with respect to study design and
methodology, the overall response rate appears to exceed 50% in OCD
for some DBS targets. In TRD, >50% of patients responded during
acute and long-term bilateral electrical stimulation in a different target.
DBS was generally well tolerated in both OCD and TRD, but some
unique, target- and stimulation-specific adverse effects were observed
(e.g., hypomania). Further research is needed to test the efficacy and
safety of DBS in psychiatric disorders, compare targets, and identify
predictors of response.
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Introduction
Deep brain stimulation (DBS) is a technique that consists of a sur-
gically implanted lead that provides focal electrical neural-network 
modulation within a brain circuit or circuits of interest. Initially, 
modern DBS systems were developed to address dysfunctional cir-
cuits in patients diagnosed with treatment-resistant tremor or other 
movement disorders; recently, DBS’s therapeutic role has expanded 
to several neuropsychiatric disorders. Neuropsychiatry is an evolv-
ing branch of medicine dealing with diseases in which the affected 
have symptoms that are both “neurologic” and “psychiatric” (1). 
The expansion of disease-specific indications has allowed scientists 
to move beyond traditional movement-related circuitry in order to 
address these relevant neuropsychiatric issues such as treatment-
resistant mood and cognitive symptoms (2).
Diseases and indications with more concrete targets and 
straightforward outcomes, such as essential tremor, motoric 
symptoms of Parkinson disease (PD), and motor symptoms 
of dystonia, have been the most studied to date. The US FDA 
issued an approval for the use of DBS in essential tremor in 
1997 and PD in 2002. A humanitarian device exemption (HDE) 
was granted for motoric symptoms of dystonia in 2003 (3). 
More complex cognitive and limbic targets, such as obsessive- 
compulsive disorder (OCD), depression, and Tourette syndrome 
(TS), have proven more difficult to study (2). The US FDA issued a 
HDE for obsessive compulsive disorder in 2009 (4). TS and depres-
sion both remain unapproved uses of DBS technology; however, 
many groups are implanting these patients under research protocols.
This review will focus on DBS in four neuropsychiatric syn-
dromes: PD, TS, major depressive disorder (MDD), and OCD. 
Each disease has multiple brain targets (Figure 1), and each of the 
targets has been demonstrated as promising, albeit with reported 
unintended negative and positive effects. Following a brief review 
of the implantation/programming process, we will summarize 
the advances in optimized targeting and stimulation parameters. 
We will then discuss the four neuropsychiatric diseases, the 
currently utilized brain targets for each disease, and both the 
neuropsychiatric and motoric effects of the intervention. Finally, 
we will conclude with a description of other potential advances 
and pitfalls in this promising area (5).
DBS placement and programming
Preimplantation. Several variables should be considered prior to per-
forming DBS surgery for a neuropsychiatric indication. Demon-
stration of treatment resistance (failure of both pharmacological 
and nonpharmacological interventions) is critical for all potential 
candidates (6, 7). The definitions for “treatment resistance” have 
been clearly defined for some (8–10), but not all neuropsychiatric 
conditions (11). There are DBS inclusion and exclusion criteria 
published for TS (12) and PD (13); however, there are less well-
defined guidelines for depression and OCD (14). In the case of 
MDD and OCD, treatment resistance has been defined as the fail-
ure of standard of care interventions such as antidepressants and 
adjunctive medications (see STAR*D) (15), and psychotherapy 
(typically cognitive behavioral therapy [CBT]) as well as electro-
convulsive therapy and/or transcranial magnetic stimulation in 
the case of MDD (16). Further, patients should be screened for 
comorbid psychiatric disease, as certain conditions predispose 
patients to worse DBS outcomes (17, 18). Moreover, clinicians 
should ensure that patients do not exhibit any clinically signifi-
cant or unstable neurological medical illnesses and assess the 
patient for the capacity to understand the potential for harm as 
well as any therapeutic misconceptions.
Implantation. DBS implantation involves the use of stereotactic 
neurosurgical technique and modern imaging, which together 
allow for the treatment team to directly target a node in a dys-
functional circuit of interest. Next, microelectrode mapping 
(if performed) and intraoperative macro- or test stimulation 
occurs. In the case of PD, the tremor or rigidity and bradykinesia 
typically respond to intraoperative stimulation (19, 20), and this 
may aid in selecting the final target. In depression or OCD, for 
a few reported cases, intraoperative stimulation has been shown 
to result in subjective feelings of calmness, improved mood, and 
increased interest/motivation during macrostimulation in the sub-
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callosal cingulate (SCC) target (21). Similarly, a contralateral smile 
and feelings of euphoria have been observed when stimulating in 
the ventral capsule/ventral striatum (VC/VS) (22). The presence of 
intraoperative stimulation effects such as the contralateral smile 
after stimulation in the ventral striatum has been demonstrated to 
predict eventual response to therapy (23). Once mapping is com-
plete, a patient then receives a battery (implantable pulse generator 
[IPG]) placement within the next one to two weeks (24).
DBS programming. DBS programming typically occurs approxi-
mately two to four weeks after DBS surgery, with the delay due 
to the lead placement itself causing a transient improvement in 
symptoms through a “microlesion effect” (25). Programming 
involves the use of a handheld machine that communicates wire-
lessly with the chest, or with the abdominal-based neurostimula-
tor (i.e., battery source) (Figure 2). The objective of the initial pro-
gramming session is to set and fine-tune stimulation parameters. 
There are several programming variables that must be set, such 
as the electrode polarity, amplitude, pulse width, and frequency. 
The optimal DBS settings may depend on the disease, the targeted 
symptoms, and the neuroanatomical location of the stimulation 
field within the desired target (26). Research protocols have also 
been enhanced by programming “sham-DBS settings” to overcome 
the placebo effect of psychiatric outcomes within neurosurgery 
(27). Concomitant medication changes may also be required. The 
general lack of immediate feedback (i.e., clinical improvement in 
the office) in DBS programming for psychiatric diseases increases 
the level of difficulty and generally renders programming complex. 
Some of the challenge can be overcome through use of standard-
ized self-rated and observer-rated instruments (26).
Some programming-related observations may be important 
predictors of chronic efficacy (21); however, no definitive immedi-
ate programming-related biomarkers have been validated. In neu-
ropsychiatric diseases such as depression and OCD, satisfactory 
results can take as long as four to six months to achieve. Recent 
advances in target selection may reduce this latency to days in the 
case of depression (28). There is a risk of device malfunction (29), 
and in all cases, neurostimulator replacement may be necessary 
(30), provided the DBS patient outlives the device (i.e., typically 
two to five years for device replacement and seven to ten years for 
rechargeable batteries).
Novel methods of DBS optimization
DBS is evolving into a field of personalized medicine (31), with 
practitioners increasingly prescribing therapy for constellations 
of symptoms and making customized modifications to optimize 
symptoms (32). Because of the microstructural variability within 
an individual’s brain connectivity (33), personalization of therapy 
will likely occur not only at the level of modifications for specific 
disease and general affected circuitry (34), but potentially even at 
the level of an individual’s differences in specific neural connec-
tions (35). The use of diffusion tractography alongside traditional 
landmark-based targeting techniques for implantation of DBS 
electrodes may offer the level of imaging support necessary to 
start this personalized microstructural mapping (36). This tech-
nique could allow derivation of individual tractography maps that 
may aid in defining patterns of connectivity that could potentially 
optimize electrode placement and therefore individualize therapy 
(37). Optogenetics is another powerful technique for probing the 
pathways potentially responsible for neuropsychiatric disease 
while leaving the surrounding neural circuitry untouched (38). 
It has already been used to demonstrate that the therapeutic 
effects of DBS within the subthalamic nucleus (STN) for PD can 
be accounted for by stimulation of the afferent axons projecting 
to the STN (38).
Modifications of stimulation parameters, such as change in the 
geometry of the waveform, have been shown to have marked effects 
on charge and energy requirements (39). While fixed compliance 
voltage for constant-current stimulation has been shown to result 
in substantial energy loss, some of this energy can be recuperated if 
the compliance voltage can be adjusted in real time (40). The utiliza-
tion of constant-current devices coupled with current steering pro-
gramming strategies where multiple cathodes are used to modify 
the field can further optimize stimulation (41). Energy optimization 
can also be improved through the computation of an individual’s 
axon fiber diameter to determine pulse width (40). Exploration of 
more target-specific electrodes could potentially optimize delivery 
through novel interactions with the circuitry of interest (42).
Figure 1
The modern version of the DBS system includes an electrode implanted 
into a deep brain target, which has been postulated to function as an 
important node that possesses the potential to modulate a dysfunc-
tional brain circuit. The DBS lead is connected through an extension 
wire to an IPG (i.e., battery, neurostimulator), which is placed in the 
chest under the clavicle, or, less frequently, in the abdomen. The system 
is telemetrically progra med through the use of an external program-
ming device to deliv r pulses of electricity into the target r gion. Th se 
electrical pulses can modulate a circuit o  interest to relieve diseas  
symptoms. Schematic is not anatomically accurate.
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callosal cingulate (SCC) target (21). Similarly, a contralateral smile 
and feelings of euphoria have been observed when stimulating in 
the ventral capsule/ventral striatum (VC/VS) (22). The presence of 
intraoperative stimulation effects such as the contralateral smile 
after stimulation in the ventral striatum has been demonstrated to 
predict eventual response to therapy (23). Once mapping is com-
plete, a patient then receives a battery (implantable pulse generator 
[IPG]) placement within the next one to two weeks (24).
DBS programming. DBS programming typically occurs approxi-
mately two to four weeks after DBS surgery, with the delay due 
to the lead placement itself causing a transient improvement in 
symptoms through a “microlesion effect” (25). Programming 
involves the use of a handheld machine th t communicates wire-
lessly with the chest, or with the abdominal-based neurostimula-
tor (i.e., bat ery source) (F gure 2). The objective of the initial pro-
gramming session is to set and fine-tune stimulation parameters. 
There are several programming variables that must be set, such 
as the electrode polarity, amplitude, pulse width, and frequency. 
The optimal DBS settings may depend on the disease, the targeted 
symptoms, and the neuroanatomical location of the stimulation 
field within the desired target (26). Research protocols have also 
been enhanced by programming “sham-DBS settings” to overcome 
the placebo effect of psychiatric outcomes within neurosurgery 
(27). Concomitant medication changes may also be required. The 
general lack of immediate feedback (i.e., clinical improvement in 
the office) in DBS programming for psychiatric diseases increases 
the level of difficulty and generally renders programming complex. 
Some of the challenge can be overcome through use of standard-
ized self-rated and observer-rated instruments (26).
Some programming-related observations may be important 
predictors of chronic efficacy (21); however, no definitive immedi-
ate programming-related biomarkers have been validated. In neu-
ropsychiatric diseases such as depression and OCD, satisfactory 
results can take as long as four to six months to achieve. Recent 
advances in target selection may reduce this latency to days in the 
case of depression (28). There is a risk of device malfunction (29), 
and in all cases, neurostimulator replacement may be necessary 
(30), provided the DBS patient outlives the device (i.e., typically 
two to five years for device replacement and seven to ten years for 
rechargeable batteries).
Novel methods of DBS optimization
DBS is evolving into a field of personalized medicine (31), with 
practitioners increasingly prescribing therapy for constellations 
of symptoms and making customized modifications to optimize 
symptoms (32). Because of the microstructural variability within 
an individual’s brain connectivity (33), personalization of therapy 
will likely occur not only at the level of modifications for specific 
disease and general affected circuitry (34), but potentially even at 
the level of an individual’s differences in specific neural connec-
tions (35). The use of diffusion tractography alongside traditional 
landmark-based targeting techniques for implantation of DBS 
electrodes may offer the level of imaging support necessary to 
start this personalized microstructural mapping (36). This tech-
nique could allow derivation of individual tractography maps that 
may aid in defining patterns of connectivity that could potentially 
optimize electrode placement and therefore individualize therapy 
(37). Optogenetics is another powerful technique for probing the 
pathways potentially responsible for neuropsychiatric disease 
while leaving the surrounding neural circuitry untouched (38). 
It has already been used to demonstrate that the therapeutic 
effects of DBS within the subthalamic nucleus (STN) for PD can 
be accounted for by stimulation of the afferent axons projecting 
to the STN (38).
Modifications of stimulation parameters, such as change in the 
geometry of the waveform, have been shown to have marked effects 
on charge and energy requirements (39). While fixed compliance 
voltage for constant-current stimulation has been shown to result 
in substantial energy loss, some of this energy can be recuperated if 
the compliance voltage can be adjusted in real time (40). The utiliza-
tion of constant-current devices coupled with current steering pro-
gramming strategies where multiple cathodes are used to modify 
the field can further optimize stimulation (41). Energy optimization 
can also be improved through the computation of an individual’s 
axon fiber diameter to determine pulse width (40). Exploration of 
more target-specific electrodes could potentially optimize delivery 
through novel interactions with the circuitry of interest (42).
Figure 1
The modern version of the DBS system incl d s a  electrode implanted 
into a deep brain target, which has been postulated to function as an 
important node that possesses the potential to modulate a dysfunc-
tional brain circuit. The DBS lead is connected through an extension 
wire to an IPG (i.e., battery, neurostimulator), which is placed in the 
ch st under the clavicle, or, less frequently, in the abdomen. The system 
is tele etrically programmed through the use of an external program-
ming device to deliver puls s of electricity into the target region. These 
electrical pulses can modulate a circuit of inter st to relieve disease 
symptom . Schematic is not anatomically accurate.
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Introduction
Deep brain stimulation (DBS) is a technique that consists of a sur-
gically implanted lead that provides focal electrical neural-network 
modulation within a brain circuit or circuits of interest. Initially, 
modern DBS systems were developed to address dysfunctional cir-
cuits in patients diagnosed with treatment-resistant tremor or other 
movement disorders; recently, DBS’s therapeutic role has expanded 
to several neuropsychiatric disorders. Neuropsychiatry is an evolv-
ing branch of medicine dealing with diseases in which the affected 
have symptoms that are both “neurologic” and “psychiatric” (1). 
The expansion of disease-specific indications has allowed scientists 
to move beyond traditional movement-related circuitry in order to 
address these relevant neuropsychiatric issues such as treatment-
resistant mood and cognitive symptoms (2).
Diseases and indications with more concrete targets and 
straightforward outcomes, such as essential tremor, motoric 
symptoms of Parkinson disease (PD), and motor symptoms 
of dystonia, have been the most studied to date. The US FDA 
issued an approval for the use of DBS in essential tremor in 
1997 and PD in 2002. A humanitarian device exemption (HDE) 
was granted for motoric symptoms of dystonia in 2003 (3). 
More complex cognitive and limbic targets, such as obsessive- 
compulsive disorder (OCD), depression, and Tourette syndrome 
(TS), have proven more difficult to study (2). The US FDA issued a 
HDE for obsessive compulsive disorder in 2009 (4). TS and depres-
sion both remain unapproved uses of DBS technology; however, 
many groups are implanting these patients under research protocols.
This review will focus on DBS in four neuropsych atric syn-
dromes: PD, TS, major depressive disorder (MDD), and OCD. 
Each disease has multiple brain targets (Figure 1), and each of the 
targets has been demonstrat d as promising, albeit with reported 
unintended negative and positive effects. Following a brief review 
of the implantation/programming process, we will summarize 
the advances in optimized targeting and stimulation parameters. 
We will then discuss the four neuropsychiatri  diseases, the 
currently utilized brain targets for each disease, and both the 
neuropsychiatric and motoric effects of the intervention. Finally, 
we will conclude with a description of other potential advances 
and pitfalls in this promising area (5).
DBS placement and programming
Preimplantation. Several variables should be considered prior to per-
forming DBS surgery for a neuropsychiatric indication. Demon-
stration of treatment resistance (failure of both pharmacological 
and nonpharmacological interventions) is critical for all potential 
candidates (6, 7). The definitions for “treatment resistance” have 
been clearly defined for some (8–10), but not all neuropsychiatric 
conditions (11). There are DBS inclusion and exclusion criteria 
published for TS (1 ) and PD (13); however, there are l ss well-
defined guidelines for depression and OCD (14). In the case of 
MDD and OCD, treatment resistance has been defined as the fail-
ure of standard of care interventions such as antidepressants and 
adjunctive medications (see STAR*D) (15), and psychotherapy 
(typically cognitive behavioral therapy [CBT]) as well as electro-
convulsive therapy and/or transcranial magnetic stimulation in 
the case of MDD (16). Further, patients should be screened for 
comorbid psychiatric disease, as certain conditions predispose 
patients to worse DBS outcomes (17, 18). Moreover, clinicians 
should ensure that patients do not exhibit any clinically signifi-
cant or unstable neurological medical illnesses and assess the 
patient for the capacity to understand the potential for harm as 
well as any therapeutic misconceptions.
Implant tion  DBS implantation involves the use of stereotactic 
neurosurgical technique and modern imaging, which together 
allow for the treatment team to directly target a node in a dys-
functional circuit of interest. Next, microelectrode mapping 
(if performed) and intraoperative macro- or test stimulation 
occurs. In the case of PD, the tremor or rigidity and bradykinesia 
typically respond to intraoperative stimulation (19, 20), an  thi  
may aid in selecting the final target. In depression or OCD, for 
a few reported cases, intraoperative stimulation has been shown 
to result in subjective feelings of calmness, improved mood, and 
increased interest/motivation during macrostimulation in the sub-
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symptoms, and psychosis has also been re-
ported with STNDBS in Parkinson patients
(114, 115, 126). DBS of the globus pallidus
interna has demonstrated anxiolytic effects
(46). Globus pallidus interna DBS has also
been associated with relief of depressive
symptoms in a patient with dyskinesia (63).
Although DBS is widely used in move-
ment disorders, fewer studies have investi-
gated its use specifically to treat psychiatric
disorders. Effects of DBS have been re-
ported in approximately 100 OCD patients
and approximately 50 patients with depres-
sion; response rates appear to exceed 50%.
Also, multiple targets have shown efficacy
for approximately 40 patients with Tourette
syndrome (20). The large number of sites
and few cases for each site preclude full dis-
cussion here. The limited data for DBS in
psychiatric disorders is also reflected by its
regulatory status; thalamic DBS for essen-
tial tremor received Food and Drug Admin-
istration approval in 1997 and STN DBS for
Parkinson was approved in 2002 followed
by globus pallidus interna DBS for Parkin-
son in 2003. Currently, the only psychiatric
disorder with Food and Drug Administra-
tion status isOCD,which, like dystonia, has
been granted a humanitarian device exemp-
tion.One additional concern for psychiatric
disorders is the delay in time to respond
following stimulation initiation. In this
context, frequent follow-up is indicated for
DBS in psychiatric disorders. Also, to limit
risks of inducing hypomania, patients
shouldbe encouraged to remain close to the
programming physician overnight follow-
ing adjustments, particularly if traveling
from far away.
The first reports of DBS treatment pri-
marily for psychiatric conditions,OCD, and
Tourette syndrome, were published in The
Lancet in 1999 (88, 120). Stimulation of the
anterior limb of the internal capsule in “tar-
gets [that] were identical to those aimed for
in capsulotomy” led to symptomatic im-
provement in three of four patients with re-
sistant OCD. Specific scale scores were not
published, but the authors state that one
patient’s parents reported 90% improve-
ment in her compulsive behaviors and ritu-
als after 2 weeks of stimulation. Data from
six OCD patients who received double-
blinded, bilateral internal capsular stimula-
tion were published in 2003 (89). These pa-
tients all had severe symptoms at baseline
as indicated by Y-BOCS scores !30 and
Global Assessment of Function scores 45.
The location of tip center in the patient with
best clinical response was reported as 3.5
mmanterior to the anterior commissure, 13
mm lateral to themidline on left and 14mm
lateral to midline on right, and at the level
of the intercommissural plane. Although
contacts 1 and 2 were in the internal cap-
sule, the most distal electrode, contact 0,
was in or near the NAc whereas the most
proximal, contact 3, was dorsal to the inter-
nal capsule.With constant stimulation, 3 of
6 patients met response criteria of 35% re-
duction inY-BOCS; the authors suggest that
nonresponse in one patient may be related
to a comorbid somatoform disorder. When
stimulationwas turnedoff, all threeof these
responders experienced significant wors-
ening of mood and OCD symptoms. The
three responders also showed reductions in
frontal metabolism, assessed by PET, after
3 months of stimulation. In 2008, these
data were republished with data from 2 re-
cently implanted patients and additional
follow-up (90).No infections, deaths, hem-
orrhages, or significant changes in vegeta-
tive function were seen. Also, no mania oc-
curred though some disinhibition that
responded to decreases in stimulation in-
tensity was noted.
STN DBS was published for 16 patients
in a multicenter 10-month, double-blind,
crossover study (76).One additional patient
was implanted in this study but postopera-
tive infection required explantation prior to
randomization and assessment. Decreases
in Y-BOCS and Clinical Global Impression
scores, along with increases in Global As-
sessment of Function scores, were signifi-
Figure 10. DBS electrode. Medtronic DBS lead and microelectrode. (Courtesy of Medtronic Inc.)
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Recent reports indicate that neural oscillations could poten-
tially be used to guide DBS programming, particularly in 
the absence of noticeable changes in clinical symptoms. Sev-
eral groups have been working to use these local field poten-
tials to develop biomarkers of efficacy such that a closed 
loop system can be developed. The use of the ` band for PD 
(43), the e band for depression in thesubcallosal cingulate 
(44), and the a band for TS (45) in the centromedian nucleus of 
the thalamus (CM) may prove to be useful. Several groups are cur-
rently using a closed-loop device to record and then stimulate on 
demand (46). The intent in all of these explorations is the devel-
opment of a marker that can be adjusted in real time. This tech-
nology has already become available in epilepsy devices where the 
electrical signature is better characterized (47).
Neuropsychiatric disease and DBS targets
PD. PD is a neurodegenerative syndrome that affects motor and 
nonmotor thalamocortical circuitry within the parallel and segre-
gated basal ganglia system. PD-related neurodegeneration results 
in characteristic changes in neuronal firing rates, firing patterns 
(48), and also in oscillatory brain-cell activity (43). Many of these 
changes are believed to manifest clinically as tremor, rigidity, bra-
dykinesia, apathy, depression, and/or cognitive dysfunction (49). 
Several randomized clinical trials in PD have revealed efficacy in 
both unilateral and bilateral STN and/or globus pallidus pars 
internus (GPi) DBS. In many of the trials, results have directly 
compared outcomes of DBS and traditional medical management 
(see Table 1). In 2006, Deuschl and colleagues demonstrated that 
STN DBS was superior to medication management in advanced 
PD (50), results that were corroborated in the 2010 PD SURG trial 
(51) and in a younger, less advanced PD group in 2013 (52).
Because of the uncertainty of both the efficacy and the side 
effects from STN DBS and GPi DBS, several studies were con-
ducted to compare GPi and STN. In 2009, the NIH COMPARE 
trial demonstrated no significant differences in mood or cognition 
when in the optimal DBS state, while simultaneously demonstrat-
ing equal motor outcomes in the two targets. Worsened verbal flu-
ency was demonstrated, however, when the STN target was in one 
of three nonoptimal DBS states (53). In 2010, Follett also demon-
strated that GPi and STN had equal motor efficacy at 24 months 
(54), but a follow-up study revealed more long-term cognitive 
problems in the STN group (55). STN is likely to be the preferred 
target for PD DBS if medication reduction is desired (56), while 
GPi is likely the best choice if dyskinesia and/or preexisting cogni-
tive issues are present (refs. 32, 53, and 57; also see Table 1).
In order to more fully explain the mechanisms that under-
lie the therapeutic efficacy of DBS for PD, efforts to model the 
pathophysiologic mechanisms of PD will ideally link abnormal 
basal ganglia activity to the cardinal parkinsonian motor signs 
(58). Computational approaches have the potential to play an 
important role in exploring these mechanisms (58). Currently, 
clinicians are utilizing methods to reduce side effects, particular-
ly mood and cognitive alterations, through the optimization of 
lead placement within the target (59). Future improvements may 
include customized modification of the electrode trajectory (60) 
and placement along with clinical stimulation parameter settings 
using a patient-specific model and atlas (PSA) (61–63). The use of 
temporally nonregular stimulation parameters may also allow for 
further honing of the therapy in an effort to increase battery life 
and to improve network delivery (64).
TS. TS is an early life–onset neuropsychiatric condition affecting 
approximately 1% of individuals worldwide. TS is characterized by 
multiple motor tics and one or more vocal tics that persist for more 
than a year. Approximately 90% of sufferers have comorbid disor-
ders, including attention-deficit/hyperactivity disorder (ADHD), 
OCD, and self-injurious behaviors (SIB). In severe adult TS cases, 
DBS has been used in disabling settings when the patient is both 
medication and behavioral intervention resistant (65). There are 
multiple TS targets including the CM and substantia periventric-
ularis (SPV) (66), the posteroventral (PV) GPi, the ventromedial 
(VM) GPi, the globus pallidus externus (GPe) (67), the STN (68), 
and the anterior limb of the internal capsule/nucleus accumbens 
(ALIC/NAc) region (69). We will discuss the two targets that have 
been the best characterized, and most utilized in clinical practice, 
the GPi (both the PV motor and VM nonmotor regions) and the 
CM. There are no large randomized controlled studies comparing 
TS targets available (69).
The largest study to date utilized the CM thalamus and demon-
strated an average 52% reduction in Yale Global Tic Severity Scores 
(YGTSS) (65). The effect appeared to be reasonably durable: the 
long-term follow-up demonstrated 17 of 18 subjects had a 30% 
or greater reduction in their YGTSS (70). Of note, the CM target 
Figure 2
General schematic of DBS targets. (A) Sagittal view of DBS targets 
including VC/VS, STN, SCC, and ITP. (B) Coronal view of DBS targets 
including STN, GPi, and CM. Schematic is not anatomically accurate.
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Figure 1
Three-dimensional (3D) illustration of bilaterally implanted deep brain stimulation (DBS) electrodes in the ventral capsule/ventral
striatum. The 3D objects (leads and brain structures) are sitting on the axial plane 5 mm below the AC–PC plane as viewed posterior to
anterior. The trajectory of the leads is down the barrel of the anterior limb of the internal capsule. Each lead has four contacts, but only
three are shown (contacts #0, #1, and #2); contact #3 is hidden by the caudate nucleus. The most ventral #0 contact is active, as
represented by red radiating stimulation fields. Abbreviations: AC–PC, anterior commissure–posterior commissure; GPe, globus
pallidus externus; GPi, globus pallidus internus. Image courtesy of Kirk Finnis, PhD (Medtronic Inc., USA).
ALIC: anterior limb
of the internal capsule
NAc: nucleus
accumbens
SCG: subcallosal
cingulate gyrus
STN: subthalamic
nucleus
place. The second stage is conducted under
general anesthesia either immediately or within
days following completion of the first stage.
The surgical techniques employed to im-
plant DBS devices for the treatment of psy-
chiatric disorders are derived from the vast ex-
perience of performing both ablative and DBS
surgery for movement disorders. In several re-
spects, the therapeutic sites for treating psychi-
atric disorders are easier to target than those for
movement disorders. First, the most common
targets—e.g., the anterior limb of the internal
capsule (ALIC), the nucleus accumbens (NAc),
and the subcallosal cingulate gyrus (SCG;Brod-
mann’s area 25)—are larger and more readily
visualized on T1-weighted magnetic resonance
imaging (MRI) than are the sites that are stim-
ulated to treat movement disorders, such as the
subthalamic nucleus (STN). Second, these tar-
gets are located in brain regions where DBS
is less likely to induce obvious adverse effects
(e.g., muscular contractions, painful paresthe-
siae, eye deviations) that would limit the clini-
cal efficacy of stimulation. One exception is hy-
pomania, which has been observed with ALIC
stimulation (see “Complications of Surgery”
below). Third, the lack of an immediate pos-
itive clinical response to stimulation allows
the surgery to be performed with the patient
fully asleep or consciously sedated—although
the “smile reflex” (12) may prove to represent
just such a positive clinical indicator (13). Of
course, the lack of an immediate therapeutic re-
sponse to stimulation also poses a disadvantage,
as there is no intraoperative feedback to the
surgeon that the therapeutic site has been
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Abstract
Deep brain stimulation (DBS) has virtually replaced ablative neuro-
surgery for use in medication-refractory movement disorders. DBS is
now being studied in severe psychiatric conditions, such as treatment-
resistant depression (TRD) and intractable obsessive-compulsive disor-
der (OCD). Effects of DBS have been reported in ∼100 cases of OCD
and ∼50 cases of TRD for seven (five common) anatomic targets. Al-
though these published reports differ with respect to study design and
methodology, the overall response rate appears to exceed 50% in OCD
for some DBS targets. In TRD, >50% of patients responded during
acute and long-term bilateral electrical stimulation in a different target.
DBS was generally well tolerated in both OCD and TRD, but some
unique, target- and stimulation-specific adverse effects were observed
(e.g., hypomania). Further research is needed to test the efficacy and
safety of DBS in psychiatric disorders, compare targets, and identify
predictors of response.
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OCD DBS, and the laterality issue remains inconclusive with most
groups performing bilateral operations.
Most of the aforementioned procedures are quite similar in that
they cover the NAcc and the ventral capsular region (Fig. 1).
However, it is possible that outcomes could be improved with more
meticulous and accurate target selection.
STN
The STN is made up of limbic, associative, and motor territories
(70). It receives input from the orbitofrontal-striato-pallido-
thalamo-cortical circuit (71). There have been four DBS studies that
have targeted the STN for treatment of OCD (4,49,50,57). This
approach was initially reported by Mallet et al. who treated two
patients with PD and OCD (57). Mallet and colleagues targeted the
limbic area of the STN, and interestingly, stimulation in this region
resulted in an improvement in obsessive behavior and also in the
symptoms of PD. The target was 2 mm anterior and 1 mmmedial to
the STN target that was previously reported in PD cases (72). Sub-
sequently, Fontaine and colleagues reported another case of OCD
also with PD who underwent STN DBS with substantial improve-
ment 12 months following surgery (50). Based on these initial favor-
able results, Mallet and colleagues performed a crossover,
randomized multicenter study, with favorable outcomes (4).
ITP
The ITP contains fibers connecting the MD thalamic nucleus with
the orbitofrontal, insular, and temporal cortices as well as the amyg-
daloid complex. Jimenez and colleagues reported that ITP could be
a potential target in DBS for OCD. It is hypothesized that this
approach will disrupt the thalamo-orbitofrontal system. Jimenez’s
reported outcomes of ITP stimulation for OCD were considered
positive, though the case series was small (54,55). Jimenez-Ponce
and colleagues reported favorable results from one case and also
five responders in an open-case series (54,55); however, a controlled
trial for DBS in the ITP to address OCD has not been performed. A
better and more controlled study protocol will be needed to assess
the true eﬃcacy of ITP DBS.
Programming Considerations
General Concepts
A logical first step in optimizingDBS programming is to define the
lead location and to establish the lead configuration (the size of the
contacts and the distance between them). Lead configuration can
diﬀer according to the specific target selected. Although DBS leads
with larger distances between contacts and larger contact sizes
(e.g., Medtronic model 3387 IES) were more likely to be used for
earlier studies of VC/VS stimulation (52,53), those with relatively
smaller configuration (i.e., Medtronic model 3389) have been used
for STN and inmore recentVC/VS cases (4,50). The bedside program-
mer should be aware of the lead type and configuration when plan-
ning treatment. Postoperative imaging can be useful in this context.
The electrode configurations utilized in each published study are
summarized in Table 1.
Figure 1. Anterior view of coronal sections of deep nuclear areas of the left hemisphere showing five diﬀerent approaches for OCD DBS. Left: electrode placement
in ALIC (a) for DBS. Middle: electrode placement targeting NAcc through ALIC utilizing three diﬀerent trajectories (b, c, and d). Right: modified VC/VS trajectory (e). a:
The ALIC trajectory (Anderson and Ahmed (2003) and Abelson et al. (2005)). b: Medial trajectory through the caudate nucleus to the NAcc utilizing Medtronic model
3387 electrode (each contact length = 1.5mm, interelectrode spacing = 1.5mm) by Aouizerate et al. (2004, 2007). c: VC/VS stimulation trajectory through the ALIC to
the NAcc using a shorter length of stimulating electrode (Medtronic model 3389: each contact length = 1.5mm, interelectrode spacing = 0.5mm) by Denys et al.
(2010). d: VC/VS trajectory through ALIC to the NAcc using a longer length of stimulating electrode (Medtronic model 3387 IES/3887: each contact length = 3mm,
interelectrode spacing = 4mm) by Greenberg et al. (2006). e. VC/VS trajectory through ALIC to the NAcc using a longer length of stimulating electrode (Medtronic
model 3387 IES/3887: each contact length = 3mm, interelectrode spacing = 4mm) by Greenberg et al. (2010). ACA, anterior cerebral artery; ALIC, anterior limb of the
internal capsule; AN, anterior nucleus of the thalamus; AntCom, anterior commissure; BN, bed nucleus; CC, corpus callosum; CL, claustrum; CN, caudate nucleus; DBS,
deep brain stimulation; DiaBd, diagonal band of Broca; EC, external capsule; EX, extreme capsule; GP, globus pallidus; LOS, lateral olfactory stria; MCA, middle cerebral
artery; MFB, medial forebrain bundle; MD, mediodorsal nucleus of the thalamus; MOS, medial olfactory stria; NA, amygdala; NAcc, nucleus accumbens; OCD, obsessive
compulsive disorder; OpCh, optic chiasm; Pu, putamen; Sep, septum pellucidum; SN, septal nucleus; STN, subthalamic nucleus; VC/VS, ventral capsule/ventral
striatum.
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Surgical Neuroanatomy and Programming in
Deep Brain Stimulation for Obsessive
Compulsive Disorder
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Objectives: Deep brain stimulation (DBS) has been established as a safe, eﬀective therapy for movement disorders (Parkinson’s
disease, essential tremor, etc.), and its application is expanding to the treatment of other intractable neuropsychiatric disorders
including depression and obsessive-compulsive disorder (OCD). Several published studies have supported the eﬃcacy of DBS for
severely debilitating OCD. However, questions remain regarding the optimal anatomic target and the lack of a bedside program-
ming paradigm for OCD DBS. Management of OCD DBS can be highly variable and is typically guided by each center’s individual
expertise. In this paper, we review the various approaches to targeting and programming for OCD DBS.We also review the clinical
experience for each proposed target and discuss the relevant neuroanatomy.
Materials and Methods: A PubMed review was performed searching for literature on OCD DBS and included all articles pub-
lished before March 2012.We included all available studies with a clear description of the anatomic targets, programming details,
and the outcomes.
Results: Six diﬀerent DBS approaches were identified. High-frequency stimulation with high voltage was applied in most cases,
and predictive factors for favorable outcomes were discussed in the literature.
Conclusion: DBS remains an experimental treatment for medication refractory OCD. Target selection and programming para-
digms are not yet standardized, though an improved understanding of the relationship between the DBS lead and the surround-
ing neuroanatomic structures will aid in the selection of targets and the approach to programming.We propose to form a registry
to track OCD DBS cases for future clinical study design.
Keywords: Deep brain stimulation, inferior thalamic peduncle, obsessive compulsive disorder, subthalamic nucleus, ventral
capsule/ventral striatum
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INTRODUCTION
Obsessive-compulsive disorder (OCD) is a potentially disabling
neuropsychiatric illness with a lifetime prevalence of 2.3% (1). In
recent years, attention has been given to a novel treatment
approach, deep brain stimulation (DBS), for those with chronic and
severe treatment-refractory OCD. Although DBS has been estab-
lished as a safe and eﬀective treatment for movement disorders
such as Parkinson’s disease (PD) and essential tremor (2), its use in
treating neuropsychiatric disorders is still experimental. The first
report of DBS in patients with OCD was described by Nuttin and
colleagues (3), who selected their target, the anterior limb of the
internal capsule (ALIC), based on the anatomic target used in the
ablative technique, the anterior capsulotomy. Following this initial
study, the use of DBS in patients with treatment-refractory OCDwas
examined in four controlled studies (4–7). In additio to a multit de
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Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
2.5	  year	  follow-­‐up	  
Figure 2.   Yale Brown Obsessive Compulsive Scale (YBOCS) scores were measured 
for M.A  over a three year and seven months period of time.  A time series plot (A) 
shows a steady decline in YBOCS scores over the period of time spanning his DBS surgery 
(s) and treatment.   Incremental adjustments to neurostimulator voltage are plotted over a 
period of time following DBS surgery (A).  Mean YBOCS scores are plotted for sets of 
measurements taken before and after his Deep Brain Stimulation (DBS) surgery (B).  A 
one-tailed  unpaired  t  test  with  Welch’s  correction  results  in  a  p  value  of 
0.0056,  demonstrating  a significant difference  between YBOCS scores measured before 
and after the time of surgery.	
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
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Abbreviations: CLIA, Clinical Laboratory Improvements Amendments; NGS, Next
generation sequencing; WGS, whole-genome sequencing.
⁎ Correspondence to: G.J. Lyon, Stanley Institute for Cognitive Genomics, Cold Spring
Harbor Laboratory, NY, United States. Tel.: +1 1446468721219.
⁎⁎ Correspondence to: J.P. Segal, New York Genome Center, New York, NY. Tel.: +1
888 415 6942.
E-mail addresses: GholsonJLyon@gmail.com (G.J. Lyon), jeremypsegal@gmail.com
(J.P. Segal).
ATG-00009; No of Pages 7
2212-0661/$ – see front matter © 2013 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.atg.2013.02.001
Contents lists available at SciVerse ScienceDirect
Applied & Translational Genomics
j ourna l homepage: www.e lsev ie r .com/ locate /atg
Please cite this article as: Lyon, G.J., Segal, J.P., Practical, ethical and regulatory considerations for the evolving medical and research genomics
landscape, Applied & Translational Genomics (2013), http://dx.doi.org/10.1016/j.atg.2013.02.001
entirely performed on Illumina equipment using one of a few library
preparation methods, with 100 base paired-end sequencing performed
in the major research sequencing centers to an average depth of 70–
100× to achieve >80% of the target region covered by 20 or more
reads. Others havemade suggestions for standardizing exome sequenc-
ing (Klein et al., 2012), and we believe it is high-time to establish such
standards, at least for exomes being sequenced from live human beings,
so that results can be returned to participants.
However, while sequencing is relatively standardizable, it is true
that many of the downstream processes are not, as bioinformatics
analyses and interpretive schemes can be extremely variable. While
the desired informatics and interpretive analysis for healthy individ-
uals might focus on alleles relevant for future disease risk, carrier sta-
tus and pharmacogenomics, genomic analyses for rare diseases might
instead focus on de novo, homozygous or X-linked disease variants,
possibly in the context of a parent–child trio or preferably in the con-
text of even larger families, including grandparents. Certain ﬁndings
seen in one patient may escape detection in another patient simply
due to differences in the basic strategy of analysis or the phenotype
of the individuals. With respect to population studies, the analytical
variation can be tremendous, with focuses ranging from ethnicity-
speciﬁc variation to variation associated with complex disease, basic
human phenotypes and evolutionary processes. The number of differ-
ent performable analyses is limited only by the imagination.While the
informed consent process for each individual study would be required
to include a discussion of the analysis details, the process can be con-
fusing for participants and easily leave them at the end unclearwheth-
er or not particular ﬁndings were investigated and frustrated by an
inability to access the data. This being the case, it would be beneﬁcial
to move towards a systemwhereby a straightforward clinical analysis
of data from research projects could be subsequently performed at a
later time, within a proper regulatory framework.
This downstream variation in informatics and interpretation raises
an important question: from the clinical standpoint, what exactly con-
stitutes a genetic laboratory test? Is it simply the analytics (the se-
quencing), or is it a combination of analytics and interpretation, or is
it the entire process from sample receipt through to the generation
and return of a report? Here, the legal deﬁnition is really quite
clear, as CLIA speciﬁcally states that a medical laboratory test is an all-
encompassing process (Anon., 2013a). The introduction to CLIA subpart
K states that “each laboratory that performsnonwaived testingmust es-
tablish and maintain written policies and procedures that implement
and monitor quality systems for all phases of the total testing process
(that is, preanalytic, analytic, and postanalytic) as well as general labo-
ratory systems” (see Table 1 for a summary of the analytic systems).
It is noteworthy that test interpretation and reporting are speciﬁ-
cally covered by the CLIA statutes and included as part of the regulated
test process. This is important because, as the community has discov-
ered, the actual sequencing has become increasingly straightforward,
whereas the true difﬁculties and pitfalls lie in the informatics, inter-
pretation and reporting. Any meaningful regulatory framework for
NGS-based diagnostics must include oversight of informatics path-
ways and interpretive criteria, as there are simply too many ways to
do informatics incorrectly, with resultant possibilities for harm to pa-
tients and participants.
This issue is beginning to get the attention of the agencies respon-
sible for overseeing clinical laboratories, now that a large number of
clinical laboratories have begun developing a variety of tests on NGS
instruments. The College of American Pathologists (CAP) has recently
released a new checklist for molecular pathology laboratories that
includes both general laboratory and test development guidelines
covering NGS wet lab practices, bioinformatics processing and data
storage and transfer practices. Additionally, the New York State De-
partment of Health Clinical Laboratory Evaluation Program (CLEP)
has issued detailed guidelines for the development and validation of
NGS cancer genomics assays (Anon., 2013b). New York is one of
two CLIA-exempt states as a result of its own state licensure regula-
tions being deemed “equal to, or more stringent than” CLIA by CMS
per CLIA subpart E, thus clinical laboratories in New York receive
their CLIA license through th tate following s ccessful state certiﬁ-
cation. The CLEP NGS oncology guidelines are quite thorough, includ-
ing requirements for quality scores, control procedures, acceptabl
numbers of sp cimens for valid tion studies and guideli es for
stablishi g read dep , accuracy, sensitivity, tc., focusing on actual
performance rather than the details of bioinformatics pipelines. Over-
all, the regulatory framework for NGS on the pure clinical side is com-
ing together, with certain aspects such as reporting criteria hopefully
being sorted out in the near future.
However, if a clinical NGS test is deﬁned by both the sequencing
and downstream informatics, and the informatics possibilities for a
standar equence are essentially limitless, how could CLIA supervi-
sion be applied to combined research and clinical genomics operations
without placi g an extreme regu atory burden on the sequencing
laboratory? Would every analysis type need to be certiﬁed, or would
a time-consuming standardized analysis be required even if it were
not needed for each p rticular peration?
6. The distributive model: an analytical-interpretive split
across genomics
Any ideal solution would allow sequencing centers to focus on
their strengths and to leverage their economies of scale, without re-
quiring them to devote their time to unnecessary informatics and in-
terpretation. How can that be achieved in keeping with the spirit of
proper CLIA oversight? As a solution, we would propose an analytic-
interpretive split (or a so-called “distributivemodel”) across both clin-
ical and research genomics. This split model simply means that one
laboratory performs analytics and then a second laboratory performs
the interpretation and reporting. Thus, together, the two laboratories
perform all the functions that make up a laboratory test. This should
be a straightforward arrangement, but while some precedent and
guidance policies exist, the regulatory structure that would govern
such a system is still evolving, as we will discuss.
The beneﬁts of enacting such a split model could be substantial,
and we believe they could be gained without signiﬁcantly burdening
our sequencing centers with undue excess costs. Under this type of
system, the basic sample processing and sequencing operation could
be standardized across clinical patients and the majority of new geno-
mics research participants. The practical effect of this split would be
to turn an exome or genome sequence into a discrete deliverable unit
that could be used for multiple downstream purposes by multiple
downstream labs. For each patient or participant, the same validated
sequencing would be performed, and that raw data, if individually
Table 1
Processes involved in a CLIA-certiﬁed genetic test.
Preanalytic system
1) Test request and specimen collection criteria
2) Specimen submission, handling and referral procedures
3) Preanalytic systems assessment
Analytic system
1) A detailed step-by-step procedure m nual
2) Test systems, equipment, instrum nts, reagents, mat rials and
supplies
3) Establishment and veriﬁcation of performance speciﬁcations
4) Maintenance and function checks
5) Calibration and calibration veriﬁcation procedures
6) Control procedures, test records, and corrective actions
7) Analytic systems assessment
Post-analytic system
1) Test report, including (among other things):
a) interpretation
b) reference ranges and normal values
2) Post-analytic systems assessment
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1.	  Sample	  CollecQon	  and	  handling	  
	  
	  
2.	  Sequencing/AnalyQcs	  
	  
	  
3.	  InterpretaQon	  
“This	  laboratory	  test	  was	  developed,	  and	  its	  performance	  characteris+cs	  
were	  determined	  by	  the	  Illumina	  Clinical	  Services	  Laboratory	  (CLIA-­‐cer+ﬁed,	  
CAP-­‐accredited).	  Consistent	  with	  laboratory-­‐developed	  tests,	  it	  has	  not	  been	  
cleared	  or	  approved	  by	  the	  U.S.	  Food	  and	  Drug	  Administra+on.	  If	  you	  have	  
any	  ques+ons	  or	  concerns	  about	  what	  you	  might	  learn	  through	  your	  genome	  
sequence	  informa+on,	  you	  should	  contact	  your	  doctor	  or	  a	  gene+c	  
counselor.	  Please	  note	  that	  Illumina	  does	  not	  accept	  orders	  for	  Individual	  
Genome	  Sequencing	  services	  from	  Florida	  and	  New	  York.”	  

Sample	  CollecQon	  and	  Handling	  	  
The	  Sample	  CollecQon	  kit	  includes	  barcoded	  collecQon	  tubes,	  a	  
Test	  RequisiQon	  form,	  an	  Informed	  PaQent	  Consent	  form,	  and	  a	  pre-­‐paid	  
shipping	  envelope.	  All	  paperwork	  must	  be	  completed	  and	  returned	  for	  
sample	  processing.	  Requests	  for	  Sample	  CollecQon	  kits	  must	  be	  
submiPed	  by	  a	  physician.	  
hPp://www.illumina.com/clinical/illumina_clinical_laboratory/igs_for_doctors/
how_to_order.ilmn	  
	  
Sequencing	  and	  AnalyQcs	  
From	  the	  Illumina	  Understand	  
Your	  Genome	  Symposium	  
October	  2012	  
Figure 2 Implementation of the analytic-interpretive split model for the clinical incorporation of a
whole genome. We have implemented the analytic-interpretive split model here with MA, with WGS
being performed in a CLIA certified and CAP accredited lab at Illumina as part of the Individual Genome
Sequencing test developed by them. The WGS acts as a discrete deliverable clinical unit from which
multiple downstream interpretive analyses were performed. We used the ERDS CNV caller, the Golden
Helix SVS CNAM for CNV calling, and the Omicial Opal and the AssureRx Health Inc. pipelines for
variant annotation and clinical interpretation of genomic variants. By archiving and oVering to him
the encrypted hard drive containing his “raw” sequencing data, any number of people, including the
individual and/or his/her health care providers can analyze his genome for years to come. Abbreviations:
CLIA, Clinical Laboratory Improvement Amendments; CAP, College of American Pathologists; CASAVA,
Consensus Assessment of Sequence and Variation; ERDS, Estimation by Read Depth with SNVs; CNAM,
Copy Number Analysis Method; WGS, Whole Genome Sequencing.
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Previous report from Illumina (10/14/2012)  
Refsum	  Disease?	  
•  Found	  to	  have	  bilateral	  cataracts,	  large	  pupils,	  
and	  loss	  of	  night	  vision.	  
•  His	  mother	  and	  grandmother	  both	  have	  large	  
pupils	  and	  loss	  of	  night	  vision.	  No	  cataracts	  
known.	  
•  Preventive measures implemented. 
•  Referred to optometry for further evaluation; 
report showed normal fatty acids profile. 
Recent report from Illumina (12/16/2013) 
Recent report from Illumina – Cont.	  
•  4182 more variants in additional 1256 genes were added into the 
more recent version of the clinical report. 
•  One variant of unknown significance (suspicious) and one likely 
pathogenic variant were reported. 
Note: However, this person has been prescribed general anesthesia before and had 
no significant side-effects. The allele frequency of c.4060A>T variant is ~1% in 
the 1000 Genomes database. 
Recent report from Illumina – Cont.	  
Note: This c.161G>A variant is classified as “Pathogenic” in ClinVar and 
classified as “with pathogenic allele” in dbSNP database. 
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Re-analyzing genomic data 
•  Significant improvements of bioinformatics 
pipelines in recent years 
•  Rapid increase of numbers of both publications 
and genomes sequenced 
•  “Refresh” views of genotype-phenotype 
relationship in an era of millions of genomes 
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* Scalpel (In press)  http://schatzlab.cshl.edu/
* CADD  (In press)  http://cadd.gs.washington.edu/
Current	  popular	  genomic	  analysis	  online	  platorms	  and	  analysis	  suits	  
DescripQon:	  Prion	  Disease,	  SuscepQbility	  
To	  Alzheimer	  Disease,	  Early-­‐onset,	  
SuscepQbility	  To,	  Included,,	  Aphasia,	  
Primary	  Progressive,	  SuscepQbility	  To,	  
Included	  
cancer-­‐associated	  
	  Pseudoxanthoma	  elasQcum	  
Viral	  infecQons,	  recurrent,	  suscepQbility	  
to	  
CondiQon:	  Hypertension,	  essenQal,	  
suscepQbility	  to	  
DescripQon:	  Reduced	  metormin	  uptake	  
in	  transfected	  cells	  
associated	  with	  shorter	  bleeding	  Qme	  
and	  less	  response	  to	  aspirin.	  	  
a	  higher	  risk	  of	  secondary	  coronary	  
events	  which	  was	  reduced	  by	  
pravastaQn	  
associated	  with	  blood	  pressure	  
response	  to	  nifedipine	  treatment.	  
Easily	  select	  variants	  with	  prior	  evidence	  
(called	  by	  both	  GATK	  and	  FreeBayes,	  but	  not	  by	  CASAVA)	  
No	  rare	  variants	  or	  CNVs	  with	  high	  biological	  eﬀect	  as	  related	  to	  
mental	  illness.	  	  
	  
3	  common	  SNVs	  in	  this	  person	  that	  have	  been	  implicated	  in	  the	  
literature	  as	  predisposing	  to	  mental	  illness.	  
Table 1 A summary of three clinically relevant alleles found in the sequencing results of MA. Variations in MTHFR, BDNF, and ChAT were
found to be of potential clinical relevance for this person as they are all implicated in contributing to the susceptibility and development of many
neuropsychiatric disorders that resemble those present within MA. A brief summary of the characteristics of each variation is shown, including the
gene name, genomic coordinates, amino acid change, zygosity, variation type, estimated population frequency and putative clinical significance.
Gene
name
Genomic
coordinates
Amino acid
change
Zygosity Variation
type
Population
frequency
Clinical significance
MTHFR chr1: 11854476 Glu> Ala heterozygous non-synon T:77% G:23% Susceptibility to psychoses, schizophrenia
occlusive vascular disease, neural tube defects,
colon cancer, acute leukemia, and methylenetetra-
hydrofolate reductase deficiency
BDNF chr11: 27679916 Val>Met heterozygous non-synon C:77% T:23% Susceptibility to OCD, psychosis, and diminished
response to exposure therapy
CHAT chr10: 50824117 Asp> Asn heterozygous non-synon G:85% A:15% Susceptibility to schizophrenia and other psy-
chopathological disorders.
be given the opportunity, like with many other traditional medical tests, to obtain “second
opinions”. For this to be possible, one must accurately describe the contents of short-read
sequencing data in terms of the existing electronic medical health standards, so that these
data can be incorporated into an electronic medical health record. Accurately describing
the contents of next generation sequencing (NGS) results is particularly critical for
clinical analysis of genomic data. However, genomics and medicine use diVerent and
often incompatible terminologies and standards to describe sequence variants and their
functional eVects. In our eVorts to treat this one person with severe mental illness, we
have implemented the GVFclin format for the variants that were discovered during the
sequencing of his whole genome (see File S12). We hope to eventually incorporate his
genetic data into his electronic health record if and when the VistA health information
system (HIS) (Conn, 2011; Protti & Groen, 2008; Kuzmak & DayhoV, 1998; Brown et al.,
2003) is upgraded to allow entry of such data.We did already counsel MA regarding several
genetic variants that may be clinically relevant to predisposing him to his psychiatric
disorder (Biesecker & Peay, 2013).
Returning genetic results
There is considerable controversy in the field of medical genetics concerning the extent of
return of genetic results to people, particularly in the context of “secondary”, “unrelated”,
“unanticipated” or “incidental” findings stemming from new high-throughput sequencing
techniques (Lyon, 2012c). Some people have concerns regarding the clinical utility
of much of the data, and in response have advocated for selectively restricting the
returnable medical content. One such set of recommendations has been provided by
the American College ofMedical Genetics which recently released guidelines in which they
recommended the “return of secondary findings” for 57 genes, without detailed guidance
for the rest of the genome (Green et al., 2013). These types of recommendations take
a more paternalistic approach in returning test results to people, and generally involve
a deciding body of people that can range in size from a single medical practitioner to
a committee of experts. We believe that anyone should be able to access and manage
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 16/26
Ripke	  et.al	  (2013)	  Nature	  GeneQcs	  
Ripke	  et.al	  (2013)	  Nature	  GeneQcs	  
PharmacogeneQcs	  
u  MA	  is	  homozygous	  for	  a	  p.Ile359Leu	  change	  in	  CYP2C9,	  and	  this	  variant	  has	  been	  linked	  to	  a	  
reducQon	  in	  the	  enzymaQc	  acQvity	  of	  CYP2C9,	  a	  member	  of	  the	  cytochrome	  P450	  superfamily	  of	  
enzymes.	  	  
	  
u  Cytochrome	  P450	  proteins	  are	  mono-­‐oxygenases,	  which	  catalyze	  many	  reacQons	  associated	  with	  
drug	  metabolism	  as	  well	  as	  reacQons	  associated	  with	  the	  synthesis	  of	  cholesterol,	  steroids	  and	  
other	  lipids.	  	  
	  
u  FluoxeQne	  is	  commonly	  used	  in	  the	  treatment	  of	  OCD;	  it	  has	  been	  shown	  to	  be	  as	  eﬀecQve	  as	  
clomipramine	  and	  causes	  less	  side	  eﬀects.	  	  
u  CYP2C9	  acts	  to	  convert	  ﬂuoxeQne	  to	  R-­‐norﬂuoxeQne,	  and	  so	  MA	  may	  not	  be	  able	  to	  adequately	  
biotransform	  ﬂuoxeQne.	  
u  It	  is	  notable	  that	  MA	  had	  no	  response	  to	  an	  80	  mg	  daily	  dose	  of	  ﬂuoxeQne.	  
u  However,	  CYP2C9	  does	  not	  play	  a	  rate-­‐limiQng	  role	  for	  other	  SSRIs	  or	  clomipramine	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Neurotrophic factor expression in expandable cell
populations from brain samples in living patients
with Parkinson’s disease
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Department of Clinical Neurological Sciences, University of Western Ontario, London,
Ontario, Canada
ABSTRACT Cell-based therapies offer promise for
patients with Parkinson’s disease (PD); however, dura-
ble and effective transplantation substrates need to be
defined. This study characterized the feasibility and
growth properties of primary cultures established from
small-volume brain biopsies taken during deep brain
stimulation (DBS) surgery in patients with PD. The
lineage and expression of neurotrophic factors with
known beneficial actions in PD-affected brain circuitry
were also evaluated. Nineteen patients with PD under-
going DBS surgery consented to brain biopsies prior to
electrode implantation. Cultures from these samples
exhibited exponential and plateau phases of growth
and were readily expanded throughout multiple pas-
sages. There was robust expression of progenitor mark-
ers and the unexpected colocalization of neural and
mesenchymal proteins. The oligodendrocyte transcrip-
tion factor, Olig1, and the myelin-specific sphingolipid,
galactocerebroside, were coexpressed with each of glial-
derived neurotrophic factor, brain-derived neurotrophic
factor, and cerebral dopamine neurotrophic factor.
Fluorescence-activated cell sorting demonstrated ho-
mogeneous expression of both nestin and Olig1
throughout the expanded cultures. Cells remained via-
ble after a year in cryostorage. These findings confirm
the feasibility of small brain biopsies as an expandable
source of autologous cell substrate in living patients
and demonstrate the complex phenotype of these cells,
with implications for therapeutic application in PD and
other neurological diseases.— Xu, H., Belkacemi, L.,
Jog, M., Parrent, A., Hebb. M. O. Neurotrophic factor
expression in expandable cell populations from brain
samples in living patients with Parkinson’s disease.
FASEB J. 27, 4157–4168 (2013). www.fasebj.org
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Parkinson’s disease (PD) is best recognized for degen-
eration within the dopaminergic mesencephalon but
widely affects neurons and non-neuronal cells in the
central, peripheral and autonomic nervous systems
(1–4). No definitive treatment is available and the
current standard of care includes dopamine replace-
ment therapy and deep brain stimulation (DBS) for
symptom control. Various neurotrophic factors (NTFs)
have been established as potent cytoprotective agents in
the brain and are currently being evaluated for thera-
peutic potential in PD and other neurological diseases.
The four main NTF families are the glial-derived neu-
rotrophic factor (GDNF) family of ligands (GFL), the
neurotrophins, the neurokines, and the cerebral dopa-
mine neurotrophic factor (CDNF)/mesencephalic as-
trocyte-derived neurotrophic factor (MANF) family.
These proteins regulate vital biological programs in the
developing and adult nervous systems and confer broad
regenerative and survival effects in experimental PD
models (5–11). Clinical application of NTF therapy has
been restricted by numerous pharmacological chal-
lenges, including poor blood brain barrier permeabil-
ity, limited tissue diffusion, and rapid intraparenchymal
metabolism. Various protein modifications have been
used to enhance uptake of systemic NTFs into the
central nervous system (CNS), and direct delivery into
the brain has been achieved using microinfusion
pumps and gene transfer methods (10, 12). Despite
these technological advances, clinical progress has
been slow and there remain concerns regarding appro-
priate selection of intracerebral delivery sites, adequacy
of parenchymal drug levels and immune sensitization
to exogenous NTFs. Transplanted cells with appropri-
ate endogenous or engineered gene expression may
serve as biological vehicles for long-term administration
of trophic agents within the PD-affected brain. The
1 Correspondence: Department of Clinical Neurological
Sciences (Neurosurgery), University of Western Ontario, 339
Windermere Rd., C7-134, London, ON, Canada N6A 5A5.
E-mail: mhebb@uwo.ca
doi: 10.1096/fj.12-226555
Abbreviations: BDNF, brain-derived neurotrophic factor;
CDNF, cerebral dopamine neurotrophic factor; CNS, central
nervous system; DAPI, 4=-6-diamidino-2-phenylindole; DBS,
deep brain stimulation; DMEM, Dulbecco’s modified Eagle’s
medium; FACS, fluorescence-activated cell sorting; FBS, fetal
bovine serum; FN, fibronectin; FSC, forward scatter; GalC,
galactocerebroside; GAPDH, glyceraldehyde 3-phosphate de-
hydrogenase; GDNF, glial-derived neurotrophic factor;
GFAP, glial fibrillary acidic protein; GFL, glial-derived neu-
rotrophic factor family of ligands; GLAST, glutamate aspar-
tate transporter; Iba1, ionized calciumbinding adaptormolecule 1;
MANF, mesencephalic astrocyte-derived neurotrophic factor;
NTF, neurotrophic factor; PBS, phosphate-buffered saline; PCR,
polymerase chain reaction; PD, Parkinson’s disease; RT-PCR, re-
verse transcription-polymerase chain reaction; SSC, side scatter
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later. At that time, both specimens were combined as a single
tissue source for each patient and subjected to a 20-min
digestion with 0.25% trypsin (Life Technologies Inc., Burl-
ington, ON, Canada) plus DNase I (75 !g; Roche Diagnostics,
Laval, PQ, Canada) in a 5-ml volume of PBS at 37°C. After
filtering through a 100-!m cell strainer (BD Biosciences,
Mississauga, ON, Canada), the tissue was centrifuged at 1200
rpm for 10 min, then resuspended in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, 1%
nonessential amino acids, and 1% penicillin/streptomycin
before plating to a 35-mm dish for 2 h to allow blood cells to
separate (Life Technologies). The upper cell suspension was
then transferred to 2 wells of a 24-well plate, freshly precoated
with 10 !g/ml poly-l-lysine (Trevigen Inc., Gaithersburg,
MD, USA) and incubated at 37°C in a humidified 5% CO2
atmosphere. Cultures were passaged at"80% confluence and
split 1:2 using 0.25% trypsin with 0.53 mM ethylenedi-
aminetetraacetic acid (Wisent Bioproducts, St. Bruno, PQ,
Canada). The medium was changed 2#/wk. At various pas-
sages, cells were resuspended in a freezing solution of DMEM
with 20% FBS and 10% dimethyl sulfoxide. Aliquots (5#106
cells/ml) were placed in cryogenic storage vials and frozen
using a CoolCell freezing container (BioCision LLC, Mill
Valley, CA, USA) prior to transfer to a$80°C freezer or liquid
nitrogen. All immunocytochemistry, Western blot, polymer-
ase chain reaction (PCR), and fluorescence-activated cell
sorting (FACS) analyses we e conducted duri g pa sages 4
through 8 using cells from a minimum of 4 randomly selected
patients for each marker.
Western blot analysis
Cells were collected in lysis buffer (50 mM Tris HCl, 150 mM
NaCl, and 1% Nonidet P40, pH 7.4) supplemented with
SigmaFast Protease Inhibitor cocktail (1:10; Sigma-Aldrich,
St. Louis, MO, USA), incubated on ice for 15 min, and then
sonicated. The cell lysates were centrifuged at 13,000 g for 15
min, and the protein supernatant was collected. Protein
similarly isolated from a frozen sample (170 mg) of non-
pathological brain obtained from the Brain Tumor Tissue
Bank (London Health Sciences Centre, London, ON, Can-
ada), a service of the Brain Tumor Foundation of Canada
(http://www.braintumour.ca/), was used as a positive control
for neural markers not expressed in the PD cells. Protein
concentrations were determined using a DC Protein Assay kit
(Bio-Rad Laboratories Ltd., Mississauga, ON, Canada), and
all fractions were frozen at $80°C until use. Each protein
extract (20 !g) was separated on a 12% sodium dodecyl
sulfate polyacrylamide gel and transferred electrophoretically
to Immun-Blot PVDF membranes (Bio-Rad Laboratories).
The membranes were blocked in 5% powdered nonfat milk
in Tris-buffered saline with 0.1% Tween-20 at room temper-
ature for 1 h, then incubated overnight at 4°C in the same
solution containing primary antibodies (Table 1). Mem-
branes were washed in Tris-buffered saline with 0.1% Tween-
20, then incubated with a horseradish peroxidase-conjugated,
goat anti-rabbit or goat anti-mouse secondary antibody (1:
3000; Bio-Rad Laboratories) for 1 h at room temperature.
Peroxidase activity was visualized using an enhanced chemi-
luminescence and detection system imager (GE Healthcare
Biosciences, Piscataway, NJ, USA). Membranes were stripped
using a buffer containing 10% sodium dodecyl sulfate solu-
tion (20 ml), Tris HCl (12.5 ml, pH 6.8, 0.5M), ultrapure
water (67.5 ml) and %-mercaptoethanol (0.8 ml) at 50°C for
up to 45 min, followed by washing in ultrapure water (2 h)
then Tris-buffered saline with 0.1% Tween-20 (5 min). The
membranes were blocked and reprobed for %-actin as a
loading control.
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Figure 1. Brain biopsies in patients with PD yield
expandable primary cell cultures. A–C) Operative
images taken during DBS surgery in a patient
with PD. A) The cortical exposure was achieved
through a 14-mm burr hole and dural opening
over the frontal lobe. B) Appearance of the
brain following pial incision and brain biopsy.
C) The biopsy site was used as the entry portal
for the microelectrode array (shown) and sub-
sequent DBS lead. The biopsy tissue yielded
cultures with robust proliferative capacity and
characteristic morphology. D, E) At subconflu-
ence (D), cells were flat with broad polygonal
somata and generous cytoplasm, while at higher
densities (E), the cytoplasm was modest and
somata spindle-shaped with fine lamellipodia.
F) Cells exhibited robust expression of the
progenitor marker, nestin. Scale bars & 50 !m
(D, E); 20 !m (F).
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later. At that time, both specimens were combined as a single
tissue source for each patient and subjected to a 20-min
digestion with 0.25% trypsin (Life Technologies Inc., Burl-
ington, ON, Canada) plus DNase I (75 !g; Roche Diagnostics,
Laval, PQ, Canada) in a 5-ml volume of PBS at 37°C. After
filtering through a 100-!m cell strainer (BD Biosciences,
Mississauga, ON, Canada), the tissue was centrifuged at 1200
rpm for 10 min, then resuspended in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, 1%
nonessential amino acids, and 1% penicillin/streptomycin
before plating to a 35-mm dish for 2 h to allow blood cells to
separate (Life Technologies). The upper cell suspension was
then transferred to 2 wells of a 24-well plate, freshly precoated
with 10 !g/ml poly-l-lysine (Trevigen Inc., Gaithersburg,
MD, USA) and incubated at 37°C in a humidified 5% CO2
atmosphere. Cultures were passaged at"80% confluence and
split 1:2 using 0.25% trypsin with 0.53 mM ethylenedi-
aminetetraacetic acid (Wisent Bioproducts, St. Bruno, PQ,
Canada). The medium was changed 2#/wk. At various pas-
sages, cells were resuspended in a freezing solution of DMEM
with 20% FBS and 10% dimethyl sulfoxide. Aliquots (5#106
cells/ml) were placed in cryogenic storage vials and frozen
using a CoolCell freezing container (BioCision LLC, Mill
Valley, CA, USA) prior to transfer to a$80°C freezer or liquid
nitrogen. All immunocytochemistry, Western blot, polymer-
ase chain reaction (PCR), and fluoresc nc -act vated cell
sorting (FACS) analyses were conducted during passages 4
through 8 using cells from a minimum of 4 rand mly selected
patients for each marker.
Western blot analysis
Cells were collected in lysis buffer (50 mM Tris HCl, 150 mM
NaCl, and 1% Nonidet P40, pH 7.4) suppl mented with
SigmaFast Protease Inhibitor cocktail (1:10; Sigma-Aldrich,
St. Louis, MO, USA), incubated on ice for 15 min, and then
sonicated. The cell lysates were centrifuged at 13,000 g for 15
min, and the protein supernatant was collected. Protein
similarly isolated from a frozen sample (170 mg) of non-
pathological brain obtained from the Brain Tumor Tissue
Bank (London Health Sciences Centre, London, ON, Can-
ada), a service of the Brain Tumor Foundation of Canada
(http://www.braintumour.ca/), was used as a positive control
for neural markers not expressed in the PD cells. Protein
concentrations were determined using a DC Protein Assay kit
(Bio-Rad Laboratories Ltd., Mississauga, ON, Canada), and
all fractions were frozen at $80°C until use. Each protein
extract (20 !g) was separated on a 12% sodium dodecyl
sulfate polyacrylamide gel and transferred electrophoretically
to Immun-Blot PVDF membranes (Bio-Rad Laboratories).
The membranes were blocked in 5% powdered nonfat milk
in Tris-buffered saline with 0.1% Tween-20 at room temper-
ature for 1 h, then incubated overnight at 4°C in the same
solution containing primary antibodies (Table 1). Mem-
branes were washed in Tris-buffered saline with 0.1% Tween-
20, then incubated with a horseradis peroxidase-conjugated,
goat anti-rabbit or goat anti-mouse secondary antibody (1:
3000; Bi -Rad L b ratori s) for 1 h at room temperature.
Peroxidase activity was visualized using an enhanced chemi-
luminescence and detection system imager (GE Healthcare
Bi sciences, Piscataway, NJ, USA). M mbranes were stripped
using a buffer containing 10% sodium dodecyl sulfate solu-
tion (20 ml), Tris HCl (12.5 ml, pH 6.8, 0.5M), ultrapure
water (67.5 l) an %-mercapt ethanol (0.8 ml) at 50°C for
up to 45 min, followed by washing in ultrapure water (2 h)
then Tris-buffered salin with 0.1% Tween-20 (5 min). The
membranes we e blocked and reprobed for %-actin as a
loading control.
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expandable primary cell cultures. A–C) Operative
images taken during DBS surgery in a patient
with PD. A) The cortical exposure was achieved
through a 14-mm burr hole and dural opening
over the frontal lobe. B) Appearance of the
brain following pial incision and brain biopsy.
C) The biopsy site was used as the entry portal
for the microelectrode rray (shown) and sub-
sequent DBS lead. The biopsy tissue yielded
cultures with robust proliferative capacity and
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Flowchart	  of	  mRNA	  reprogramming	  
Protocol	  from	  MSSM	  based	  on	  Stemgent’s.	  
Mandal	  PK	  et	  al,	  Nat	  Protoc.	  2013	  Mar;	  8(3):	  568-­‐82.	  	  
Flowchart	  of	  mRNA	  reprogramming	  
Protocol	  from	  Stemgent.	  
Mandal	  PK	  et	  al,	  Nat	  Protoc.	  2013	  Mar;	  8(3):	  568-­‐82.	  	  
Generation of induced Pluripotent Stem Cells from wild-type (control) 
fibroblasts. (A) Bright-field images taken during the derivation in the new iPS 
facility of iPSCs from WT fibroblasts showing small hESC-like colonies (Day 12) 
and (B) appearance of a mature iPSC clone (Day 17). Immunocytochemical 
analysis of pluripotency marker TRA-1-60 on the same iPSC clone (Day 18). (C) 
Immunocytochemical showing expression of two additional pluripotency markers in 
iPSC clones (passage 3) after mechanical picking and expansion.  
Scale bar represents 100 µm.  
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Flowchart	  of	  Sendai	  Virus	  mediated	  reprogramming	  
Based	  on	  CytoTune™	  protocol	  from	  Invitrogen.	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  4x	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Summary	  
•  ﬁrst	  study	  in	  the	  clinical	  neurosciences	  that	  
integrates	  detailed	  neuropsychiatric	  
phenotyping,	  deep	  brain	  sQmulaQon	  for	  OCD	  
and	  clinical-­‐grade	  WGS	  with	  management	  of	  
geneQc	  results	  in	  the	  medical	  treatment	  of	  
one	  person	  with	  severe	  mental	  illness.	  
•  InvesQgaQng	  iPS	  cells	  as	  one	  more	  way	  to	  
understand	  the	  geneQc	  architecture	  and	  
phenotype.	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Q:	  How	  frequent	  can	  we	  observe	  people	  
with	  all	  three	  SNPs?	  
•  Empirical	  genotype	  frequencies:	  	  
•  1000G:	  3.20%	  (35	  out	  of	  1092,	  phenotypes	  unknown)	  	  
•  UFBR:	  4.58%	  (7	  out	  of	  153,	  including	  M.A.	  and	  M.A.’s	  father)	  
IdenQfy	  of	  Refsum	  disease	  related	  variant	  in	  Ingenuity	  
Huﬀaker	  et.al	  (2009)	  	  Nature	  Medicine	  
Huﬀaker	  et.al	  (2009)	  	  Nature	  Medicine	  
O’Rawe	  (2013)	  	  PeerJ	  
Huﬀaker	  et.al	  (2009)	  Nature	  Medicine	  
Wulﬀ	  et.al	  (2009)	  Nat.	  Rev.	  Drug	  Discovery	  
Fig	  3.	  TheoreQcal	  eﬀects	  of	  KV	  channel	  inhibitors	  and	  
acQvators	  on	  pathologically	  altered	  neuronal	  acQvity	  
Fig	  1.	  AssociaQon	  of	  risk	  SNPs	  with	  cogniQve	  measures,	  brain	  
structure	  volumes	  and	  regional	  brain	  	  acQvity	  during	  memery-­‐
based	  tasks.	  
Figure2.	  Eﬀect	  of	  KCNH2-­‐3.1	  overexpression	  in	  rat	  corQcal	  
neurons	  on	  acQon	  potenQal	  discharge	  evoked	  by	  long	  
depolarizing	  pulse	  (40	  pA,	  1	  s)	  before	  (lel)	  and	  aler	  (right)	  
applicaQon	  of	  E-­‐4031.	  
DBS:A pace-maker in this person’s brain? 
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appeared to have effects on OCD, depression, and anxiety symp-
toms, with an average reduction of 9 points on the Yale-Brown 
Obsessive Compulsive Scale (YBOCS) (42% reduction in the score), 
a reduction of 17 points on the Beck Depression Inventory (BDI) 
(55% reduction in the score), and an approximately 20-point 
reduction in the State-Trait Anxiety Inventory (STAI) (54% reduc-
tion in the score) (70). Two other smaller CM DBS studies demon-
strated similar improvements (71, 72). For the GPi target, Marti-
nez-Fernandez and colleagues demonstrated an average reduction 
of approximately 30% in the YGTSS (73). In a more recent study, 
10 of 11 patients reported improvement in tic severity with an 
overall 48% reduction in motor tics and a 56.5% reduction in pho-
nic tics at final follow-up. Six patients (54.5%) had a more than 
50% reduction (ref. 74 and see Table 2). Additionally, the nonmo-
tor target, NAc, has been explored for TS and surprisingly has 
demonstrated improvements in TS motor symptoms (69).
There are many unanswered questions in TS DBS. Does the 
altered connectivity in TS (75) explain the apparent improve-
ments in motor tics after stimulation of a “limbic” target 
(NAc DBS) (76)? Which subcomponent of the GPi should be 
targeted (73)? Advances in the treatment of TS could involve 
a head-to-head comparison of major targets (such as the GPi 
versus CM versus NAc) in order to determine not only which 
of the targets has the greatest efficacy in reducing motor tics, 
but additionally which one has the greatest efficacy in reduc-
ing the comorbid psychiatric symptoms (77). Only one study 
has attempted to answer this question, and it demonstrated 
superiority of GPi with a small number of patients (78). Future 
studies should determine ideal stimulation conditions (should 
continuous stimulation be used for a paroxysmal disorder?) (46) 
and characterize alterations in downstream neurotransmitter 
function (79). Future directions will most certainly include the 
use of closed-loop systems and may utilize a patient-controlled 
function, since tics are intermittent and the sufferer often has 
a premonitory urge (80). In the future, a TS patient may utilize 
multiple leads to treat different symptom clusters (81–83).
MDD. Depression is defined as a state of extreme sadness or 
melancholia that affects a person’s activities in daily life as well 
as social functioning. Nearly one in five people experience an epi-
sode of major depression in their lifetime, and the World Health 
Organization declared major depression one of the four most dis-
abling illnesses worldwide (84). Currently, antidepressants and/or 
psychotherapy are the mainstay of treatment, along with electro-
convulsive therapy, which is reserved for treatment-resistant indi-
viduals. DBS is being utilized in a research setting for patients who 
do not respond to conventional therapies (see Table 4).
Four main targets exist for depression DBS: the VC/VS, the sub-
callosal cingulate (SCC) (brain area 25 [BA 25]), the NAc, and the 
medial forebrain bundle (MFB) (28), although the inferior tha-
lamic peduncle (ITP) (85) and lateral habenula (86) are also poten-
tially efficacious DBS targets. All four of the major DBS targets 
for depression have been studied for treatment-resistant individu-
als, and all have demonstrated positive results in small series, but 
there are no major randomized studies comparing these targets. 
For MDD, the response is defined as greater than or equal to a 50% 
reduction in the Hamilton Depression Rating Scale score (HDRS) 
or Montgomery-Asberg Depression Rating Scale (MADRS), while 
remission is a score of “nondepressed” on HDRS or MADRS.
The SCC has been demonstrated to be an important node in the 
mood regulation circuitry (87) and a novel neurosurgical target 
for depression (21). It carries the benefit of treating both unipolar 
and bipolar depression (88) while appearing not to have the risk 
of mania seen with other depression targets (89). For SCC, an ini-
tial response rate (24–26 weeks) of 41%–66% has been reported, 
while at two to six years, the response rates increased to 64%–92% 
with remission rates of 42%–58% (90). In a different pooled analy-
sis from the same group, the initial response rate at six months 
was 46.4% (16, 88, 91, 92). Mood, interest, psychic anxiety, middle 
insomnia, and suicidality are affected by this intervention and are 
therefore primary contributors to the HDRS score improvement 
(91). The Mayberg group has demonstrated that they can isolate 
the exact white matter projections that interface with the active 
contacts of those in remission through the use of tractography 
methods. This method has shown that the SCC target is effective 
when it contacts tracts that cause downstream changes in the mid-
line thalamus, ventral pallidum, and medial frontal cortex (93). 
The long-term response rate for SCC DBS was approximately 60% 
(94). In addition to appropriate electrode placement, program-
ming parameters within this node have not been fully explored 
(95) and optimized (96). Future trials, such as the ongoing multi-
Table 1
Summary of studies of PD DBS, both DBS versus medical management and GPi DBS versus STN DBS
Study No. patients Target F/u Outcome Positive effects Outcome Negative effects
Deuschl 2006 (ref. 50) 156 STN 6 mo Significant PD symptom improvement Weight gain 
    and decrease of levadopa use and worsening of dyskinesias
Okun 2012 (ref. 165) 168 STN 3 mo Significant PD symptom improvement Dysarthria, depression, fatigue 
    and decrease of levadopa use
Schuepbach 2013 (ref. 52) 251 STN 24 mo Significant PD symptom improvement Impulse control worsening,  
    and decrease of levadopa use depression, suicide attempt
Okun 2009 (ref. 53) 52 23 GPi,  7 mo Significant PD symptom improvement Significant decrease in verbal 
  22 STN   fluency and increase in anger
Williams 2010 (ref. 51) 183 STN or GPi 12 mo Significant PD symptom improvement Psychosis, anxiety, suicide
Follett 2010 (ref. 54) 299 152 GPi,  24 mo Significant PD symptom improvement Slight decrease in 
  147 STN  and decrease of levadopa use memory function, NS
Odekerken 2012 (ref. 166) 128 65 GPi,  12 mo Significant PD symptom improvement Slight increase in 
  63 STN  and decrease of levadopa use dementia score, NS
F/u, follow-up.
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site randomized control trial (BROADEN), may potentially utilize 
parameters described above to optimize treatment delivery.
The VC/VS target could potentially treat depression through its 
apparent mood effects in individuals who received this interven-
tion for OCD. The response and remission rates of VC/VS at six 
months were 40% and 20%, respectively (97), and 71% and 35% at 
last follow-up (14–67 months) (98). The long-term response rate 
for VC/VS DBS was approximately 71% (98). A recent large study 
of VC/VS DBS conducted by the Medtronic company failed to 
show efficacy for this target; however, this could have been due to 
methodological limitations, especially in how the stimulation was 
delivered (99). One important methodological limitation in the 
study was that devices were programmed below the euphoria and 
hypomania threshold and patients could have been underdosed.
Two depression targets, the NAc and the superolateral MFB 
(slMFB), are central components of the reward system, which has 
been shown to be dysfunctional in depression (100). The response 
and remission rates of NAc are 50% and 30%, respectively, at 
12 months (101) and 45% and 9% at two years (102). A recent pilot 
study investigating the MFB target suggests that it may be part of 
the system for reward seeking with stimulation causing a state of 
positive affective excitement (103). For this small series, six out 
of seven patients attained the response criterion within days of 
stimulation activation. At last observation (12–33 weeks), six out 
of seven patients were responders and four were classified as remit-
ters (see Table 4).
Depression is a heterogenous disorder that manifests with a 
variety of symptom constellations arising from several dysfunc-
tional nodes (104) in one or several mood networks that is/are 
dysfunctional (105). DBS studies targeting the SCC (21), internal 
capsule (97), and the reward circuitry (28, 101) have shown effi-
cacy in not only severe unipolar depression, but also in individuals 
with bipolar disorder that were in an extended depressive episode 
(88). It is also clear that efficacy will increase when programming 
settings (96), the lead position in relation to the relevant circuitry 
(106), and the exact microstructural targets of modulation (93) 
are optimized. Ultimately, the DBS target choice for an individu-
al’s depression may be selected using the nature of the depressive 
symptoms (91) coupled with the side-effect profile and relevant 
comorbidities (107).
Table 2
Summary of studies of TS DBS including CM DBS and GPi DBS
Study No. patients Target F/u Outcome summary
Porta 2012 (ref. 70) 18 CM 5–6 yr Tics, OCD, depression, and anxiety significantly decreased
Ackermans 2011 (ref. 72) 6 CM 12 mo Tics significantly decreased; OCD, depression, 
    and anxiety decreased, but NS
Maciunas 2007 (ref. 71) 5 CM 3 mo Tics, OCD, depression, and anxiety decreased
Cannon 2012 (ref. 74)  11 GPi 4–30 mo 10 out of 11 had decreased TS symptoms, 
    but one did not tolera e DBS 
   and two had increased anx ety
Fernandez 2011 (ref. 73) 5 GPi 3–24 mo Tics and OCD decreased
 
Table 3
Summary of studies of OCD DBS including VC/VS DBS and STN DBS
Study No. patients Response rate F/u DBS target Outcome summary
Huff 2010 (ref. 110)  10 8/10 (80%) 12 mo Unil NAc  YBOCS, HDRS, and GAF significantly 
improved; 
      HARS improved, but NS
Abelson 2005 (ref. 112) 4 2/4 (50%) 4–23 mo Bil ant limb IC YBOCS, HARS, HDRS, 
      and GAF improved; no data about 
significance
Greenberg 2006 (ref. 113) 8 6/8 (75%) 36 mo Bil VC/VS YBOCS, HARS, HDRS, 
      and GAF significantly improved
Goodman 2010 (ref. 167)  6 4/6 (66.67%) 12 mo Bil VC/VS YBOCS an 
      HARS significantly improved
Denys 2010 (ref. 168) 16 9/16 (56.25%) 12 mo Bil NAc  YBOCS, HARS 
      and HDRS significantly improved
Jimenez-Ponce 2009 (ref. 114)  5 5/5 (100%) 12 mo Bil inf thal YBOCS, HARS, HDRS, 
      and GAF significantly improved
Greenberg 2010 (ref. 107) 26 19/26 (73.1%) 36 mo Bil VC/VS YBOCS and 
      GAF significantly improved
Chabardès 2012 (ref. 108) 4 4/4 (100%) 6 mo Bil STN YBOCS improved; 
      no data about significance
Mallet 2008 (ref. 115) 16 14/16 (87.5%) 3 mo Bil STN YBOCS and GAF significantly improved; 
      HDRS improved, but NS
Unil, unilateral; Bil, bilateral; ant limb IC, anterior limb of the internal capsule; inf thal, inferior thalamic peduncle; GAF, global assessment of function.
Downloaded on November  4, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68341
review
4550 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013
site randomized control trial (BROADEN), may potentially utilize 
parameters described above to optimize treatment delivery.
The VC/VS target could potentially treat depression through its 
apparent mood effects in individuals who received this interven-
tion for OCD. The response and remission rates of VC/VS at six 
months were 40% and 20%, respectively (97), and 71% and 35% at 
last follow-up (14–67 months) (98). The long-term response rate 
for VC/VS DBS was approximately 71% (98). A recent large study 
of VC/VS DBS conducted by the Medtronic company failed to 
show efficacy for this target; however, this could have been due to 
methodological limitations, especially in how the stimulation was 
delivered (99). One important methodological limitation in the 
study was that devices were programmed below the euphoria and 
hypomania threshold and patients could have been underdosed.
Two depression targets, the NAc and the superolateral MFB 
(slMFB), are central components of the reward system, which has 
been shown to be dysfunctional in depression (100). The response 
and remission rates of NAc are 50% and 30%, respectively, at 
12 months (101) and 45% and 9% at two years (102). A recent pilot 
study investigating the MFB target suggests that it may be part of 
the system for reward seeking with stimulation causing a state of 
positive affective excitement (103). For this small series, six out 
of seven patients attained the response criterion within days of 
stimulation activation. At last observation (12–33 weeks), six out 
of seven patients were responders and four were classified as remit-
ters (see Table 4).
Depression is a heterogenous disorder that manifests with a 
variety of symptom constellations arising from several dysfunc-
tional nodes (104) in one or several mood networks that is/are 
dysfunctional (105). DBS studies targeting the SCC (21), internal 
capsule (97), and the reward circuitry (28, 101) have shown effi-
cacy in not only severe unipolar depression, but also in individuals 
with bipolar disorder that were in an extended depressive episode 
(88). It is also clear that efficacy will increase when programming 
settings (96), the lead position in relation to the relevant circuitry 
(106), and the exact microstructural targets of modulation (93) 
are optimized. Ultimately, the DBS target choice for an individu-
al’s depression may be selected using the nature of the depressive 
symptoms (91) coupled with the side-effect profile and relevant 
comorbidities (107).
Table 2
Summary of studies of TS DBS including CM DBS and GPi DBS
Study No. patients Target F/u Outcome summary
Porta 2012 (ref. 70) 18 CM 5–6 yr Tics, OCD, depression, and anxiety significantly decreased
Ackermans 2011 (ref. 72) 6 CM 12 mo Tics significantly decreased; OCD, depression, 
    and anxiety decreased, but NS
Maciunas 2007 (ref. 71) 5 CM 3 mo Tics, OCD, depression, and anxiety decreased
Cannon 2012 (ref. 74)  11 GPi 4–30 mo 10 out of 11 had decreased TS symptoms, 
    but one did not tolerate DBS 
    and two had increased anxiety
Fernandez 2011 (ref. 73) 5 GPi 3–24 mo Tics and OCD decreased
 
Table 3
Summary of studies of OCD DBS including VC/VS DBS and STN DBS
Study No. patients Response rate F/u DBS target Outcome summary
Huff 2010 (ref. 110)  10 8/10 (80%) 12 mo Unil NAc  YBOCS, HDRS, and GAF significantly 
improved; 
      HARS improved, but NS
Abelson 2005 (ref. 112) 4 2/4 (50%) 4–23 mo Bil ant limb IC YBOCS, HARS, HDRS, 
      and GAF improved; no data about 
significance
Greenberg 2006 (ref. 113) 8 6/8 (75%) 36 mo Bil VC/VS YBOCS, HARS, HDRS, 
      and GAF significantly improved
Goodman 2010 (ref. 167)  6 4/6 (66.67%) 12 mo Bil VC/VS YBOCS an 
      HARS significantly improved
Denys 2010 (ref. 168) 16 9/16 (56.25%) 12 mo Bil NAc  YBOCS, HARS 
      and HDRS significantly improved
Jimenez-Ponce 2009 (ref. 114)  5 5/5 (100%) 12 mo Bil inf thal YBOCS, HARS, HDRS, 
      and GAF significantly improved
Greenberg 2010 (ref. 107) 26 19/26 (73.1%) 36 mo Bil VC/VS YBOCS and 
      GAF significantly improved
Chabardès 2012 (ref. 108) 4 4/4 (100%) 6 mo Bil STN YBOCS improved; 
      no data about significance
Mallet 2008 (ref. 115) 16 14/16 (87.5%) 3 mo Bil STN YBOCS and GAF significantly improved; 
      HDRS improved, but NS
Unil, unilateral; Bil, bilateral; ant limb IC, anterior limb of the internal capsule; inf thal, inferior thalamic peduncle; GAF, global assessment of function.
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OCD. OCD affects 2%–3% of the population and is character-
ized by obsessions, which have been defined as recurrent unwant-
ed ideas, images, or impulses, and compulsions, which have been 
defined as repetitive, stereotyped behaviors or mental acts that 
are often performed with the intention of neutralizing anxiety 
induced by obsessions. The variability of OCD symptoms mir-
rors its heterogeneity with respect to the response of the syn-
drome to conventional treatments such as CBT and medication. 
Following conventional treatment, 20%–40% of patients with 
OCD remain severely disabled. DBS has become an option for 
treatment-refractory OCD patients (108) initially through clini-
cal studies, then through a HDE. To date, there is still a need for 
a large, randomized controlled trial to determine the effective-
ness of DBS in OCD (109).
Several targets have been explored for OCD DBS including 
the NAc (110, 111), ALIC (112), VC/VS region (27, 107, 113), the 
ITP (114), and the STN (108, 115). An early study investigating 
ALIC as a potential target demonstrated a response rate of 50% in 
4 patients (112). Two studies have examined unilateral (110) and 
bilateral (111) NAc DBS, reporting response rates of 80% (n = 10) 
and 56% (n = 16), respectively. The VC/VS region has been elec-
trically interrogated to determine the downstream effects of such 
stimulation (116). For OCD, the VC/VS target has the most data 
and has been shown to have similar efficacy between groups with 
a 61.5% response (>35% reduction in YBOCS) (107) in a world-
wide, pooled study. STN DBS for OCD has also been reported as a 
potential target. Two studies, with 16 and 5 subjects, respectively, 
demonstrated response rates of 87.5% (115) and 100% (108), where 
response was defined as greater than 25% improvement on the 
YBOCS in the Mallet study (115) which is lower than the usual 
response criteria (ref. 116 and see Table 3).
The next critical step in the advancement of this work is to 
hone in on the exact regions that are involved in the pathogen-
esis of OCD (117, 118). A combination of structural and func-
tional imaging prior to and after implantation could potentially 
provide additional insight required to identify specific elements, 
which would allow for enhanced efficacy (119, 120). All of the 
DBS targets appear to exert their effects at least in part by alter-
ing activity in the orbital frontal cortex (OFC), anterior cingulate 
cortex (ACC), and striatum (121). OCD DBS alters neural firing 
patterns, information transmission, and coherence between dif-
ferent regions in the network (121). In the future, target selec-
tion may be guided by a combination of the major symptom 
dimensions and by neuroanatomical subtypes discovered on 
detailed neuroimaging (122, 123). Optimization of lead position 
is evolving, and better results have been observed when ALIC and 
VC/VS electrodes were moved closer to the junction of the ante-
rior capsule and the anterior commissure (107). Enrollment of 
more patients through trials instead of utilization of the HDE 
would allow further data collection (109).
Positive and negative effects of DBS
Positive neuropsychiatric effects from DBS of “motoric targets.” Ini-
tial signals that DBS may be an intervention for psychiatric 
conditions came from changes that resulted from implanting 
in the motor circuitry (124).These unintended improvements 
have shaped later inquiries into new diseases and neuroana-
tomical targets (125, 126). Patients implanted in the GPi for PD 
and tardive dyskinesia have reported improvements in mood 
(127, 128), and patients with comorbid PD and OCD have also 
had improvements in anxiety with STN DBS (125, 129). Some 
TS patients implanted in the CM thalamus unexpectedly dem-
onstrated reductions in OCD and depression symptoms (65). 
STN DBS for PD has been shown to improve alertness in some 
cohorts (130). Limbic improvements from intended motor tar-
gets may be the result of crossstimulation of nearby circuits, or 
alternatively, limbic-motor connections (125). The positive lim-
bic and motoric benefits observed from a single DBS field may 
also be produced as a disease-specific effect (131) where micro-
structural differences in the basal ganglia and limbic circuits 
may allow for a traditionally “limbic” target to modulate motor 
circuitry (ref. 132; see Table 5).
Negative neuropsychiatric effects from DBS of “motoric targets.” 
While motoric stimulation has shown some positive effects, sev-
eral negative effects have also been identified. STN DBS may 
adversely affect cognitive and limbic circuitry in some cases 
(124). A case reported by Stefurak in 2003 illustrates the dis-
sociation of mood and motor circuitry in STN DBS where a 
female patient with STN DBS would have voltage-dependent 
crying after turning on the stimulator and would stop when the 
stimulator was turned off (133). De novo impulse control disor-
der (134), mania (135), increased anger (136), worsening apathy 
(137), fatigue (138), cognitive decline (55), binge eating (139), 
worsening depression (124), de novo psychosis (124), and sui-
cidality (140) all appear to be uncommon, but possible effects. 
While verbal fluency has been shown to be affected in STN DBS, 
Table 4
Summary of studies of depression DBS including NAc, VC/VS DBS and SCC DBS
Study F/u HDRS MADRS GAF Clinical global HAMA 
     impression
Bewernick 2012 (ref. 102) 24 mo Improved Improved No data No data Improved 
  significantly significantly   significantly
Malone 2009/2010 (refs. 97 and 98) 12 mo Improved Improved Improved No data No data 
  significantly significantly significantly
Holtzheimer 2012 (ref. 88)  24 mo Improved No data Improved No data No data 
  significantly  significantly
Lozano 2012 (ref. 92) 12 mo Improved No data No data Improved No data 
  significantly   significantly
Lozano 2008 (ref. 16) 12 mo Improved No data No data Improved No data 
  significantly   significantly
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Psychiatric neurosurgery teams in the United States and Europe have studied deep brain
stimulation (DBS) of the venlral anterior l imb of the internal capsule and adjacent ventral
striatum (VC^/S) for severe and highly treatment-resistant obsessive-compulsive disorder.
Four groups have collaborated most closely, in small-scale studies, over the past 8 years. First
to begin was Leuven/Antwerp, followed by Butler Hospital/Brown Medical School, the
Cleveland Clinic and most recently the University of Florida. These centers used comparable
patient selection criteria and surgical targeting. Targeting, but not selection, evolved during
this period. Here, we presenl combined long'term results of those studies, which reveal
clinically significant symptom reductions and functional improvement in about two-thirds of
patients. DBS was well tolerated overall and adverse effects were overwhelmingty transient.
Results generally improved for patients implanted more recently, suggesting a ' learning curve'
both within and across centers. This is well known from lhe development of DBS for movement
disorders. The main factor accounting for these gains appears to be the refinement of the
implantation site. Init ially, an anterior-posterior location based on anterior capsulotomy
lesions was used. In an attempt to improve results, more posterior sites were investigated
resulting in the current target, at the junction of the anterior capsule, anterior commissure and
posterior ventral striatum. Clinical results suggest that neural networks relevant to therapeutic
improvement might be modulated more effectively at a more posterior target. Taken together,
lhese data show that the procedure can be successfully implemented by dedicated
interdisciplinary teams, and support its therapeutic promise.
Molecular Psychiatry advance online publication, 20 May 2008; doi:10.1038/mp.2008.55
Keywords: deep brain stimulation; obsessive-compulsive disorder; internal capsule; ventral
striatum; learning curve
affected fail to obtain adequate relief despite years of
conventional behavioral and d*g therapies. After
exhausting these treatments, the remaining therapeutic
option was ablative sugery including anterior capsulo-
tomv (review Greenberg ef o1.r) and anterior cingulotomy,
Dougherty ef o/.' used for over 40 years.
Deep bra in s t imulat ion (DBS) has emerged as a
well-accepted alternative to ablative procedures for
movement d isorders such as Park inson's  d isease and
dystonia. It is currently being investigated for highly
resistant OCD. Srnall-scale use in controlled'-t or
open studiesn-"  have suggested therapeut ic  promisc.
Although DBS has been applied at several locations
along the rostral-caudal extent of the anterior l imb of
Deep brain stimulation of the ventral internal
capsule/ventral striatum for obsessive-compulsive
disorder: worldwide experience
Introduction
In its most severe and treatment-resistant form,
obsessive-compulsive disorder (OCD) results in
marked suffering and impairment in self-care, education,
work and social life. Sorne patients who are severely
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it appears that GPI DBS does not have as large an effect on flu-
ency (141). In many cases these side effects are reversible (133) 
and may be stimulation related (142), resolving when the DBS is 
turned off (133). Some of these cases may be related to lead posi-
tion and stimulation parameters. Some effects (e.g. verbal flu-
ency) may be related to the surgery itself (i.e., microlesion effect). 
Optimization may lead to motor and nonmotor improvements 
(refs. 143, 144; see Table 5).
Positive neuropsychiatric effects from DBS of “limbic based targets.” 
The NAc target was presumed to have an antianxiety effect, and 
because of improvements in OCD, it was hypothesized to have 
an independent antidepressant effect (102). Unintended improve-
ments for other comorbid disorders have led to expansion of the 
potential neuropsychiatric DBS indications. Acute changes in 
memory were associated with unintended stimulation of the for-
nix in an intervention whose intent was to stimulate the lateral 
hypothalamus for obesity (126). DBS in the lateral hypothala-
mus was ineffective for obesity in that study, but utilization of 
novel programming techniques demonstrated efficacy in a later 
study (145). NAc DBS has also resulted in weight loss, and there 
are some reports of improvements in recreational drug use for 
patients receiving this treatment for OCD (ref. 146; see Table 5). 
The NAc is also a potential target for the treatment of addiction 
(147), and patients with comorbid OCD and addiction demon-
strated reductions in addictive behaviors (148, 149). The addic-
tion-like behaviors that have shown improvement include alcohol 
intake, nicotine dependence, and opiate use (149, 150).
Negative neuropsychiatric effects from DBS of “limbic targets.” Mania 
is one of the most concerning negative neuropsychiatric effects 
resulting from DBS (89), but paradoxical worsening of anxiety 
and depression has also been reported (151).Feelings of suicidal-
ity can emerge; however, it is unclear whether these feeling are the 
result of the stimulation itself or of an augmentation of a preim-
plantation suicidality. Feelings of irritability and anger have been 
reported (53, 136, 152). Cognitive dysfunction at high amplitudes 
has been observed with BA 25 DBS along with the occurrence 
of paradoxical worsening of depressive symptoms (21). Limbic 
STN DBS for OCD has been associated with hypomania, anxiety, 
impulsiveness, depression symptoms, and obsessive-compulsive 
thoughts (ref. 152 and see Table 5).
Table 5
Positive/negative neuropsychiatric effects from motoric/limbic DBS
Study Symptom Effect Comments
Kosel et al. 2007A (ref. 127) Depression Improvement Case report with 1 patient
Damier et al. 2007A (ref. 128) Depression Improvement in 1 of 10 
Fontaine et al. 2004 (ref. 125) OCD improvement Case report with 1 patient
Okun 2009 (ref. 53) Happy mood Increase NS
  Sad mood Decrease NS
  Tense mood Increase NS
Graff-Radford 2010 (ref. 169)  Tense mood Decrease Significant
Moum 2012 (ref. 134) ICD Resolved in 2 and appeared de novo in 2 2 out of 6 patients for both
  DDS no change 
  Both no change 
Chopra 2012 (ref. 135) Mania Resolved 12 out of 14 patients
Kluger 2012 (ref. 138) Fatigue 58% of patients 
Voon 2008 (ref. 140) Suicidal ideation 0.45% (24/5311) after DBS 
  Suicide attempt 0.90% (48/5311) after DBS 
Zahodne 2011 (ref. 139)  Binge eating Increased 
  Subthreshold BED increased 
Burdick 2011 (ref. 136) Anger Increased after STN, GPi;  
   decreased after VIM
  Confusion Increased after GPi, decreased after VIM 
Kirsch-Darrow 2011 (ref. 137) Apathy Increased in middle aged,  
   not in older patients
Kuhn 2007 (ref. 148) Alcohol abuse Cessation Case report with 1 patient
Kuhn 2009 (ref. 170) Smoking Cessation 3 out of 10
Mantione 2010 (ref. 146) Smoking, overeating Cessation Case report with 1 patient
Zhou 2011 (ref. 171) Heroin abuse Cessation Case report with 1 patient
  Smoking Decrease 
Valencia-Alfonso 2012 (ref. 172) Heroin abuse Cessation Case report with 1 patient
Shapira 2006 (ref. 151) panic Reproducible with stimulation Case report with 1 patient 
   of ventral-most contacts
Haq 2010 (ref. 89) OCD, mania Present with specific DBS settings Case report with 1 patient
Flaherty 2004 (ref. 173) Mania High voltage in dorsal-most contacts Case report with 1 patient
  Depression, apathy High voltage in ventral-most contacts 
Nuttlin 2002 (ref. 174)  Memory function Decrease 1 out of 4
  Hypomania Present with specific DBS settings 2 out of 4
  Fear Present with specific DBS settings 
ICD, impulse control disorder; DDS, dopamine dysregulation syndrome; BED, binge eating disorder; VIM, ventral intermediate nucleus of the thalamus.
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Table 2 Published reports on deep brain stimulation for obsessive-compulsive disorder (OCD) and treatment-resistant depression (TRD) showing
anatomic targeta and numberb of cases treated
ALIC NAc VC/VS SCG ITP STN HAB
OCD N = 4 (1); N = 4 (27);
N = 1 (49); N = 1
(73); N = 1 (15);
N = 1 (51)
N = 2 (74); N = 2 (75);
N = 5 (76); N = 16
(28); N = 1 (49);
N = 10 (30)
N = 6 (29); N = 21 (32);
N = 1 (77)
– N = 5 (78) N = 16 (31) –
Totals N = 12 N = 36 N = 28 – N = 5 N = 16 –
TRD – N = 3 (79);
N = 10 (80)
N = 15 (45) N = 20 (46);
N = 1 (81)
N = 1 (47) – N = 1 (48)
Totals – N = 13 N = 15 N = 21 N = 1 – N = 1
Abbreviations: ALIC, anterior limb of the internal capsule; OCD, obsessive-compulsive disorder; TRD, treatment-resistant depression; SCG, subcallosal cingulate gyrus (Brodmann’s area 25);
VC/VS, ventral capsule/ventral striatum; ITP, inferior thalamic peduncle; STN, subthalamic nucleus; NAc, nucleus accumbens; HAB, lateral habenula.
aAlthough the ALIC, VC/VS, and NAc are labeled as different targets, there is considerable overlap in these areas. Moreover, the actual position of the active electrode contact (or contacts),
the specific stimulating lead used (which can differ in contact spacing), and the characteristics of the stimulation field account for considerable variance within a given intended target. For the
purpose of this review, the name of the target used in each publication is retained, but it should be understood these targets might not be as distinct as the different names imply.
bBecause counting the number of unique cases in the literature is challenging, these figures should be considered approximate. For example, some articles on long-term follow-up may not be
clear as to how many cases are included from previous reports on acute response.
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Abstract
Deep brain stimulation (DBS) has virtually replaced ablative neuro-
surgery for use in medication-refractory movement disorders. DBS is
now being studied in severe psychiatric conditions, such as treatment-
resistant depression (TRD) and intractable obsessive-compulsive disor-
der (OCD). Effects of DBS have been reported in ∼100 cases of OCD
and ∼50 cases of TRD for seven (five common) anatomic targets. Al-
though these published reports differ with respect to study design and
methodology, the overall response rate appears to exceed 50% in OCD
for some DBS targets. In TRD, >50% of patients responded during
acute and long-term bilateral electrical stimulation in a different target.
DBS was generally well tolerated in both OCD and TRD, but some
unique, target- and stimulation-specific adverse effects were observed
(e.g., hypomania). Further research is needed to test the efficacy and
safety of DBS in psychiatric disorders, compare targets, and identify
predictors of response.
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Fig.	  1.	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Three-Year Outcomes in Deep Brain Stimulation for Highly
Resistant Obsessive–Compulsive Disorder
Benjamin D Greenberg*,1,2, Donald A Malone3,4, Gerhard M Friehs1,2, Ali R Rezai3,4, Cynthia S Kubu3,4,
Paul F Malloy1,2, Stephen P Salloway1,2, Michael S Okun5,6, Wayne K Goodman5,6 and Steven A Rasmussen1,2
1Departments of Psychiatry and Human Behavior, Brown Medical School, Butler Hospital and Rhode Island Hospital, Providence, RI, USA;
2Department of Clinical Neurosciences (Neurosurgery Division), Brown Medical School, Butler Hospital and Rhode Island Hospital, Providence,
RI, USA; 3Department of Psychiatry, Cleveland Clinic Foundation, Cleveland, OH, USA; 4Center for Neurological Restoration, Cleveland Clinic
Foundation, Cleveland, OH, USA; 5Departments of Psychiatry and Neurology, University of Florida, Gainesville, FL, USA; 6Movement Disorders
Center, University of Florida, Gainesville, FL, USA
Deep brain stimulation (DBS) of the anterior limb of the internal capsule has been shown to be beneficial in the short term for
obsessive–compulsive disorder (OCD) patients who exhaust conventional therapies. Nuttin et al, who published the first DBS for OCD
series, found promising results using a capsule target immediately rostral to the anterior commissure extending into adjacent ventral
capsule/ventral striatum (VC/VS). Published long-term outcome data are limited to four patients. In this collaborative study, 10 adult
OCD patients meeting stringent criteria for severity and treatment resistance had quadripolar stimulating leads implanted bilaterally in the
VC/VS. DBS was activated openly 3 weeks later. Eight patients have been followed for at least 36 months. Group Yale-Brown Obsessive
Compulsive Scale (YBOCS) scores decreased from 34.670.6 (mean7SEM) at baseline (severe) to 22.372.1 (moderate) at 36 months
(po0.001). Four of eight patients had aX35% decrease in YBOCS severity at 36 months; in two patients, scores declined between 25
and 35%. Global Assessment of Functioning scores improved from 36.671.5 at baseline to 53.872.5 at 36 months (po0.001).
Depression and anxiety also improved, as did self-care, independent living, and work, school, and social functioning. Surgical adverse
effects included an asymptomatic hemorrhage, a single seizure, and a superficial infection. Psychiatric adverse effects included transient
hypomanic symptoms, and worsened depression and OCD when DBS was interrupted by stimulator battery depletion. This open study
found promising long-term effects of DBS in highly treatment-resistant OCD.
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INTRODUCTION
Severe, treatment-resistant obsessive–compulsive disorder
(OCD) is a chronic, debilitating disorder, imposing
considerable suffering and markedly impairing affected
individuals’ ability to work, interact socially, or live
independently. Therapeutic options in this group were
previously limited to ablative surgery, such as anterior
capsulotomy (see review by Greenberg et al, 2003) or
anterior cingulotomy (Dougherty et al, 2002). Beginning
with the work of Nuttin et al, small-scale controlled (Nuttin
et al, 1999, 2003b; Gabriels et al, 2003; Abelson et al, 2005)
and open studies (Anderson and Ahmed, 2003; Aouizerate
et al, 2004; Sturm et al, 2003; Aouizerate et al, 2005) have
suggested that deep brain stimulation (DBS) of the internal
capsule and/or the adjacent ventral striatal region may be of
benefit to severely affected OCD patients who have
exhausted conventional therapies. The implantation sites
were all generally similar to those for anterior capsulotomy
lesions, but the specific targets, surgical approaches, and
electrode designs have varied. The specific target used by
Nuttin et al, whose results have been particularly promising,
was based in part on our own gamma knife capsulotomy
work (Rasmussen, in preparation). The target for gamma
capsulotomy is within the ventral half of the anterior limb of
the internal capsule, impinging inferiorly on the ventral
striatum. We refer to it as the ventral capsule/ventral
striatum (VC/VS) site. Determining the long-term efficacy
and safety outcomes of VC/VS, DBS are particularly
important in determining its viability as a therapy. Long-
term effects of VC/VS DBS have been reported in a single
published study totaling three patients who had DBS for at
least 21 months (Nuttin et al, 2003b). The purpose of this
study was to examine the outcomes of DBS over 3 years in
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Three-Year Outcomes in Deep Brain Stimulation for Highly
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Deep brain stimulation (DBS) of the anterior limb of the internal capsule has been shown to be beneficial in the short term for
obsessive–compulsive disorder (OCD) patients who exhaust conventional therapies. Nuttin et al, who published the first DBS for OCD
series, found promising results using a capsule target immediately rostral to the anterior commissure extending into adjacent ventral
capsule/ventral striatum (VC/VS). Published long-term outcome data are limited to four patients. In this collaborative study, 10 adult
OCD patients meeting stringent criteria for severity and treatment resistance had quadripolar stimulating leads implanted bilaterally in the
VC/VS. DBS was activated openly 3 weeks later. Eight patients have been followed for at least 36 months. Group Yale-Brown Obsessive
Compulsive Scale (YBOCS) scores decreased from 34.670.6 (mean7SEM) at baseline (severe) to 22.372.1 (moderate) at 36 months
(po0.001). Four of eight atients had aX35% decrease in YBOCS severity at 36 months; in two patients, scores declined betwee 25
and 35%. Global Assessment of Functioning sc res improved from 36.671.5 at baseline to 53.872.5 at 36 months (po0.001).
Depression and anxiety also improved, as did self-car , independent living, and ork, school, and social functioning. Surgical adverse
effects included an asymptomatic hemorrhag , a single seizure, and a superficial infection. Psychiatric adverse effects included transient
hypomanic symptoms, and worsened depression and OCD when DBS was interrupted by stimulator battery depletion. This open study
found promising long-term effects of DBS in highly treatment-resistant OCD.
Neuropsychopharmacology (2006) 31, 2384–2393. doi:10.1038/sj.npp.1301165; published online 19 July 2006
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INTRODUCTION
Severe, treatment-resistant obse siv –compulsive disorder
(OCD) is a chronic, debilit ting disorder, imposing
considerable suffering a markedly impa ring affected
individuals’ ability to work, in ract socially, or live
independently. Therapeutic options in this group were
previously limited to ablative surgery, such as ant rior
capsulotomy (see review by Greenberg al, 2003) or
anterior cingulotomy (Dougherty et al, 2002). Beginning
with the work of Nuttin et al, small-scale controlled (Nuttin
et al, 1999, 2003b; Gabriels et al, 2003; Abelson et al, 2005)
and open studies (Ander on and Ahmed, 2003; Aouizerate
et al, 2004; Sturm et al, 2003; Aouizerate t al, 2005) have
suggested that deep brain s imulation (DBS) of the internal
capsule and/or the adj cent ventral str atal region may be of
benefit to severely affected OCD patients who have
exhausted conventional therapies. The implantation sites
were all generally similar to those for nterio capsulotomy
lesions, but the specific targets, surgical approach s, and
electrode designs have v ried. The specific target used by
Nuttin et al, whose results h ve been particularly promising,
was based in part on our wn gamma knife capsulotomy
work (Rasmussen, in prepar tion). The target for gamma
capsulotomy is within the ventral half of he anterior limb of
the internal capsule, impinging infer orly on the ven ral
striatum. We refer to it as the ventral capsule/ventral
striatum (VC/VS) site. Determining the long-term efficacy
and safety outcomes of VC/VS, DB are particularly
important in determining its viability as a th ra y. Long-
term effects of VC/VS DBS have been reported in a single
published study totaling three patients who had DBS for at
least 21 months (Nuttin et al, 2003b). The purpose of this
study was to examine the outcomes of DBS over 3 years in
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patients with severe, treatment-resistant OCD, in multiple
domains of interest. These included severity of core OCD
symptoms, affective and non-OCD anxiety pathology
commonly comorbid with OCD, and global functioning.
PATIENTS AND METHODS
This was a collaborative study including the psychiatric
neurosurgery groups at Butler Hospital (BH)/Brown Med-
ical School and the Cleveland Clinic (CC). Each site enrolled
five adult patients beginning in February 2001 after IRB and
FDA Investigational Device Exemption approvals were
obtained at each site. Patient selection was based on the
criteria developed to determine eligibility for neurosurgery
for otherwise intractable OCD (Dougherty et al, 2002) and
followed the guidelines of the DBS for OCD Collaborative
Group (Nuttin et al, 2003a).
Detailed patient screening, record review, interviews with
treating clinicians, and baseline assessments were used to
assure that OCD was the primary diagnosis (using the
Structured Clinical Interview for DSM-IV) (First et al,
2001). The minimum level of OCD severity required for
entry was a Yale-Brown Obsessive Compulsive Scale
(YBOCS; Goodman et al, 1989) score of 28. Treatment
resistance was defined as failure to obtain meaningful OCD
improvement after pharmacotherapy, including adequate
trials (X3 months, with doses at or, if tolerated, beyond the
FDA maximum recommended dose) of at least three
serotonin reuptake inhibitors (SRIs), one of which had to
be clomipramine. Trials of augmentation of an SRI with a
neuroleptic and with a benzodiazepine were required, as
was a minimum of 20 sessions of therapist-guided behavior
therapy (exposure and response prevention). In practice, all
patients exceeded the number of treatments required to
satisfy this entry criterion. In no case did sustained efforts
at behavior therapy plus pharmacotherapy reduce symp-
toms to a tolerable level. All patients had chronic OCD,
ranging from 11 to 39 years in duration. Patients were
excluded if there was a history of a current or past psychotic
disorder, a manic episode within the preceding 3 years, any
current clinically significant neurological disorder or
medical illness (except for tic disorders), any clinical
significant abnormality on preoperative magnetic resonance
imaging (MRI), any labeled DBS contraindication and/or
inability to undergo presurgical MRI, current or unstably
remitted substance abuse or dependence, pregnancy or lack
of use of effective contraception in women of childbearing
age, a clinical history of severe personality disorder,
inability to adhere to the operational requirements of the
study, and imminent suicidal risk. At each site, the
evaluations and consent process were reviewed by an
independent committee (including psychiatrists who were
not connected with the study), which made final eligibility
determinations. All patients were informed that lesion
procedures, specifically gamma knife capsulotomy or
anterior cingulotomy, were potential alternative treatments.
Patients (Table 1) were aged 21–58 (six men and four
women). Presurgical baseline severity on the YBOCS was
32–38 (mean7SEM: 34.670.6), and did not differ between
the BH and CC groups. Eight of 10 patients had comorbid
DSM-IV major depression. The BH patients scored
significantly higher on the 24-item Hamilton Rating Scale
for Depression (Hamilton 1967; HRSD-24; overall range:
16–29; BH mean: 25.2; CC mean: 17.0; F (1,8)¼ 32.96,
po0.001).
Of the 10 patients implanted, one died (owing to
recurrent breast cancer) 9 months after implantation. Her
data are not carried forward in the analysis. Eight patients
have reached the 36-month rating point, whereas one has
Table 1 Patient Characteristics
Patient Age at surgery, gender OCD onset OCD duration Baseline YBOCS Primary symptoms MDD?
BH1 32, M 10 22 32 CK, AR, CTM, PF Y
BH2 40, F 16 24 34 WSH, INC, HRD Y
BH3 39, M 12 27 35 CK, AR, GR, INC Y
BH4 26, F 15 11 34 INC, PF Y
BH5 32, M 10 22 33 CTM, DT, RE Y
CC1a 59, F 19 40 38 CK, FH, CTM N
CC2 35, F 12 23 36 INC, RP Y
CC3 22, M 8 14 35 SYM, INC, OFF, WSH Y
CC4 23, M 7 16 33 CK, SYM Y
CC5 45, M 19 26 36 INC, CTM N
Mean 35.3 years 12.8 years 22.5 years 34.6
Min 22 7 11 32
Max 59 19 40 38
BH¼ Butler Hospital; CC¼Cleveland Clinic.
OCD symptom abbreviations: CK¼ checking; AR¼ arranging/ordering; CTM¼ contamination fears; PF¼ perfectionism; WSH¼washing; MDD¼ comorbid DSM-IV
depression; INC¼ ‘incompleteness’ (Rasmussen and Eisen, 1992); HRD¼ hoarding; GR¼ grooming rituals; DT¼ doubt; RE¼ reassurance seeking; FH¼ fear of
harming others; RP¼ repeating; SYM¼ symmetry obsessions/compulsions; OFF¼ fear of offending others.
aPatient CC1 died of recurrent breast cancer at 9 months. Her data were not carried forward in the analysis.
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Comorbid Depressive and Anxiety Symptoms
Figure 3 shows changes in ratings on the 24-item HDRS-24
(top) and HARS (bottom) during DBS. At presurgical
baseline, HDRS-24 mean (7SEM) was 21.171.5. Three
weeks after implantation, but before stimulation, scores
were 19.972.0. Depression scores decreased to 14.772.1 by
3 months, after which they remained essentially stable. At
36 months, HDRS-24 scores were 15.472.6 (repeated
measures ANOVA for time: F (9,63)¼ 2.53; p¼ 0.015).
Anxiety measured by the HARS also improved during long-
term DBS. HARS scores were 18.271.9 at presurgical
baseline, decreasing to 13.171.8 3 weeks after implantation
(before DBS began). After 3 months of DBS, mean HARS
ratings were 9.071.4. After that they changed little. At 36
months, HARS scores were 8.071.9 (repeated measures
ANOVA for time: F (9,63)¼ 5.70; po0.001).
Global Functioning
Figure 4 shows that mean scores on the GAF improved
significantly over time during long-term DBS, from 36.671.5
at presurgical baseline to 53.872.5 at 36 months (repeated
measures ANOVA: F (9,63)¼ 7.57; po0.001). Table 3 in-
cludes a description of functioning before and after stimula-
tion in four categories: work or school, ADLs, ability to live
independently, and social engagement. No patient was
working or in school before DBS; six were during chronic
stimulation. Ability to perform ADLs independently was
markedly impaired in seven patients at baseline; this was true
of one patient during DBS. No patient lived independently
before DBS, whereas six did so afterwards. With the exception
of the patient who died owing to recurrent breast cancer 9
months after implantation, social engagement improved in
eight of nine patients, to varying degrees ranging from greater
social contact to becoming engaged to marry.
Adverse Effects
Potential complications of DBS can be separated into those
related to surgical implantation, device failure, and the
stimulation itself. There were no device failures beyond the
expected stimulation interruptions owing to INS battery
depletion or owing to device shutoff if the magnetic switch
on the Soletra INS device was tripped by a metal or theft
detector.
Adverse effects of implantation. One patient had a small
asymptomatic intracerebral hemorrhage after lead inser-
tion. This appeared to result from blood from a ruptured
superficial bridging vein tracking down the insertion guide
cannula. The hemorrhage resolved on repeat CT scans
within days after implantation; no clinical intervention was
Table 2 Categorical Responses during Long-Term DBS for OCD
DBS
duration
o25%
YBOCS k
(no. of pts, %)
X25 o35%
YBOCS k
(no. of pts, %)
X35%
YBOCS k
(no. of pts, %)
Total
N
1 month 7 (70) 2 (20) 1 (10) 10
3 months 5 (50) 2 (20) 3 (30) 10
6 months 4 (40) 4 (40) 2 (20) 10
12 months 4 (44) 2 (22) 3 (33) 9
18 months 3 (33) 3 (33) 3 (33) 9
24 months 2 (22) 3 (33) 4 (44) 9
30 months 3 (38) 1 (12) 4 (50) 8
36 months 2 (25) 2 (25) 4 (50) 8
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Comorbid Depressive and Anxiety Symptoms
Figure 3 shows changes in ratings on the 24-item HDRS-24
(top) and HARS (bottom) during DBS. At presurgical
baseline, HDRS-24 mean (7SEM) was 21.171.5. Three
weeks after implantation, but before stimulation, scores
were 19.972.0. Depression scores decreased to 14.772.1 by
3 months, after which they remained essentially stable. At
36 months, HDRS-24 scores were 15.472.6 (repeated
measures ANOVA for time: F (9,63)¼ 2.53; p¼ 0.015).
Anxiety measured by the HARS also improved during long-
term DBS. HARS scores were 18.271.9 at presurgical
baseline, decreasing to 13.171.8 3 weeks after implantation
(before DBS began). After 3 months of DBS, mean HARS
ratings were 9.071.4. After that they changed little. At 36
months, HARS scores were 8.071.9 (repeated measures
ANOVA for time: F (9,63)¼ 5.70; po0.001).
Global Functioning
Figure 4 shows that mean scores on the GAF improved
significantly over time during long-term DBS, from 36.671.5
at presurgical baseline to 53.872.5 at 36 months (repeated
measures ANOVA: F (9,63)¼ 7.57; po0.001). Table 3 in-
cludes a description of functioning before and after stimula-
tion in four categories: work or school, ADLs, ability to live
independently, and social engagement. No patient was
working or in school before DBS; six were during chronic
stimulation. Ability to perform ADLs independently was
markedly impaired in seven patients at baseline; this was true
of one patient during DBS. No patient lived independently
before DBS, whereas six did so afterwards. With the exception
of the patient who died owing to recurrent breast cancer 9
months after implantation, social engagement improved in
eight of nine patients, to varying degrees ranging from greater
social contact to becoming engaged to marry.
Adverse Effects
Potential complications of DBS can be separated into those
related to surgical implantation, device failure, and the
stimulation itself. There were no device failures beyond the
expected stimulation interruptions owing to INS battery
depletion or owing to device shutoff if the magnetic switch
on the Soletra INS device was tripped by a metal or theft
detector.
Adverse effects of implantation. One patient had a small
asymptomatic intracerebral hemorrhage after lead inser-
tion. This appeared to result from blood from a ruptured
superficial bridging vein tracking down the insertion guide
cannula. The hemorrhage resolved on repeat CT scans
within days after implantation; no clinical intervention was
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DBS
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(no. of pts, %)
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Figure 3 shows changes in ratings on the 24-item HDRS-24
(top) and HARS (bottom) during DBS. At presurgical
baseline, HDRS-24 mean (7SEM) was 21.171.5. Three
weeks after implantation, but before stimulation, scores
were 19.972.0. Depression scores decreased to 14.772.1 by
3 months, after which they remained essentially stable. At
36 months, HDRS-24 scores were 15.472.6 (repeated
measures ANOVA for time: F (9,63)¼ 2.53; p¼ 0.015).
Anxiety measured by the HARS also improved during long-
term DBS. HARS scores were 18.271.9 at presurgical
baseline, decreasing to 13.171.8 3 weeks after implantation
(before DBS began). After 3 months of DBS, mean HARS
ratings were 9.071.4. After that they changed little. At 36
months, HARS scores were 8.071.9 (repeated measures
ANOVA for time: F (9,63)¼ 5.70; po0.001).
Global Functioning
Figure 4 shows that mean scores on the GAF improved
significantly over time during long-term DBS, from 36.671.5
at presurgical baseline to 53.872.5 at 36 months (repeated
measures ANOVA: F (9,63)¼ 7.57; po0.001). Table 3 in-
cludes a description of functioning before and after stimula-
tion in four categories: work or school, ADLs, ability to live
independently, and social engagement. No patient was
working or in school before DBS; six were during chronic
stimulation. Ability to perform ADLs independently was
markedly impaired in seven patients at baseline; this was true
of one patient during DBS. No patient lived independently
bef re DBS, whereas six did so afterwards. With the exception
of the patient who died owing to recurrent breast cancer 9
months after implantation, social engagement improved in
eight of nine patients, to varying degrees ranging from greater
social contact to becoming engaged to marry.
Adverse Effects
Potential complications of DBS can be separated into those
related to surgical implantation, device failure, and the
stimulation itself. There were no device failures beyond the
expected stimulation interruptions owing to INS battery
depletion or owing to device shutoff if the magnetic switch
on the Soletra INS device was tripped by a metal or theft
detector.
Adverse effects of implantation. One patient had a small
asymptomatic intracerebral hemorrhage after lead inser-
tion. This appeared to result from blood from a ruptured
superficial bridging vein tracking down the insertion guide
cannula. The hemorrhage resolved on repeat CT scans
within days after implantation; no clinical intervention was
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our collaborative group. That experience, and the results of
our intra- and postoperative testing converged to indicate
that the best combination of therapeutic benefit and
tolerability was generally achieved when the ventral
contacts (0 and/or 1) were active and negative, although
in three patients, contact 2, more dorsal in the capsule, was
active as well. Across patients, DBS frequency was 100–
130Hz, pulse width was 90–210 ms, and amplitude 8–17mA.
Charge density always remained below the FDA limit of
30 mC/cm2. The following electrode contacts were active and
negative: 0 (8/10 patients), 1 (7/10 patients), and 2 (3/10
patients). Electrode configurations were bipolar (using
contact 3 as the anode) in six patients, and monopolar in
four. Stimulation was continuous. It was bilateral in 8/10
patients, and unilateral in 2/10 (left and right unilateral in
one patient each).
Patients were closely monitored for deterioration in
psychiatric status or stimulation-related adverse effects
throughout. DBS continued until it was interrupted by
stimulator battery depletion, which occurred over a range of
5.5–13 months after the start of chronic DBS across patients.
After INS depletion, the devices were replaced in utpatient
surgery under local anesthesia.
Concomit nt Therapies
As DBS was used as an adjunctive treatment in a severely
affected group, concomitant pharmacotherapy was allowed.
Medications were held constant f r at l ast 3 months: SRI
(7/10 patient ); benzodiazepine (5/10); typical neuroleptic
(2/10); atypical neuroleptic (4/10); and anticonvulsant (2/
10). Patients were also allowed to continue behavior therapy
if established at least months before implantation. Medica-
tion changes and new or resumed behavior therapy were
allowed beginning 6 months after stimulation began. In
practice, patients with at least a 25% improvement in
YBOCS OCD severity at 36 months received a mean of
3.470.9 psychotropic medications at presurgical baseline,
and 2.970.6 at 36 months; in contrast, patients who failed
to improve were on a mean of 3.070 psychotropics at
baseline, and 6.071.0 medications at 36 months.
Outcome Measures
Data were collected at presurgical baseline, after about 3
weeks of postoperative recovery, but before DBS began, and
then at 1, 3, 6, 16, 18, 24, 30, and 36 months of chronic DBS.
Ratings were made by one study nurse at each study site,
who was not aware of DBS parameters. The primary
outcome measure was the YBOCS. Sco es wer analyzed
as a continuous outcome with repeated-measures analysis
of variance (ANOVA, two-tailed). YBOCS OCD severity was
also assessed categorically at each rating point.
As clinical experience indicates that depression and
anxiety symptoms are highly comorbid with otherwise
intractable OCD patients who present for surgery, we used
the Hamilton Depression Rating Scale (HDRS)-24 and the
Hamilton Anxiety Rating Scale (HARS; Hamilton, 1959) as
secondary instruments, analyzed with repeated-measures
ANOVA. Global functional status was assessed with the
Global Assessment of Functioning (GAF; Hall, 1995) as a
continuous measure using repeated-measures ANOVA.
Functional outcomes were also assessed descriptively in
four categories: occupation, activities of daily living (ADLs),
independent living, and social engagement. Cognitive
functioning was assessed before implantation and after
chronic DBS with a neuropsychological battery including
measures of IQ, visuomotor speed and mental flexibility,
verbal and visual learning, memory, and conceptual reason-
ing. A brief summary of these results is presented below;
they are discussed in detail in a forthcoming manuscript
(Kubu et al, in preparation).
RESULTS
OCD Severity after Chronic DBS
Figure 2 shows that the mean preimplantation baseline
YBOCS score (7SEM) was 34.670.6, indicating severe
illness. At 3 weeks postoperatively, just before stimulation
began, scores were 33.371.0, indicating no effect of lead
insertion alone on OCD severity several weeks after
implantation. YBOCS scores decreased during DBS, reach-
ing 22.372.1 at 36 months (repeated measu overall
ANOVA for time: F (9,6 )¼ 7.47; po0.001). Most of the
improvement occurred ov the first months of stimulation;
mean YBOCS was 2571.6 at 3 months.
We used a categorical approach to examine changes in
YBOCS at the individual level. Table 2 shows the number of
study patients in each of three, mutually exclusive,
categories from 1 to 36 months after the start of chronic
DBS. Those with less than a 25% reduction in YBOCS
compared to pr surgical baseline are at left, those with
between a 25 nd 35% YBOCS reduc ion in the cent r, and
those with a 35% or greater YBOCS reduction re at right.
The total N in the right-most column reflects that one
patient of the original 10 died (of recurrent cancer) at 9
months, and one patient has just reached the 24-month
rating as of this report. The number of responders using the
35% YBOCS criterion increased from one of 10 at 1 month
to four of eight at 36 months. The number of patients with
less than a 25% decrease in YBOCS declined from seven of
10 at 1 month o two of eight a 36 months.
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Figure 2 OCD severity (YBOCS) during long-term DBS.
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required. Another patient had a single intraoperative
generalized tonic–clonic seizure after lead implantation.
She was treated with prophylactic phenytoin for 30 days
afterwards. Seizures have not recurred during the following
3 years. One patient, who had comorbid insulin-dependent
diabetes mellitus, developed a superficial surgical wound
infection after implantation, successfully treated with
antibiotics.
Adverse effects of stimulation. Acute adverse effects of DBS
included transient sadness, anxiety, and euphoria or giddi-
ness. Patients also experienced motor effects. One displayed a
unilateral ‘smile’ contralateral to the side of test stimulation
(see Nuttin et al (2003b) and Okun et al (2004) for
descriptions of similar events in different series). One patient
developed jaw muscle tightness associated with dysarthria.
Another patient developed a transient, epigastric, ‘physical
sensation of sadness’ lasting about 30 s, unaccompanied by a
sad mood, which abated without parameter change. Another
patient had stimulation-related olfactory and gustatory
sensations, described as a ‘chemical’ or ‘metallic’ smell alone,
or a smell plus taste (at higher amplitudes). These effects
occurred within seconds to minutes of DBS onset. They all
reversed, typically within seconds and always within minutes,
usually when DBS was stopped or parameters were changed,
but sometimes spontaneously.
Mood elevation/hypomania. Five patients developed a
transient elevated mood associated with noticeably in-
creased energy, speech production, and spontaneity of
social interactions, but without an increase in behavioral
impulsivity. In four of these cases, the events occurred
within minutes after DBS began, lasted for hours and abated
without parameter change, and so did not meet DSM-IV
criteria for a hypomanic episode. In the fifth case, this
behavioral state, which had equally rapid onset, lasted for 4
days and reversed within minutes after DBS parameter
change.
A few stimulation-related adverse events developed or
persisted over days. One patient, after an increase in
amplitude at the distal contact (0), developed brief memory
experiences for events surrounding the surgery itself. These
recurred several times a day over several days and ceased
when she reported them and parameters were changed. A
patient with insulin-dependent diabetes mellitus had an
unexplained syncopal episode while on stimulation, which
was possibly owing to hypoglycemia.
The adverse effects above, particularly increased anxiety
and/or flushing (which was seen in five of 10 patients), were
most common when the most distal electrode contact 0 was
active and negative. Two of these patients experienced
increased anxiety during stimulation of contact 1 as well.
Anxiety was more frequent with monopolar than with
bipolar stimulation. The lowest monopolar stimulation
amplitude producing increased anxiety was 3mA in one
patient. In the four others, monopolar stimulation of
contact 0 resulted in increased anxiety at DBS intensities
of 5–7mA. In contrast, bipolar stimulation produced
flushing only when the amplitude reached 13mA, and only
in one patient. Similar anxiogenic effects of monopolar
stimulation of the distal contact at this DBS site have been
reported in one OCD case (Shapira et al, 2006).
Table 3 Clinical Assessment of Functioning before and during Chronic DBS
Baseline During chronic DBS
Pt.
Working
or in
school?
Independent
ADLs?
Able to live
independently?
Social
engagement
Working
or in
school?
Independent
ADLs?
Able to live
independently?
Social
engagement
YBOCS
k (%)
BH1 No Extreme slowness No Limited Finished
degree
program
Yes Yes Good 38
BH2 No No No Minimal Entered
job training
Mainly Yes Limited 12a
BH3 No No No Minimal No Mainly Yes Limited 31
BH4 No No No Limited No No No Limited 12a
BH5 No No No Minimal Entered
technical
training
Mainly No Limited 33
CC1 No Total care No Minimal Deceased (at month 7)
CC2 No No No Limited No Mainly Limited VN
services
Dating, brief
engagement
39
CC3 No Yes No Limited Works FT Yes Yes Dating 49
CC4 No Yes No Limited Works FT Yes Yes Engaged to
marry
64
CC5 No No; unable to leave
room
No; assisted living Minimal Travels
alone to
day
program
Improved No Limited 35
aThe two patients who discontinued stimulation before the 36-month end point.
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Table 1 Patient characterist ics: demographic and cl inical features of subjects
Patient (center) M/F OCD
onset
OCD
duration
Axis I
comorbid
Axis II Follow-up
durotion
Butler (BH)
B H 1
BH2
BH3
BH4
B H 5
Clevelond Clinic (CC)
CC1
CC2
CC3
CC4
CC5
U of Florida (UF)
UF1
LIF2
UF3
UF4
UF5
Leuven (LV)
LV1
LV2
LV3
LV4
LV5
LV6
LV7
LV8
LV9
LVlO
LV1 1
Mean
s , e . m .
3 2
40
3 9
2 6
3 2
5 9
3 5
2 2
4 5
M
F
M
F
M
(years)
1 0
1 6
"t2
1 5
1 0
(years)
2 2
24
t 1
2 2
4 0
2 3
1.4
1 6
2 6
o
1 6
1 6
2 2
1 7
t 2
2 8
, ?
ta .
26
2"1
24
2 6
7"1
2 1
41.
2 Z . O
L C
MDD
BPN
Dysthymia
MDD
MDD
None
MDD
MDD
MDD
None
MDD
N{DD
MDD
MDD
MDD
MDD
MDD; GAD
MDD; PD
MDD
MDD
MDD
MDD
MDD; PD
MDD
None
MDD
OCPD
STYP(tr)
HST(tr);
NARItrJ
DEP PD
(months)
3 6
3 6
3 6
3 6
1 A
24
L 2
"12
6
3
12*
Il
i '
M
M
M
r
M
M
M
F
3 6
3 6
3 6
24
1 9
1 2
B
7
1 9
5 0
3 B
3 2
J Z
24
2 2
1 0
1 5
"12J J
5 2
3 9
4 0
3 9
40
2 3
3 0
J / . l
1 . 9
M
F
F
M
F
M
F
M
M
F'
F
24
1 6
1.2
1 4
1 6
1 5
1 4
7 2
I
1 6
1 5 . 1
r . b
3 6
3 6
3 6
3 6
3 6
24
\ z
6
3
31.4
4 . 1
Abbreviat ions: BPII,  bipolar I I  mood disorder; DEP PD, dependent personali ty disorder; F, female; GAD, general ized anxiety
disorder; HST(tr),  histr ionic traits; M, male; MDD, maior depressive disorder; NAR(tr),  narcissist ic traits; OCD, obsessive-
compulsive disorder; OCPD, obsessive-compulsive personali ty disorder; pD, panic disorder; STyp(tr),  schizotypal traits.
"Detai ls in text.
of clinical, anatomical and neuroimaging findingsu
suggested that stimulation of a more posterior and
inferior target (the caudal nucleus accumbens) might
be advantageous in OCD. Finally, electric f ieid
modeling suggested that the effective stimulation
volumes during DBS were small relative to those of
lesions (R Testerman, personal communication).
These considerations contributed to the hypothesis
that  the neural  systems impl icated in  OCD-might  be
more efficiently modulated by stimulation at the more
posterior/inferior VC/VS localion, where cortico-basal
fibers become more compact. The collective
experience with intraoperative test stimulation also
supported this vieq as it appeared that effects on
mood, anxiety and OCD symptoms could be elicited
using lower stimulation energies with more posterior
targets.
Investigators from the collaborating centers were
present especially for the first implantations at each
study site, which helped ensure comparabii ity and
consistency of targeting. Leads were implanted to
follow the trajectory of the anterior capsule in the
coronal plane, extending ventrally so that the most
distal contact was below the caosule white matter. In
the later patients, with more posterior targeting,
electrode contact 0 was placed in the ventral striatum
just below the axial plane defined by the anterior and
posterior commissures, contacts 1 and 2 in the ventral
half of the capsule, and contact 3 at the dorsal margin
of the capsule. This is i l lustrated in Figure 1 that
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in  OCD sever i tv  and (3)  those wi th at  least  a 35%
decrease.
Doto included in this report, Across centers, data
were col lected at  presurgical  basel ine af ter  3,  6, '1 .2,24
and 36 months of  chronic DBS. In tota l ,  17 pat ients
had at least 24 months of follow-up, and tz had
reached 36 months (mean durat ion:  24.0 !  2 .5
months). The two sites (LV and UF) where pationts
underwent masked sham DBS trials (using different
designs) wil l report those data separately.
Of  the 26 pat ients implanted,  one (CC1) d ied (due
to recurrence of breast cancer 1 year after implanta-
tion). Her data were not carried forward. Stimulation
was discontinued in three patients after 1.2 months
(LV1,  BHz and BH4) due to inadequate improvement .
Patient LV1, first in the overall series whose device
implantation was the most anterior, was )udged a
nonresponder after 12 months and chose to undergo
thermocapsulotomy, after which he improved.
Pat ients BH2 and BH4 cont inued t reatment  as usual ,
and were followed and rated with DBS off. As
discont inuat ion of  DBS in some proport ior . t  o f
patients is l ikely after long-term treatment, their data,
including the later t ime points rvith DBS off, were
inc luded in the in tent- to- t reat  analvs is .  An addi t ional
pat ient  (LV4) underwent  device iemoval  and later
capsulotomy (due to lack of stable improvement) after
3 vears of follow-up had been completed.
Results
OCD severits,
Figure 4 shows YBOCS severity scores before and
dur ing chronic DBS. The mean pre implantat ion
basel ine YBOCS score ( t  s .e.m.)  was 34.0 t  0 .5,
indicating severe i l lness. Postoperative, pre-DBS
Baseline 1 3 6 12 24 36
N=26 N=25 N=26 N=24 N=21 N=17 N=12
Follow-up Period
(Months)
Figure 4 Mean (+s.e.m.) Yale-Brown Obsessive Compul-
sive Scale (YBOCS) severitv scores pretreatment and at each
deep brain st imulat ion (DBS) treatment rat ing point.
ratings were available for a subset of 15 patients (not
col lected for  LV pat ients)  af ter  device implantat ion
but before stimulation began. Mean YBOCS scores
remained in the severe range (31.501 1,2)  at  th is  t ime
point .  Only one pat ient  (UF 1)  had a c l in ica l ly
significant pre-DBS score drop, from 37 to 21 points,
rvhich returned essentially to baseline (36 points) by
the 1-month rating point. The score of 21 was
obtained the day after surgery and may have reflected
perioperative factors, including insertional edema,
residual effects of anesthesia or intraoperative stimu-
lation, Mean YBOCS scores decrcased after stimula-
t ion onset ,  reaching 20.9+2.4 at  36 months ( repeated
measures overal l  GEE for  t ime:  c2 =20.35:  P=O.OO2).
This degree of improvement lvas apparent by the
th i rd month of  act ive st imulat ion,  when the mean
YBOCS had decl ined to 21.0 t  1 .8.  On average,  there
was a 1,2.5!1, .4 point  decrease in YBOCS scores
observed between baseline and treatment phases
(c ' z=  19 .59 ;  P<  0 .001 ) .
We also examined changes in YBOCS during
chronic s t imulat ion categor ica l ly .  Table 2 shows the
number of study patients in each of three, mutuallv
exclusive, categories from 1 to 36 months after the
start of chronic DBS. The percentage of patients
meeting the full response criterion {>35% YBOCS
decrease) increased from 2Bo/" at 1 month (7 of 25
patients-one of the total was not rated at 1 month) to
61 .5o/o (16 of 26) at last follorv-up. Conversely, the
percentage with less than a 259l" YBOCS decrease
(nonresponse) decl ined f rom 68% (17 of  25)  at  1.
nronth to 27o/o (7 of 26) at last follorv-up (Table 2).
Overall, a total of 73o/o of patients had at least a 25%
YOBCS improvement at last follow-up; a large
majority of those improvements were a 35% or greater
YBOCS reduction.
In addition, categorical YBOCS outcomes were
examined in l ight of patients' primary OCD symptoms
(that is, those symptoms identif ied by patients and
study physicians as causing the greatest distress and
impairment). Symptom categories followed an influ-
ential four-subtype model derived from factor analy-
sis,'n The proportions of patients lvith at Ieast a 35%
YBOCS score reduction in each primary symptom
category during stimulation were as follows: Obses-
s ions and Checking:  s ix  of  s ix  pat ients (100%);
Symmetry and Ordering: f ive of nine patients
(s5.6%):  Cleanl iness and Washing:  f ive of  e leven
pat ients (455%).  There were no pat ients enro l led for
whom compulsive hoarding was the primary symp-
tom subtype.
Outcome differences vs date of implontation
Across centers, the data show better OCD outcomes
for patients implanted more recently. Figure 5
il lustrates the reiationship between implant date
and clinical response at last follow-up in the three
subgroups of patients for both continuous (%YBOCS
reduclion) and categorical (percent responders) measrues.
YBOCS decreases were 29.0 16.6% (range: O-ZOo/o);
53.91 8.3% (range:  12-B1o/o)  and 5q.3 !12.7% (range:
40
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T1b^1" 2 Number (and percentage) of  pat ients by catcgor ical  response designat ion at  each t reatment rat ing point  dur ing r :hronicDBS st imulat ion
DBS durotion <2s% YBOCS !(no. of potients)
>25 <35% YBOCS !
(no. of patients)
>-35% t'Bocs !(no. of patients)
7olo1 N
1 Month
3 Months
6 Months
12 Months
24 N4onths
36 Months
Last fol low-up
77 (680/0)
1,1 (42o/o)
e  [ 37 . s%)
7 (33%)
3  ( 1 7 . 5 % )
3  t 2 5 % )
7  ( 2 7 % )
1, [4o/")
2  ( 8 % )
4  ( 1 6 . s % )
4 (1e%)
3  ( 1 7 . s % )
2  ( 2 5 % )
3  ( 1 1 . 5 % )
7 (28%)
1 3  { 5 0 % )
11(46%)
1,O (48o/o)
11  (6s9 /o)
7 l58Yo)
1 6  ( 6 1 . 5 % )
2 6
2 4
) 1
' t 7
1-2
2 6
Abbreviat ions: DBS, deep brain st imulat iont yBOCS, yale-Brown Obsessive Compulsive Scale
o %YBOCSdecrease r % Resnonders
o
o
tl,O  / ^
o(!
A (1-s)  B (10-18)  C (1e-26)
Patient Group
Figure 5 Clinical response for the three patient subgroups:
average percent Yale-Brown Obsessive Compulsive Scale(YBOCS) decrease and percentage of patients meeting
responder criterion (357o reduction in yBOCS).
6-940/0) in groups A, B and C, respectively. The
percentage of patients meeting the 35 percent yBOCS
reduction (full response) criterion in each group were
333%,77.8 and 75.Oo/o of pat ients in  groups A,  B and
C, respectively (see Figure 2 for lead location
di f ferences) ,  The degree of  c l in ica l  improvement  in
the latter two groups was nearly identical, using
either a continuous decrease in YBOCS severity or th6
percentage meeting the 35% YBOCS decrejse res-
ponse criterion.
Relationship of YBOCS chonge to medicotjon chonges
Across centers, OCD severity reductions at last
follow-up were greater in itru subgroup whose
medicat ions remained unchanged (N= 15;  mean
YBOCS decrease: S3.B"h) compared to those whose
B a s e l i n e 1 3 6 1 2 2 4 3 6
N=21 N=20 N=21 N=20 N=18 11=16 N=12
Follow-up Period
(Months)
Figure 6 Average (+s.e,m.) Global Assessment of Func-
tioning (GAF) scores over time.
medicat ions changed ( l /= 11;  mean YBOCS decrease:
34o/o) .
CIobal functioning
Figure 6 shows that mean scores on the GAF
improved significantly over time during long-term
DBS. At presurgical baseline, the mean GAF was
34.8 t  1 .1 ( for  the 21 pat ients adminis tered the scale,
which was not used at UF). IN total Z0 of 21 patients
scored 40 or less (consistent with maior functional
impairment) at presurgical baseline. After 3 months of
st imulat ion,  the mean GAF had r isen to SJ.g !2.4,
and was 59.0 13.3 at  last  fo l low-up ( repeated mea-
sures overal l  GEE for  T ime:  c '=18.05;  P=0.006).  On
average, a 19.8 + 2.3 point increase in GAF scores was
observed between baseline and treatment phases
(c 'z=L6.46;  P<0,001).  At  last  fo l low-up,  on\  two
pat ients cont inued to score in  that  range;  61.9% of  the
patients scored 51 or higher, a score demonstrated by
none of the patients at baseline.
To represent global outcomes in the entire sample,
study physicians at each site also provided an
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impression of the overall condition of the patients
after chronic DBS, including symptom severity,
functioning and quaiity of l i fe, using a five-point
rating (from 'worse' to 'much better'). None of the 26
patients were rated as globally 'worse' or 'sl ightly
worse' after stimulation; 4 (tS.+%) rt 'ere rated 'un-
changed' ;  5  (1,5.2%) were rated 's l ight ly  bet ter '  and 1Z
(65.4%) were rated 'much bet ter ' .  In  addi t ion,
detailed clinical narratives were used to describe
patient functioning before and after stimulation in
three categories: (1) work, school or homemaking
functioning; (2) independent l iving and activit ies of
daily I iving and (3) social engagement. At last follow-
up, work, school or homemaking functioning was
described as fair or good in 21 of the 25 patients.
Capacitv for independent l iving was considered fair
or  good in 20 of  25 pat ients.  Socia l  engagement was
considered fa i r  or  good in 21 pat ients,  and min imal  or
poor in  the remain ing 4,  Thus,  socia l  engagement was
judged to have improved in a l l  but  four  pat ients,  o
varying degrees ranging from greater social contact to
o e t t i n o  m a r r i a d
Effects on Comorbid Depressive Svmptoms and on non-
OCD-specific Anxiety
Comorbid depressive and non-OCD anxiety symp-
toms were common in the pat ients s tudied.  Al though
diff 'erent HAM-D versions were used across centers,
a l l  but  t  o f  the 26 pat ients had a HAM-D score of  1  r
h igher  at  basel ine,  scores which are above a com-
n)onlv proposed threshold for  depression remiss ion
8 L 1 3 6 1 2 2 4 3 6
(N=26)  (N=25)  (N=26)  (N=24)  (N=21)  (N=17)  (N=12)
Follow-up
(Months)
Figure 7 Average (+s.e.m.) change in depression ( left) and
(a HAM-D score of 7). 'o Figure 7 (left) shows the
percent change from baseline in depression ratings
over time. After 36 months of DBS, average scores
were progressively reduced by 432% (repeated
rreasures overall GEE for t ime: c2 =20.36; P=0.002).
At last follow-up for each patient, HAM-D scores
lvere < 7 in 1,4 of the 26 patients (overall mean
percent  reduct ion:  52.8!6.2"k) .  On average,  there
was a 40.0 !5.9o/o decrease in HAM-D scores between
basel ine and t reatment  phases (c2 =16.76;  P< 0.001).
Similarlv, patients commonly had significant anxi-
et-v at baseline. Of the 21. patients who were
adminis tered the HAM-A (not  used at  UF),  19
patients scored 13 or higher, above the proposed
HAM-A remiss ion threshold (<rO) for  non-OCD
anxiety disorders." Figure 7 (right) shows percent
change from preimplantation baseline in HAM-A
scores (N=21). After 36 months of DBS, average
scores were progressively reduced by 58,7% (repeated
easures overal l  GEE for  I ime' .  cz = 18.33;  P=0.006).
Assessment of the last follolv-up scores indicated that
14 of  the 21 pat ients scored <10 on the HAM-A
(overal l  mean percent  reduct ion:  50,0 + 6.5%).  On
average,  a52.6+ 4.5% decrease in HAM-A scores was
observed between basel ine and t reatment  phases
( c z = 1 8 . 2 3 ' , P < 0 . 0 0 1 ) .
Serious odverse effects
Potent ia l  compl icat ions of  DBS can ar ise ( t )  as a
resr,rlt of surgery [ 'procedure re]ated'), (2) due to the
implanted device ( 'device re lated ' )  and (3)  due to
10
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8 L 1 3 6 1 2 2 4 3 6
(N=21)  (N=20)  (N=21)  (N=20)  (N=18)  (N=17)  (N=13)
Follow-up
(Months)
anxietv (r ight) measures over t ime.
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Deep Brain Stimulation for Intractable Obsessive
Compulsive Disorder: Pilot Study Using a Blinded,
Staggered-Onset Design
Wayne K. Goodman, Kelly D. Foote, Benjamin D. Greenberg, Nikki Ricciuti, Russell Bauer, Herbert Ward,
Nathan A. Shapira, Sam S. Wu, Candy L. Hill, Stephen A. Rasmussen, and Michael S. Okun
Background: Prior promising results have been reported with deep brain stimulation (DBS) of the anterior limb of the internal capsule in
cases with severe obsessive compulsive disorder (OCD) who had exhausted conventional therapies.
Methods: In this pilot study, six adult patients (2 male; 4 female) meeting stringent criteria for severe (minimum Yale-Brown Obsessive
Compulsive Scale [Y-BOCS] of 28) and treatment-refractory OCD had DBS electrode arrays placed bilaterally in an area spanning the ventral
anterior limb of the internal capsule and adjacent ventral striatum referred to as the ventral capsule/ventral striatum. Using a randomized,
staggered-onset design, patients were stimulated at either 30 or 60 days following surgery under blinded conditions.
Results: After 12 months of stimulation, four (66.7%) of six patients met a stringent criterion as “responders” (!35% improvement in the
Y-BOCS and end point Y-BOCS severity "16). Patients did not improve during sham stimulation. Depressive symptoms improved signifi-
cantly in the group as a whole; global functioning improved in the four responders. Adverse events associated with chronic DBS were
generally mild andmodifiable with setting changes. Stimulation interruption led to rapid but reversible induction of depressive symptoms
in two cases.
Conclusions: This pilot study suggests that DBS of the ventral capsule/ventral striatum region is a promising therapy of last resort for
carefully selected cases of severe and intractable OCD. Future research should attend to subject selection, lead location, DBS programming,
and mechanisms underpinning therapeutic benefits.
Key Words: Arousal, deep brain stimulation, major depression,
obsessive compulsive disorder, ventral capsule, ventral striatum
Despite advances in pharmacological and behavioral ther-apies for obsessive compulsive disorder (OCD), a num-ber of patients fail to improve sufficiently following
years of conventional, as well as experimental interventions (1).
An option of last resort has been the use of stereotactic neuro-
surgery (either cingulotomy or anterior capsulotomy) for seri-
ously ill patients with OCD who have exhausted most existing
treatments. The available, albeit limited, evidence suggests that
ablative procedures may lead to long-term benefits with accept-
able levels of risk (2). Although deep brain stimulation (DBS) is
also an invasive procedure with potentially serious adverse
events, in contrast to ablative approaches, it is an adjustable and
partially reversible therapy (3).
Deep brain stimulation has been successfully employed for
the treatment of a variety of movement disorders (4). Deep brain
stimulation was first reported to be a promising intervention for
OCD in a study by Nuttin et al. (5). The specific target in this
study, referred to as the ventral capsule/ventral striatum (VC/VS),
was chosen in part on positive experiences with gamma knife
capsulotomy by the Brown University group (6). These studies,
which were staged lesions over two operative sessions over time,
demonstrated that adding a more ventral region lesion of the
anterior limb of the internal capsule, impinging inferiorly on the
ventral striatum, improved outcome (S.A. Rasmussen, unpub-
lished data, 2009). This experience was important to refining and
choosing an appropriate target for DBS.
Following the Nuttin et al. (5) publication, a team from the
University of Florida was funded by the National Institute of
Mental Health to conduct an independent pilot study of DBS in
six patients with treatment-refractory OCD who might otherwise
have been candidates for ablative neurosurgery. In consultation
with National Institute of Mental Health staff, a blinded, stag-
gered-onset design was adopted to enhance objectivity of the
behavioral ratings while minimizing withholding of active DBS
treatment to a maximum of 2 months following surgery.
Methods andMaterials
Patients
This study was conducted at the University of Florida as a
collaboration of the departments of Psychiatry, Neurology, and
Neurosurgery in consultation with Dr. Benjamin Greenberg of
Brown University. Prior to recommending surgery, an indepen-
dent internal multidisciplinary team (psychiatrist, neurologist,
neurosurgeon, and medical ethicist) reviewed all past treatments,
evaluations, and procedures to ensure appropriateness of the
candidate. Psychiatric diagnoses were based upon administration
of the Structured Clinical Interview for DSM-IV (7), review of
medical records, and expert clinical interview.
All subjects were adults who met DSM-IV criteria for OCD
with a minimum score of 28 on the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS) (8,9). Subjects must have had at
least a 5-year history of treatment-refractory OCD symptoms
since age 18, and the disorder must have caused substantial
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Compulsive Scale [Y-BOCS] of 28) and treatment-refractory OCD had DBS electrode arrays placed bilaterally in an area spanning the ventral
anterior limb of the internal capsule and adjacent ventral striatum referred to as the ventral capsule/ventral striatum. Using a randomized,
staggered-onset design, patients were stimulated at either 30 or 60 days following surgery under blinded conditions.
Results: After 12 months of stimulation, four (66.7%) of six patients met a stringent criterion as “responders” (!35% improvement in the
Y-BOCS and end point Y-BOCS severity "16). Patients did not improve during sham stimulation. Depressive symptoms improved signifi-
cantly in the group as a whole; global functioning improved in the four responders. Adverse events associated with chronic DBS were
generally mild andmodifiable with setting changes. Stimulation interruption led to rapid but reversible induction of depressive symptoms
in two cases.
Conclusions: This pilot study suggests that DBS of the ventral capsule/ventral striatum region is a promising therapy of last resort for
carefully selected cases of severe and intractable OCD. Future research should attend to subject selection, lead location, DBS programming,
and mechanisms underpinning therapeutic benefits.
Key Words: Arousal, deep brain stimulation, major depression,
obsessive compulsive disorder, ventral capsule, ventral striatum
espite advances in pharmacological and behavioral ther-
apies for obsessive compulsive disorder (OCD), a num-
ber of patients fail to improve sufficiently following
years of conventional, as well as experimental interventions (1).
An option of last resort has been the use of stereotactic neuro-
surgery (either cingulotomy or anterior capsulotomy) for seri-
ously ill patients with OCD who have exhausted most existing
treatments. The available, albeit limited, evidence suggests that
ablative procedures may lead to long-term benefits with accept-
able levels of risk (2). Although deep brain stimulation (DBS) is
also an i vasive procedure with potentially serious adverse
events, in contrast to ablative approaches, it is an adjustable and
partially reversible therapy (3).
Deep brain stimulation has been successfully employed for
the treatment of a variety of movement disorders (4). Deep brain
stimulation was first reported to be a promising intervention for
OCD in a study by Nuttin et al. (5). The specific target in this
study, referred to as the ventral capsule/ventral striatum (VC/VS),
was chosen in part on positive experiences with gamma knife
capsulotomy by the Brown University group (6). These studies,
which were staged lesions over two operative sessions over time,
demonstrated that adding a more ventral region lesion of the
anterior limb of the internal capsule, impinging inferiorly on the
ventral striatum, improved outcome (S.A. Rasmussen, unpub-
lished data, 2009). This experience was important to refining and
choosing an appropriate target for DBS.
Following the Nuttin et al. (5) publication, a team from the
University of Florida was funded by the National Institute of
Mental Health to conduct an independent pilot study of DBS in
six patients with treatment-refractory OCD who might otherwise
have been candidates for ablative neurosurgery. In consultation
with National Institute of Mental Health staff, a blinded, stag-
gered-onset design was adopted to enhance objectivity of the
behavioral ratings while minimizing withholding of active DBS
tre tment to a maximum of 2 months following surgery.
Methods andMaterials
Pati nts
This study was conducted at the University of Florida as a
collaborat on of the departme ts of Psychiatry, Neurology, and
Neurosurgery in consultation with Dr. Benjamin Greenberg of
Brown University. Prior to recommending surgery, an indepen-
dent internal multidisciplinary team (psychiatrist, neurologist,
neurosurgeon, and medical ethicist) reviewed all past treatments,
evaluations, and procedures to ens re appropriateness of the
candidate. Psychiatric diagnoses were based upon administration
of the Structured Clinical Interview for DSM-IV (7), review of
medical records, and expert clinical interview.
All subjects were adults who met DSM-IV criteria for OCD
with a minimum score of 28 on the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS) (8,9). Subjects must have had at
least a 5-year history of treatment-refractory OCD symptoms
since age 18, and the disorder must have caused substantial
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suffering as well as a reduction in the subject’s functioning.
Additional inclusion/exclusion criteria are available in Supple-
ment 1.
Six subjects signed informed consents and were apprised of
the risks, possible benefits of, and alternatives to DBS surgery.
Partial outcome data from these subjects were included in a
recently published report on a worldwide experience with DBS
in OCD (10). The first subject was implanted in October 2003; the
sixth subject completed 12 months of DBS in January 2008. The
two men and four women had a mean age of 36.2 years (range:
27–52) (Table S1 in Supplement 1). Five of the six subjects had
childhood onset (i.e., before age 18 years) OCD and the mean
duration of illness was 24 years for the cohort (range: 11–35
years). Presurgical mean severity on the Y-BOCS at screening
and at baseline was 32.7 and 33.7, respectively. All six subjects
had lifetime diagnoses of major depression that were deemed
secondary to OCD. One met criteria for a current diagnosis of
secondary major depression but most reported depressive symp-
toms. One subject met criteria for Tourette syndrome. Although
tics were present, his obsessive compulsive symptoms caused
more subjective distress and dysfunction.
The medications prescribed at baseline were held constant
and continued at the same doses as much as possible during
chronic DBS. In some cases, the dosages were reduced. Patients
were encouraged to apply the cognitive and behavioral skills
they had previously learned during Exposure and Response
Prevention.
Stimulation and Optimization
At 30 days postsurgery, subjects were randomized to either
true DBS stimulation or sham stimulation. Half of the patients
had DBS turn on at that point. At 60 days postsurgery, the three
subjects previously assigned to sham underwent true DBS stim-
ulation. Patients, raters, and the study psychiatrists were kept
blind to the manipulations made (true stimulation, sham stimu-
lation, or no change) at the postsurgery 30-day and 60-day visits
and assignment was not disclosed until 120 days postimplanta-
tion after ratings were obtained. The standardized sham-con-
trolled programming procedure was performed by the study
neurologist (M.S.O.) as previously described (11). Patients were
informed that they would have the device activated at some point
during the first 90 days following the 1-month postoperative visit.
Active settings were kept stable for the first 6 months and for at
least 30 days before assessments whenever possible.
Details of device implantation and intraoperative testing are
provided in Supplement 1.
OutcomeMeasures
Yale-Brown Obsessive Compulsive Scale severity was as-
sessed categorically at each rating point according to percentage
change from baseline. In this study, a responder was defined as
both a 35% percentage change and an actual score of 16 or less
at the time of assessment. The score of 16 was selected because
it corresponded to mild-to-moderate symptoms at the diagnostic
threshold for OCD and generally would not qualify a patient for
entry into a clinical drug trial. Yale-Brown Obsessive Compulsive
Scale scores were also analyzed as a continuous outcome with
repeated-measures analysis of variance (ANOVA; two-tailed).
The Y-BOCS was administered by expert clinicians, either the
principal investigator (W.K.G.), one of the study psychiatrists, or
a psychiatric research nurse (N.R.). For the most part, these
assessments were conducted face-to-face, but some were com-
pleted on the telephone because of long travel distances.
Secondary outcome measures included the Hamilton Rating
Scale for Depression (12), the Clinical Global Impressions Sever-
ity Scale (13), the Profile of Mood States (POMS) (14), and the
SF-36 (15) as a measure of quality of life. Cognitive performance
was assessed before implantation and after chronic DBS with a
neuropsychological battery that included the Wisconsin Card
Sorting Test (WCST) (16), the Karolinska Scales of Personality
(17), Controlled Oral Word Association Test (18), Hopkins Verbal
Learning Task (19), Grooved Pegboard (20), Tower of London
Task (21), and a measurement of working memory capacity
(Wechsler Adult Intelligence Scale-Third Edition Digit Span) (22).
With respect to the WCST, the computerized version was used
(WCST-Computerized Version Three, for Windows) to allow
more computation of expected test-retest changes and to com-
pare treatment-associated alterations in performance. In evaluat-
ing the degree to which treatment-associated neuropsychological
change exceeded that expected by chance, a reliable change
score was calculated to reflect the amount of test-retest change
expected by chance.
Patients were closely monitored for deterioration in psychiat-
ric status or stimulation-related adverse effects throughout the
study. Deep brain stimulation continued until it was interrupted
by stimulator battery depletion, at which time the implantable
neurostimulators were replaced in outpatient surgery. In one
case that required higher voltage settings, the two Soletra models
(Medtronic, Minneapolis, Minnesota) were replaced by two
larger Kinetra models (Medtronic) to reduce the frequency of
replacement surgeries.
Results
DBS Lead Locations and Programming
A summary of the active DBS contacts used for chronic
stimulation is provided in Table 1 along with lead locations.
Three patients (patients 2, 3, and 5) had sham DBS programming
for 1 month and then were subsequently activated at the next
study visit under double-blind conditions. All patients were
activated in a single contact monopolar setting for the first 6
Table 1. DBS Programming and Lead Locations at 12 Months of Chronic
Stimulation
Patient DBS Setting Lateral AP Axial
1a Rt 1-C!, 5 V, 210 "s, 135 Hz 10.4 16.2 1.7
Lt 0-C!, 4 V, 210 "s, 135 Hz 6.3 13.7 #3.8
2 Rt 2-C!, 3.5 V, 210 "s, 135 Hz 10.5 17.3 8.4
Lt 2-C!, 3.5 V, 210 "s, 135 Hz 12.8 18.1 9.4
3a Rt 0-1-C!, 8.5 V, 150 "s, 130 Hz 4.8 (0 contact) 18.0 #3.8
Lt 0-1-C!, 7.5 V, 150 "s, 130 Hz 10.4 (0 contact) 18.8 #3.8
4 Rt 1-C!, 6.5 V, 180 "v, 135 Hz 8.9 12.4 #2.6
Lt 1-C!, 6.5 V, 180 "v, 135 Hz 13.4 16.0 #2.3
5a Rt 0-1-C!, 2.5 V, 210 "v, 135 Hz 9.2 (0 contact) 12.2 #1.7
Lt 1-C!, 2.5 V, 210 "v, 135 Hz 12.2 (1 contact) 14.8 4.8
6a Rt 1-O!, 3.5 V, 90 "s, 135 Hz 9.4 15.9 1.5
Lt 1-O!, 3.3 V, 90 "s, 135 Hz 11.2 15.2 .9
Table shows patients 1 through 6with chronic DBS settings at the active
contact at 12 months of DBS. The DBS settings show right side, left side,
volts, pulse width, and rate. The lateral, anteroposterior, and axial coordi-
nates of the center of the active contact relative to the mid-commissural
point are provided.
AP, anteroposterior; DBS, deep brain stimulation; Hz, rate; Lt, left side;",
pulse width; Rt, right side; V, volts; Y-BOCS, Yale-Brown Obsessive Compul-
sive Scale.
aPatients who had a clinical response based on Y-BOCS criteria.
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months. Following the 6-month time point, trials of multiple
monopolar stimulation resulted in salvage of one patient (patient
3) but not in the other two nonresponders (patients 2 and 4).
OCD Severity
Plots of individual patient Y-BOCS scores over time were
grouped by assignment to early (panel A) or delayed (panel B)
activation (Figure 1). Visual inspection of these data suggests that
little improvement occurred in either group until the device was
activated.
In addition, a mixed-model ANOVA was fitted for the avail-
able monthly data of the primary outcome Y-BOCS during the
first 12 months of active DBS, using SAS version 9.13 (SAS
Institute, Inc., Cary, North Carolina). The model included factors
group (activation at month 1 vs. at month 2) and categorical
months since DBS activation; a first-order autoregressive covari-
ance structure was used for the repeated measures. We found
that there were significant reductions in Y-BOCS scores over time
[F (12,55) ! 2.02, p ! .0392; with decrease of 15.67 " 11.60 after
12 months of activation] (Table 2); whereas the group effect was
not significant [F (1,4) ! .02, p ! .9040] with Y-BOCS reductions
of 5.33 " 11.67 for early group and #.67 " 2.52 for late group at
month 2.
Categorical response and number of patients attaining a
Y-BOCS score !16 are shown in Table 3 for the 12 months of
DBS activation. Four (67%) of six patients met criteria for a
responder status (Y-BOCS "35% change from baseline and
Y-BOCS!16) after 12 months of DBS. Three (S1, S5, and S6 from
Figure 1) of four responders reached these criteria after 2 to 3
months of active DBS. The remaining responder (S3 from Figure
1) did not show improvement in either OCD or mood until a
second monopolar contact was activated after month 8 and
voltage was increased. Within 2 months of these setting changes,
Y-BOCS scores decreased from 33 to 10 (at 10 months) and this
improvement was sustained.
SecondaryMeasures
Based on ANOVAs, Hamilton Rating Scale for Depression
scores decreased significantly for the entire group [F (12,50) !
2.22, p ! .0249] during the 12 months of DBS (Table 2). Similar
mixed models indicated that the POMS-V (vigor-activity) in-
creased and POMS-F (fatigue-inertia) decreased significantly
over time [F (7,20) ! 4.21, p ! .0053; F (7,20) ! 3.08, p ! .0228;
respectively], while changes in the POMS total score were
nonsignificant (p ! .0723) (Table 2). The SF-36-V (vitality) score
significantly increased (improved) [F (9,22) ! 3.50, p ! .0079]
(Table 2).
As noted in Table S2 in Supplement 1, patients classified as
responders after 12 months of DBS showed corresponding
improvements in functioning, as reflected in changes on the
double blind
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Figure1.Patients and raterswereblind to treatment condition (shamvs. active) for the 90-dayperiod startingwith the first postoperative visit as notedby the
yellow double arrow. (A) Three patients (S1, S4, and S6) randomized to active DBS at 1month postimplantation (denoted by green arrow); (B) three patients
(S2, S3, and S5) randomized to active at month 2 (denoted by green arrow). In (A) patients received 12months of active DBS at 13 months postimplantation
(marked by dotted vertical line), whereas in (B) patients received 12 months of active DBS at 14 months postimplantation (marked by dotted vertical line).
Unbeknownst to subject 1 or the research treatment team, this individual’s right-sided battery was depleted between 11 and 12 months (red triangle)
following surgery. This event was closely followed by an exacerbation in OCD symptoms that normalized shortly after device replacement (green triangle).
Subject 3 did not show a response until after major changes in DBS settings at week 8 status post surgery (see text for details). The reasons for the temporary
worsening of subject 5 between months 10 and 12 postimplantation are unclear. Possibilities include impact of significant life events or setting changes at
month 10 that improvedmood but lowered threshold for panic attacks. These settingswere furthermodified atmonth 12. DBS, deep brain stimulation; OCD,
obsessive compulsive disorder; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
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Clinical Global Impressions Severity Scale or work/school activ-
ity on the SF-36. The four responders progressed from global
severity ratings of “severe” or “extremely severe” at baseline to
scores of “not at all” or “marginal” illness at 12 months of DBS.
Unfortunately, the two nonresponders remained “severe” on this
measure. Two of the three responders who were taking psych-
otropic medications at baseline were able to have dosages
lowered or the number of different medications reduced during
DBS.
Adverse Effects
Potential complications of DBS can be separated into those
related to surgical implantation, stimulation, and device failure or
interruption. There were no device failures beyond the expected
stimulation interruptions owing to implantable neurostimulator
battery depletion or inadvertent device shutoffs if the magnetic
switch was tripped by a theft detector.
Adverse Effects of Implantation. No unexpected adverse
events occurred as a result of implantation. There were no
serious adverse events such as seizures or cerebral hemorrhages.
All adverse events associated with implantation/anesthesia were
anticipated and time-limited. These included discomfort at the
surgical site, incision pain, headache, nausea, scalp tingling or
numbness, and intubation-related sore throat.
Adverse Effects of Stimulation. Effects of acute and chronic
DBS are best distinguished. During intraoperative testing or
subsequent optimization, a wide range of settings were surveyed
that in some instances led to unwanted or unusual emotional,
perceptual, or somatic experiences. All these effects occurred
within seconds or minutes of DBS onset and could be reversed,
typically within seconds and always within minutes of changing
the stimulation parameters. Transient emotional effects included
euphoria, giddiness, anxiety, panic attacks (previously reported
[23]), or sadness. A contralateral smile accompanied by mirth was
induced intraoperatively in five of six patients and was previ-
ously reported in one of these cases (24). Ventral stimulation
(contact 0) was more likely to induce anxiety/panic (23,25).
Transient olfactory and gustatory sensations such as smelling
popcorn or tasting metal were experienced with deep contacts
only.
Hypomania was observed at some point during chronic DBS
in four (including one of the nonresponders, S2) of the six
patients. In all cases, the degree of mood elevation abated over
time or responded to device adjustment. None of the subjects
gave a history of bipolar disorder. Difficulty falling asleep was a
common complaint that was dealt with by adding as required
sedative-hypnotics or by device adjustment. In one case (S5),
DBS-induced insomnia was alleviated by lowering the ongoing
dose of escitalopram from 80 mg to 30 mg daily. A serious
adverse event (classified as such because hospitalization was
required) secondary to a change in DBS settings occurred in S2.
In this instance, DBS-induced improvement in mood was accom-
panied by a reciprocal worsening in OCD. This exacerbation in
OCD resolved after adjustment of DBS. After this event, we
extended the in-clinic observation period following major
changes in DBS parameters.
Effects of DBS Interruption. The clinical effects and time
course of DBS interruption were similar to those reported
Table 3. Categorical Responses and End Point Severity During DBS for
OCD (n! 6)
Duration of
DBS Activation
(months)
"25% 25%–35% !35% Severity
Total Y-BOCS2 Y-BOCS2 Y-BOCS2 Y-BOCS" 16
n (n, %) (n, %) (n, %) (n, %)
1 6 4 (67) 0 (0) 2 (33) 0 (0)
2 6 2 (33) 1 (17) 3 (50) 1 (17)
3 6 3 (50) 0 (0) 3 (50) 3 (50)
4 6 3 (50) 0 (0) 3 (50) 2 (33)
5 6 3 (50) 0 (0) 3 (50) 3 (50)
6 5 3 (60) 0 (0) 2 (40) 2 (40)
7 6 1 (17) 0 (0) 5 (83) 4 (67)
8 5 2 (40) 0 (0) 3 (60) 3 (60)
9 4 2 (50) 0 (0) 2 (50) 2 (50)
10 5 3 (60) 0 (0) 2 (40) 2 (40)
11 6 2 (33) 0 (0) 4 (67) 3 (50)
12 6 2 (33) 0 (0) 4 (67) 4 (67)
Categorical response is shown against duration of DBS activation, which
is not the same as time since implantation. Number of nonresponse is
indicated in the column labeled"25% reduction on the Y-BOCS. Number of
responders is shownusing twodifferent criteria: 25%–35% reduction on the
Y-BOCS and the more stringent definition of !35% reduction on the
Y-BOCS. The last column shows the number of individuals who had
a Y-BOCS score"16 at that time point.
DBS, deep brain stimulation; OCD, obsessive compulsive disorder;
Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
Table 2. Analyses of Changes in Primary and Secondary Rating Scales
During 12 Months of DBS Activation for All Participants (n! 6)
Variable Num df Den df F Value Pr# F
Y-BOCSa 12 55 2.02 .0392a
POMS Total 9 32 2 .0723
POMS T 7 20 1.23 .3347
POMS-D 7 20 1.75 .1550
POMS-A 7 20 1.49 .2256
POMS-Va 7 20 4.21 .0053a
POMS-Fa 7 20 3.08 .0228a
POMS-C 7 20 1.15 .3743
HAM-D17a 12 50 2.22 .0249a
SF-36 PF 9 22 1.52 .2025
SF-36 RP 9 22 .94 .5143
SF-36 BP 9 21 2.27 .0587
SF-36 GH 9 22 .98 .4861
SF-36 Va 9 22 3.5 .0079a
SF-36 SF 9 22 1.77 .1326
SF-36 RE 9 22 1.63 .1680
SF-36 MH 9 22 1.39 .2536
SF-36 Total 9 22 .82 .6038
DBS, deep brain stimulation; HAM-D17, Hamilton Depression 17-Item
Rating Scale; POMS-A, Profile of Mood States anger-hostility subscore;
POMS-C, Profile of Mood States confusion-bewilderment subscore;
POMS-D, Profile of Mood States depression-dejection subscore; POMS-F,
Profile of Mood States fatigue-inertia subscore; POMS T, Profile of Mood
States tension subscale; POMS Total, Profile of Mood States total score;
POMS-V, Profile of Mood States vigor-activity subscore; SF-36 BP, Medical
Outcomes Study Short Form Health Survey bodily pain subscale; SF-36 GH,
MedicalOutcomes Study Short FormHealth Surveygeneral health subscale;
SF-36MH,MedicalOutcomesStudyShort FormHealthSurveymental health
subscale; SF-36 PF, Medical Outcomes Study Short Form Health Survey
physical functioning subscale; SF-36 RE, Medical Outcomes Study Short
Form Health Survey role limitations due to emotional problems subscale;
SF-36 RP, Medical Outcomes Study Short Form Health Survey role limita-
tions due to personal health problems subscale; SF-36 SF, Medical Out-
comes Study Short Form Health Survey social functioning subscale; SF-36
Total, Medical Outcomes Study Short Form Health Survey total score; SF-36
V, Medical Outcomes Study Short Form Health Survey vitality subscale;
Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
aSignificant difference on analysis of variance for repeated measures
obtained during the first 12months of DBS activation.
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Clinical Global Impressions Severity Scale or work/school activ-
ity on the SF-36. The four responders progressed from gl bal
severity ratings of “severe” or “extremely sever ” at baseline to
scores of “not at all” or “marginal” illness at 12 months of DBS.
Unfortunately, the two nonresponders remained “sev re” on this
measure. Two of the three responders who were taking psych-
otropic medications at baseline were able to have dosages
lowered or the number of different medications educed during
DBS.
Adverse Effects
Potential complications of DBS can be separated into those
related to surgical implantation, stimulation, and device failure or
interruption. There were no device failures beyond the expecte
stimulation interruptions owing to implantable neurostimulat r
battery depletion or inadvertent device shutoffs if the magnetic
switch was tripped by a theft detector.
Adverse Effects of Implantation. No unexpecte adverse
events ccur ed as a result of implantation. Th re were n
serious adverse events such as seizures or cerebral hemorrhages.
All adverse events associated with implantation/anesthesia were
anticipated and time-limited. These included discomfort at the
surgical site, incision pain, headache, nausea, scalp tingling or
numbness, and intubation-related sore throat.
Adverse Effects of Stimulation. Effects of acute and chronic
DBS are best distinguished. During intraoperative testing or
subsequent optimization, a wide range of settings were surveyed
that in some instances led to unwanted or unusual emotional,
perceptual, or somatic experiences. All these effects occurred
within seconds or minutes of DBS onset and could be reversed,
typically within seconds and always within minutes of changing
the stimulation parameters. Transient emotional effects included
euphoria, giddiness, anxiety, panic attacks (previously reported
[23]), or sadness. A contralateral smile accompanied by mirth was
induced intraoperatively in five of six patients and was previ-
ously reported in one of these cases (24). Ventral stimulation
(contact 0) was more likely to induce anxiety/panic (23,25).
Transient olfactory and gustatory sensations such as smelling
popcorn or tasting metal were experienced with deep contacts
only.
Hypomania was observed at some point during chronic DBS
in four (including one of the nonresponders, S2) of the six
patients. In all cases, the degree of mood elevation abated over
time or responded to device adjustment. None of the subjects
gave a history of bipolar disorder. Difficulty falling asleep was a
common complaint that was dealt with by adding as required
sedative-hypnotics or by device adjustment. In one case (S5),
DBS-induced insomnia was alleviated by lowering the ongoing
dose of escitalopram from 80 mg to 30 mg daily. A serious
adverse event (classified as such because hospitalization was
required) secondary to a change in DBS settings occurred in S2.
In this instance, DBS-induced improvement in mood was accom-
panied by a reciprocal worsening in OCD. This exacerbation in
OCD resolved after adjustment of DBS. After this event, we
extended the in-clinic observation period following major
changes in DBS parameters.
Effects of DBS Interruption. The clinical effects and time
course of DBS interruption were similar to those reported
Table 3. Categorical Responses and End Point Severity During DBS for
OCD (n! 6)
Duration of
DBS Activation
(months)
"25% 25%–35% !35% Severity
Total Y-BOCS2 Y-BOCS2 Y-BOCS2 Y-BOCS" 16
n (n, %) (n, %) (n, %) (n, %)
1 6 4 (67) 0 (0) 2 (33) 0 (0)
2 6 2 (33) 1 (17) 3 (50) 1 (17)
3 6 3 (50) 0 (0) 3 (50) 3 (50)
4 6 3 (50) 0 (0) 3 (50) 2 (33)
5 6 3 (50) 0 (0) 3 (50) 3 (50)
6 5 3 (60) 0 (0) 2 (40) 2 (40)
7 6 1 (17) 0 (0) 5 (83) 4 (67)
8 5 2 (40) 0 (0) 3 (60) 3 (60)
9 4 2 (50) 0 (0) 2 (50) 2 (50)
10 5 3 (60) 0 (0) 2 (40) 2 (40)
11 6 2 (33) 0 (0) 4 (67) 3 (50)
12 6 2 (33) 0 (0) 4 (67) 4 (67)
Categorical response is shown against duration of DBS activation, which
is not the same as time since implantation. Number of nonresponse is
indicat d n the column labeled"25% reduction on the Y-BOCS. Number of
responders is shownusing twodifferent criteria: 25%–35% reduction on the
Y-BOCS and the more stringent definition of !35% reduction on the
Y-BOCS. The last column shows the number of individuals who had
a Y-BOCS score"16 at that time point.
DBS, deep brain stimulation; OCD, obsessive compulsive disorder;
Y-BOCS, Yale-Brown Obsessive C mpulsive Scale.
Table 2. Analyses of Changes in Primary and Secondary Rating Scales
During 12 Months of DBS Activation for All Participants (n! 6)
Variable Num df Den df F Value Pr# F
Y-BOCSa 12 55 2.02 .0392a
POMS Total 9 32 2 .0723
POMS T 7 20 1.23 .3347
POMS-D 7 20 1.75 .1550
POMS-A 7 20 1.49 .2256
POMS-Va 7 20 4.21 .0053a
POMS-Fa 7 20 3.08 .0228a
POMS-C 7 20 1.15 .3743
HAM-D17a 12 50 2.22 .0249a
SF-36 PF 9 22 1.52 .2025
SF-36 RP 9 22 .94 .5143
SF-36 BP 9 21 2.27 .0587
SF-36 GH 9 22 .98 .4861
SF-36 Va 9 22 3.5 .0079a
SF-36 SF 9 22 1.77 .1326
SF-36 RE 9 22 1.63 .1680
SF-36 MH 9 22 1.39 .2536
SF-36 Total 9 22 .82 .6038
DBS, deep brain stimulation; HAM-D17, Hamilton Depression 17-Item
Rating Scale; POMS-A, Profile of Mood States anger-hostility subscore;
POMS-C, Profile of Mood States confusion-bewilderment subscore;
POMS-D, Profile of Mood States depression-dejection subscore; POMS-F,
Profile of Mood States fatigue-inertia subscore; POMS T, Profile of Mood
States tension subscale; POMS Total, Profile of Mood States total score;
POMS-V, Profile of Mood States vigor-activity subscore; SF-36 BP, Medical
Outcomes Study Short Form Health Survey bodily pain subscale; SF-36 GH,
MedicalOutcomes Study Short FormHealth Surveygeneral health subscale;
SF-36MH,MedicalOutcomesStudyShort FormHealthSurveymental health
subscale; SF-36 PF, Medical Outcomes Study Short Form Health Survey
physical functioning subscale; SF-36 RE, Medical Outcomes Study Short
Form Health Survey role limitations due to emotional problems subscale;
SF-36 RP, Medic l Outcomes Study Short Form Health Survey role limita-
tions due to personal health problems subscale; SF-36 SF, Medical Out-
comes Study Short Form Health Survey social functioning subscale; SF-36
Total, Medical Outcomes Study Short Form Health Survey total score; SF-36
V, Medical Outcomes Study Short Form Health Survey vitality subscale;
Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
aSignificant difference on analysis of variance for repeated measures
obtained during the first 12months of DBS activation.
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previously by Greenberg et al. (25). Worsening in mood or
increased anxiety were typically the first symptoms reported
following battery depletion or inadvertent inactivation by metal
detectors. Other signs of depression, such as diminished energy
or interest, also emerged within days of device interruption but
none expressed suicidality. Exacerbation of OCD symptoms
generally lagged the emergence of affective or anxiety symp-
toms. In all cases, restoration of DBS function led to reversal of
the transient clinical deterioration. An illustration of these phe-
nomena is shown for S1 (Figure 1, panel A). Other than drainage
of battery power over time, there were no device failures or lead
fractures.
Neuropsychological Test Performance. The results of four-
teen measures from six neuropsychological tests are reported
here. All measures were administered at each patient visit. Test
order was counterbalanced across visits to reduce order effects,
though some measures (e.g., HVLT) with delayed performance
trials were typically administered during the first half of testing to
allow the appropriate delay interval to transpire. For each
measure, 90% confidence intervals for reliable change were
computed using established measures, and each patient’s results
were categorized as representing an improvement, no change, or
a decline from baseline. Results from the 6- and 12-month
evaluations are presented in Table 4.
Overall, results indicated that the clinical effectiveness of DBS
in this population was achieved without significant neuropsy-
chological morbidity. At 6 months post-DBS, only 2.1% (1 of 42)
of the change comparisons showed a decline in the responders
(one patient declined in HVLT recognition), while only 7.1% (3 of
42) of comparisons showed a decline in the non-responders (one
showed reduction in HVLT recognition, one showed a decline in
non-dominant Pegboard performance, and one showed a reduc-
tion in WAIS-III digit span raw score). At 1 year, 5.4% (3 of 56) of
the responder comparisons showed a decline, while 10.7% (3 of
28) of the non-responder comparisons declined. In contrast,
14.3% (6 of 42) of the responder comparisons and 21.4% (9 of 42)
of the non-responder comparisons showed improvement at 6
months. The corresponding values at one year were 17.9% (10 of
56 responder comparisons) and 10.7% (3 of 28 non-responder
comparisons) respectively. Thus, the vast majority (77.4%) of
comparisons for both responders and non-responders showed
no reliable change in neuropsychological test performance at
either the 6- or 12-month postsurgical evaluation.
Discussion
Twelve months of bilateral stimulation of the VC/VS was
associated with marked improvement in obsessive compulsive
symptoms in four (66.7%) of six subjects with severe and
intractable OCD. Even the two individuals who were classified as
nonresponders requested that stimulation be continued because
they experienced some subjective relief of anxiety, depressive, or
tic symptoms. For the six subjects as a whole, both OCD and
depressive symptoms improved significantly compared with
baseline at the 12-month mark. The procedures were generally
well tolerated and the only serious adverse event leading to
urgent hospitalization was an exacerbation in OCD symptoms
due to stimulation that was reversed by changing the device
settings. Both subjects who experienced hypomania as an early
stimulation-induced side effect were ultimately clinical respond-
ers. Other transient stimulation-induced side effects, including
panic, gustatory, and olfactory hallucinations, have been previ-
ously described (25). No significant changes in neuropsycholog-
ical performance were detected at either 6 or 12 months of
stimulation.
With a few notable exceptions (26–28), most published
reports of DBS in OCD have been uncontrolled and open-label.
The study by Abelson et al. (26) of anterior capsular DBS in OCD
included a double-blind phase in which subjects received active
or sham stimulation in a randomized “on-off” sequence of four
Table 4. Reliable Changes in Neuropsychological Performance from Baseline Among Responders and Nonresponders
Baseline Mean (SD)
6 Month 1 Year
Responders (3) Nonresponders (3) Responders (4) Nonresponders (2)
! nc — ! nc — ! nc — ! nc —
WAIS 3 DS
Forward 7.00 (1.9) 0 3 0 0 3 0 0 4 0 0 2 0
Backward 5.33 (1.6) 0 3 0 0 3 0 0 4 0 0 2 0
WAIS raw 19.33 (6.0) 0 3 0 0 2 1 0 4 0 0 1 1
Verbal Fluency CFL 44.50 (15.64) 0 3 0 1 2 0 0 3 1 1 1 0
Wisconsin Card Sort
Categories 5.67 (.82) 0 3 0 0 3 0 0 4 0 0 2 0
Persev errors 6.33 (2.58) 0 3 0 0 3 0 0 4 0 0 2 0
Persev responses 6.33 (2.58) 0 3 0 0 3 0 0 4 0 0 2 0
Tower of London
Movement count 44.50 (19.77) 0 3 0 1 2 0 0 4 0 1 1 0
Total time 415.17 (199.36) 2 1 0 2 1 0 2 1 1 1 1 0
Grooved Pegboard
Dominant 101.83 (28.62) 2 1 0 1 2 0 3 1 0 0 2 0
Nondominant 124.17 (41.90) 2 1 0 1 1 1 3 1 0 0 1 1
Hopkins VLT
Total 26.33 (3.33) 0 3 0 2 1 0 1 3 0 0 2 0
Delayed recall 8.67 (2.80) 0 3 0 1 2 0 1 3 0 0 2 0
Recog discrimination 11.17 (1.17) 0 2 1 0 2 1 0 3 1 0 1 1
!, improvement beyond the 90% confidence interval for reliable change; —, decline in performance beyond the 90% confidence interval for reliable
change; nc, no change frombaseline; Persev, perseveration errors; Recog, recognition; VLT, verbal learning task;WAIS,Wechsler Adult Intelligence Scale;WAIS
3 DS, Wechsler Adult Intelligence Scale version 3 Digit Span.
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Historic Review  
of Psychiatric Surgery
Surgical interventions for the treatment 
of psychiatric illness began in 1932, when 
Antonio Egas Moniz observed that an ex-
tensive bilateral frontal lobe lesioning in a 
monkey produced a tame, calm animal.1 
He then extended this result to humans 
in 1936 and developed the first somatic 
therapy of the modern era for psychiatric 
conditions—the frontal lobotomy. He 
was corecipient of the 1949 Nobel Prize 
for this work. James Papez formulated 
the so-called Papez Circuit at about the 
same time based on his work involving 
feline rabies infections. The Papez Circuit 
defined a core circuit of neuroanatomical 
connections that were thought to underlie 
emotional behaviors.2 Many of these struc-
tures have been studied since those times, 
in vast detail, and found to be excellent 
targets for surgical therapy.
From the beginning, psychiatric surgery 
has been exalted and celebrated but also 
mired in ethical, moral, and scientific 
controversy. These swings reflect not only 
the complex social currents of the time but 
also the evolving scientific milieu and the 
personalities of the prominent advocates 
of psychiatric surgery. In Moniz’s time, 
the bilateral frontal lobotomy promised 
“salvation” and stood in contrast to bleak 
alternatives, which included lifetime 
institutionalization under inhumane 
conditions. Less attention, therefore, was 
focused on the obvious adverse sequelae 
of loss of frontal initiative and personal-
ity changes caused by these nonspecific 
ablative procedures. These procedures 
reached their pinnacle with Freeman’s 
cavalier application of orbital frontal 
leucotomies in the mid-1960s.3 The emer-
gence of successful pharmacologic agents 
for the treatment of psychiatric illnesses 
was the final force driving orbital frontal 
leucotomies from favor.
A subsequent somatic therapy, electro-
convulsive therapy, did little to increase 
enthusiasm for nonpharmacologic somatic 
therapies.4 Despite the loss of interest in 
ablative surgical interventions for psychi-
atric diseases, centers in Europe and in 
the US continued to refine indications, 
techniques, and targets for psychosur-
gery. Ultimately, these centers helped 
define criteria for surgical intervention 
and localize targets of ablation. The Mas-
sachusetts General Hospital group refined 
cingulotomy for refractory obsessive-
compulsive disorder (OCD), and a group 
at the Catholic University of Leuven in 
Belgium refined capsulotomy for the same 
indications.5,6 Remarkably, both groups 
independently defined similar indications 
for surgery. They both discovered that the 
interventions improved OCD. Appropriate 
surgical candidates were defined as those 
who had failed all somatic therapies, 
inclusive of multiple trials of pharmaco-
logic agents and appropriate behavioral 
therapies. 
The use of these approaches, particu-
larly in the US, was hampered by a vigor-
ous debate about the potential misuse of 
psychiatric somatic therapies as an instru-
ment of social control, based on fears of 
mind control by the government amidst 
the prevailing social climate. These fears 
were reinforced with the publishing of 
Ervin and Marks’ Violence and the Brain,7 
which proposed the use of these therapies 
for control of what was then perceived as 
sociopathic behaviors arising from aber-
rant neural processes.8-10 These concerns 
led to the State of California adopting 
legislation to regulate somatic therapies 
for psychiatric diagnosis, inclusive of 
psychiatric surgery.11
As technology evolved, stereotactic 
radiosurgery, an incisionless technique, 
first came into significant use in the 1970s 
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Abstract
Deep brain stimulation is a rapidly expanding therapy initially designed for the treatment 
of movement disorders and pain syndromes. The therapy includes implantation of electrodes 
in specific targets of the brain, delivering programmable small and safe electric impulses, 
like a pacemaker, that modulates both local and broad neurologic networks. The effects are 
thought to primarily involve a focus in the brain, probably inhibitory, which then restores 
a network of neural circuitry. Psychiatric diseases can be refractory and severe, leading to 
high medical costs, significant morbidity, and even death. Whereas surgery for psychiatric 
disease used to include destructive procedures, deep brain stimulation allows safe, revers-
ible, and adjustable treatment that can be tailored for each patient. Deep brain stimulation 
offers new hope for these unfortunate patients, and the preliminary results are promising.
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and involved ablating either the anterior 
limb of the internal capsule (capsulotomy) 
or the posterodorsal cingulum bundle (cin-
gulotomy), which connects the cingulate 
cortex with orbitofrontal and dorsolateral 
convexities (Figure 1).12,13 This procedure 
has had a response rate of up to 64% in 
individuals with OCD. Enlargement of the 
initial ablative zone in a second procedure, 
however, is often required to achieve the 
64% response rate and can lead to major 
complications including altered frontal 
lobe functioning (disinhibition and abulia) 
as well as radiation necrosis.14 Although 
outcomes reflected an impressive long-term 
response in an otherwise intractable disease 
and desperate population, the irreversible 
nature of the intervention and the historic 
misapplication of other ablative psychiatric 
surgeries limited the adoption of stereotactic 
radiosurgery for psychiatric indications. 
Psychiatric surgery, however, has taken 
on new vigor with the introduction of 
a minimally invasive, reversible somatic 
therapy: deep brain stimulation (DBS). 
DBS has evolved and gained in popularity 
through its safe application in the treatment 
of Parkinson disease, essential tremor, and 
dystonia.15,16 Both the efficacy and complica-
tion rate for the DBS implantation procedure 
are now well defined, derived from out-
comes of tens of thousands of DBS implanta-
tions performed worldwide for movement 
disorders.17 Serious complications with 
long-lasting, severe neurologic sequelae or 
death occur at a rate between 0.5% and 1%. 
Remaining complications, such as stroke 
or intracranial hemorrhage without lasting 
symptoms, skin erosions, seizures, device 
failure, and infection, have been reported 
to occur at rates of 3% to 15%.18 
The relative safety of DBS coupled with 
identification of potential efficacious thera-
peutic targets has led to trials of its effective-
ness in treatment-refractory OCD.6,19,20 The 
results of these trials led to the US Federal 
Drug Administration’s Humanitarian Device 
Exempti  approval of DBS for treatment-
refractory OCD in 2009.21 
Obsessive-Compulsive 
Disorder and Deep Brain 
Stimulation
OCD is categorized as an anxiety dis-
order and is marked by recurrent obses-
sive thoughts and compulsive behaviors.22 
Affecting about 1% to 3% of the adult 
Figure 2. Frontal section 
through the target area, giv-
ing the topographic relations 
between internal capsule, 
nucleus accumbens, and bed 
nucleus of stria terminalis. 
Target point: 3 mm rostral CA, 
7 mm right lateral of midline. 
3-4 mm ventral of AC-PC line. 
Green: rostral edge of bed 
nucleus of stria terminalis. 
White: caudal part of anterior 
limb of internal capsule.1
1. Sturm V, Lenartz D, Koulousakis A, 
et al. The nucleus accumbens: a 
target for deep brain stimulation in 
obsessive-compulsive- and anxiety-
disorders. J Chem Neuroanat 2003 
Dec;26(4):293-9.  
DOI: http://dx.doi.org/10.1016/j.
jchemneu.2003.09.003 
Figure 1. Diffusion tensor image demonstrating connections between prefrontal cortex 
regions and the ventral portion of the anterior limb of the internal capsule (ALIC) and 
the adjacent ventral capsule ventral striatum (VC/VS). Yellow box in upper left corner is 
a 3x3mm voxel seed point. Tractography was set at threshold of 0.15 and minimal fiber 
length of 15mm. Intense orbitofrontal connections are se n. Other fibe  pathways include 
dorsolateral prefrontal cortex, supplementary motor, sensorimotor, uncinate fasciculus, 
inferior occipitofrontal fasciculus, thalamus, and various dorsal mesencephalic pathways. 
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64% response rate and can lead to major 
complications including altered frontal 
lobe functioning (disinhibition and abulia) 
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outcomes reflected an impressive long-term 
response in an otherwise intractable disease 
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nature of the intervention and the historic 
misapplication of other ablative psychiatric 
surgeries limited the adoption of stereotactic 
radiosurgery for psychiatric indications. 
Psychiatric surgery, however, has taken 
on new vigor with the introduction of 
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DBS has evolved and gained in popularity 
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of Parkinson disease, essential tremor, and 
dystonia.15,16 Both the efficacy and complica-
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Historic Review  
of Psychiatric Surgery
Surgical interventions for the treatment 
of psychiatric illness began in 1932, when 
Antonio Egas Moniz observed that an ex-
tensive bilateral frontal lobe lesioning in a 
monkey produced a tame, calm animal.1 
He then extended this result to humans 
in 1936 and developed the first somatic 
therapy of the modern era for psychiatric 
conditions—the frontal lobotomy. He 
was corecipient of the 1949 Nobel Prize 
for this work. James Papez formulated 
the so-called Papez Circuit at about the 
same time based on his work involving 
feline rabies infections. The Papez Circuit 
defined a core circuit of neuroanatomical 
connections that were thought to underlie 
emotional behaviors.2 Many of these struc-
tures have been studied since those times, 
in vast detail, and found to be excellent 
targets for surgical therapy.
From the beginning, psychiatric surgery 
has been exalted and celebrated but also 
mired in ethical, moral, and scientific 
controversy. These swings reflect not only 
the complex social currents of the time but 
also the evolving scientific milieu and the 
personalities of the prominent advocates 
of psychiatric surgery. In Moniz’s time, 
the bilateral frontal lobotomy promised 
“salvation” and stood in contrast to bleak 
alternatives, which included lifetime 
institutionalization under inhumane 
conditions. Less attention, therefore, was 
focused on the obvious adverse sequelae 
of loss of frontal initiative and personal-
ity changes caused by these nonspecific 
ablative procedures. These procedures 
reached their pinnacle with Freeman’s 
cavalier application of orbital frontal 
leucotomies in the mid-1960s.3 The emer-
gence of successful pharmacologic agents 
for the treatment of psychiatric illnesses 
was the final force driving orbital frontal 
leucotomies from favor.
A subsequent somatic therapy, electro-
convulsive therapy, did little to increase 
enthusiasm for nonpharmacologic somatic 
therapies.4 Despite the loss of interest in 
ablative surgical interventions for psychi-
atric diseases, centers in Europe and in 
the US continued to refine indications, 
techniques, and targets for psychosur-
gery. Ultimately, these centers helped 
define criteria for surgical intervention 
and localize targets of ablation. The Mas-
sachusetts General Hospital group refined 
cingulotomy for refractory obsessive-
compulsive disorder (OCD), and a group 
at the Catholic University of Leuven in 
Belgium refined capsulotomy for the same 
indications.5,6 Remarkably, both groups 
independently defined similar indications 
for surgery. They both discovered that the 
interventions improved OCD. Appropriate 
surgical candidates were defined as those 
who had failed all somatic therapies, 
inclusive of multiple trials of pharmaco-
logic agents and appropriate behavioral 
therapies. 
The use of these approaches, particu-
larly in the US, was hampered by a vigor-
ous debate about the potential misuse of 
psychiatric somatic therapies as an instru-
ment of social control, based on fears of 
mind control by the government amidst 
the prevailing social climate. These fears 
were reinforced with the publishing of 
Ervin and Marks’ Violence and the Brain,7 
which proposed the use of these therapies 
for control of what was then perceived as 
sociopathic behaviors arising from aber-
rant neural processes.8-10 These concerns 
led to the State of California adopting 
legislation to regulate somatic therapies 
for psychiatric diagnosis, inclusive of 
psychiatric surgery.11
As technology evolved, stereotactic 
radiosurgery, an incisionless technique, 
first came into significant use in the 1970s 
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Abstract
Deep brain stimulation is a rapidly expanding therapy initially designed for the treatment 
of movement disorders and pain syndromes. The therapy includes implantation of electrodes 
in specific targets of the brain, delivering programmable small and safe electric impulses, 
like a pacemaker, that modulates both local and broad neurologic networks. The effects are 
thought to primarily involve a focus in the brain, probably inhibitory, which then restores 
a network of neural circuitry. Psychiatric diseases can be refractory and severe, leading to 
high medical costs, significant morbidity, and even death. Whereas surgery for psychiatric 
disease used to include destructive procedures, deep brain stimulation allows safe, revers-
ible, and adjustable treatment that can be tailored for each patient. Deep brain stimulation 
offers new hope for these unfortunate patients, and the preliminary results are promising.
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population, it is one of the most common 
anxiety disorders.23 In 50.6% of these pa-
tients, OCD is classified as severe.24 OCD 
can be extremely disabling because of 
the time the affected individual spends 
performing compulsive behaviors and the 
mental energy required to distract oneself 
from obsessive thoughts. In a 2000 World 
Health Organization mental health report,25 
OCD was estimated to be the 11th leading 
cause of nonfatal burden in the world, 
accounting for 2.5% of total global years 
lost to disability. Moreover, many other 
research reports cite OCD as the fourth-
most common mental illness, after phobias, 
substance abuse, and major depression. 
Conventional treatments for OCD are 
well established.26 Cognitive-behavioral 
therapy, including exposure and ritual 
prevention, and medications, particularly 
serotonin reuptake inhibitors, are first-line 
treatments. In a naturalistic clinical study, 
over one-third of participants receiving 
recommended doses of serotonin reup-
take inhibitors did not perceive substantial 
long-term benefit from pharmacothera-
py.27 Treatment of OCD rarely results in 
complete remission.
OCD exacts a huge toll on patients and 
is a heavy economic burden. Between 
10% and 27% of OCD patients attempt 
suicide at least once in their lifetime.28 
Total annual cost of OCD was estimated 
to be $8.4 billion, constituting 5.7% of the 
total mental health care cost in 1990. This 
includes both direct and indirect costs. 
Direct costs are for outpatient services 
by physicians and other professionals, 
hospital care, supported housing and 
administrative costs, and private health 
insurance. These accumulate to $2.1 
billion. Indirect costs, reflecting lost 
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Historic Review  
of Psychiatric Surgery
Surgical interventions for the treatment 
of psychiatric illness began in 1932, when 
Antonio Egas Moniz observed that an ex-
tensive bilateral frontal lobe lesioning in a 
monkey produced a tame, calm animal.1 
He then extended this result to humans 
in 1936 and developed the first somatic 
therapy of the modern era for psychiatric 
conditions—the frontal lobotomy. He 
was corecipient of the 1949 Nobel Prize 
for this work. James Papez formulated 
the so-called Papez Circuit at about the 
same time based on his work involving 
feline rabies infections. The Papez Circuit 
defined a core circuit of neuroanatomical 
connections that were thought to underlie 
emotional behaviors.2 Many of these struc-
tures have been studied since those times, 
in vast detail, and found to be excellent 
targets for surgical therapy.
From the beginning, psychiatric surgery 
has been exalted and celebrated but also 
mired in ethical, moral, and scientific 
controversy. These swings reflect not only 
the complex social currents of the time but 
also the evolving scientific milieu and the 
personalities of the prominent advocates 
of psychiatric surgery. In Moniz’s time, 
the bilateral frontal lobotomy promised 
“salvation” and stood in contrast to bleak 
alternatives, which included lifetime 
institutionalization under inhumane 
conditions. Less attention, therefore, was 
focused on the obvious adverse sequelae 
of loss of frontal initiative and personal-
ity changes caused by these nonspecific 
ablative procedures. These procedures 
reached their pinnacle with Freeman’s 
cavalier application of orbital frontal 
leucotomies in the mid-1960s.3 The emer-
gence of successful pharmacologic agents 
for the treatment of psychiatric illnesses 
was the final force driving orbital frontal 
leucotomies from favor.
A subsequent somatic therapy, electro-
convulsive therapy, did little to increase 
enthusiasm for nonpharmacologic somatic 
therapies.4 Despite the loss of interest in 
ablative surgical interventions for psychi-
atric diseases, centers in Europe and in 
the US continued to refine indications, 
techniques, and targets for psychosur-
gery. Ultimately, these centers helped 
define criteria for surgical intervention 
and localize targets of ablation. The Mas-
sachusetts General Hospital group refined 
cingulotomy for refractory obsessive-
compulsive disorder (OCD), and a group 
at the Catholic University of Leuven in 
Belgium refined capsulotomy for the same 
indications.5,6 Remarkably, both groups 
independently defined similar indications 
for surgery. They both discovered that the 
interventions improved OCD. Appropriate 
surgical candidates were defined as those 
who had failed all somatic therapies, 
inclusive of multiple trials of pharmaco-
logic agents and appropriate behavioral 
therapies. 
The use of these approaches, particu-
larly in the US, was hampered by a vigor-
ous debate about the potential misuse of 
psychiatric somatic therapies as an instru-
ment of social control, based on fears of 
mind control by the government amidst 
the prevailing social climate. These fears 
were reinforced with the publishing of 
Ervin and Marks’ Violence and the Brain,7 
which proposed the use of these therapies 
for control of what was then perceived as 
sociopathic behaviors arising from aber-
rant neural processes.8-10 These concerns 
led to the State of California adopting 
legislation to regulate somatic therapies 
for psychiatric diagnosis, inclusive of 
psychiatric surgery.11
As technology evolved, stereotactic 
radiosurgery, an incisionless technique, 
first came into significant use in the 1970s 
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Abstract
Deep brain stimulation is a rapidly expanding therapy initially designed for the treatment 
of movement disorders and pain syndromes. The therapy includes implantation of electrodes 
in specific targets of the brain, delivering programmable small and safe electric impulses, 
like a pacemaker, that modulates both local and broad neurologic networks. The effects are 
thought to primarily involve a focus in the brain, probably inhibitory, which then restores 
a network of neural circuitry. Psychiatric diseases can be refractory and severe, leading to 
high medical costs, significant morbidity, and even death. Whereas surgery for psychiatric 
disease used to include destructive procedures, deep brain stimulation allows safe, revers-
ible, and adjustable treatment that can be tailored for each patient. Deep brain stimulation 
offers new hope for these unfortunate patients, and the preliminary results are promising.
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number of patients to 20 (all with MDD ex-
cept 1 with BD) and the time beyond 3 years
(58, 72). These studies demonstrated that
mood improvement persisted. Response
rateswere 60%at 3 years andmore thanone
third of these patients were in clinical re-
mission at both 3 years and the last follow-
up. Other improvements in mental and
physical health aswell as social functioning
were also maintained. However, there were
significant adverse events, including six
hospitalizations for worsening depression
and suicidal ideation, two completed sui-
cides (these two patients experienced four
of the six psychiatric hospitalizations), six
hospitalizations that were nonpsychiatric
and likely unrelated to DBS (e.g., pancreati-
tis, colon cancer, knee replacement, hemo-
lytic-uremic syndrome, allergic drug reac-
tion), eight battery replacement surgeries,
and four wound infections (three from the
initial group of eight). More recently, this
group reported on a multicenter study
where 21 patients received subgenual ACC
DBS with slightly lower efficacy (response
rate of 29% at 1 year that increased to 40%
with response criteria of 40% improve-
ment) (71). Adverse eventswere also similar
with one completed suicide, one suicide at-
tempt, andone surgical hardwaremodifica-
tion. Another study of this site included 17
patients, 10 with MDD and 7 with BD (48).
This study included single-blind sham
lead-in and discontinuation phases. Poor
response following interruption of treat-
ment in all of the first three patients who
were discontinued led to elimination of the
discontinuation phase for ethical reasons.
No significant differences were reported
between patients with MDD and those with
BD, and as a whole decreases in HDRS of
43.6%, 43.0%, and 70.1% were reported 24
weeks, 1 year, and 2 years after initiating
treatment and remission (HDRS !8) rates
were 18%, 36%, and 58% at these times.
Spontaneous relapses, hypomania, mania,
and intraoperative hemorrhages were not
reported, though 22 AEs and 12 SAEs were
noted that were unrelated to active stimula-
tion. These included 1 patient who became
infected bilaterally, leading to explantation,
anxiety in 2 patients, worsening depression
in 1, suicidal ideation in 1, and 1 suicide
attempt in each of 2 others. These data sup-
port the efficacy and long-term safety of
SCC DBS in patients with MDD and BD.
Based on mood improvements in pa-
tients treated with ventral capsule/ventral
striatum DBS for OCD, Malone et al. inves-
tigated this target for patients with primary
affective disorder (77). Fifteen patients (14
with MDD and 1 with BD) received ventral
capsule/ventral striatum DBS; response
rates were 40% at 6 months and 53% at last
follow-up. Significant remission was also
reported, 20% at 6 months and 40% at last
follow-up. Twenty-five significant adverse
events were reported in this study, includ-
ing 1 lead fracture, hypomania in the patient
withBD thatwasmanagedwith stimulation
and medication adjustment, 2 syncopal ep-
isodes in one patient, as well as increased
depression/suicidal ideation, insomnia,
and hypomania. No single adverse event
was reported in more than 2 patients.
Figure 12. Brodmann area 25 circuitry. Schematic diagram and the main
(A) afferent and (B) efferent from and to Brodmann area 25. Acb,
nucleus accumbens; ACC, anterior cingulate cortex; amygdala (AB,
accessory basal nucleus; Bl, basolateral nucleus; Co, cortical nucleus; I,
intercalated nucleus; L, lateral nucleus; Me, medial nucleus); BST, bed
nucleus of the stria terminalis; Cd, caudate nucleus; CnF, cuneiform
nucleus; DB, diagonal band of Broca; EC, entorhinal cortex;
hypothalamus (DH, dorsal hypothalamus; DMH, dorsomedial
hypothalamus; LH, lateral hypothalamus; PH, posterior hypothalamus;
Mpre, medial preoptic area; TM, tuberomammillary nucleus; VMH,
ventromedial hypothalamus); Ia, agranular insular cortex; LC, locus
coeruleus; LS, lateral septal nucleus; OFC, orbitofrontal cortex; PAG,
periaqueductal gray; PB, parabrachial nucleus; PHC, parahippocampal
cortex; PPN, pedunculopontine nucleus; SI, substantia innominata; TP,
temporal pole; thalamus (AM, anteromedial nucleus; MD, mediodorsal
nucleus; MDpc, parvicellular portion of the mediodorsal nucleus; PT,
parataenial nucleus; Re, nucleus reuniens; CL, central lateral nucleus;
lim, nucleus limitans; PF, parafascicular nucleus; PV, paraventricular
nucleus); VTA, ventral tegmental area. (Reproduced with permission
from Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM:
The subcallosal cingulate gyrus in the context of major depression. Biol
Psychiatry 69:301-308, 2011.)
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significant adverse events, including six
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hospitalizations that were nonpsychiatric
and likely unrelated to DBS (e.g., pancreati-
tis, colon cancer, knee replacement, hemo-
lytic-uremic syndrome, allergic drug reac-
tion), eight battery replacement surgeries,
and four wound infections (three from the
initial group of eight). More recently, this
group reported on a multicenter study
where 21 patients received subgenual ACC
DBS with slightly lower efficacy (response
rate of 29% at 1 year that increased to 40%
with response criteria of 40% improve-
ment) (71). Adverse eventswere also similar
with one completed suicide, one suicide at-
tempt, andone surgical hardwaremodifica-
tion. Another study of this site included 17
patients, 10 with MDD and 7 with BD (48).
This study included single-blind sham
lead-in and discontinuation phases. Poor
response following interruption of treat-
ment in all of the first three patients who
were discontinued led to elimination of the
discontinuation phase for ethical reasons.
No significant differences were reported
between patients with MDD and those with
BD, and as a whole decreases in HDRS of
43.6%, 43.0%, and 70.1% were reported 24
weeks, 1 year, and 2 years after initiating
treatment and remission (HDRS !8) rates
were 18%, 36%, and 58% at these times.
Spontaneous relapses, hypomania, mania,
and intraoperative hemorrhages were not
reported, though 22 AEs and 12 SAEs were
noted that were unrelated to active stimula-
tion. These included 1 patient who became
infected bilaterally, leading to explantation,
anxiety in 2 patients, worsening depression
in 1, suicidal ideation in 1, and 1 suicide
attempt in each of 2 others. These data sup-
port the efficacy and long-term safety of
SCC DBS in patients with MDD and BD.
Based on mood improvements in pa-
tients treated with ventral capsule/ventral
striatum DBS for OCD, Malone et al. inves-
tigated this target for patients with primary
affective disorder (77). Fifteen patients (14
with MDD and 1 with BD) received ventral
capsule/ventral striatum DBS; response
rates were 40% at 6 months and 53% at last
follow-up. Significant remission was also
reported, 20% at 6 months and 40% at last
follow-up. Twenty-five significant adverse
events were reported in this study, includ-
ing 1 lead fracture, hypomania in the patient
withBD thatwasmanagedwith stimulation
and medication adjustment, 2 syncopal ep-
isodes in one patient, as well as increased
depression/suicidal ideation, insomnia,
and hypomania. No single adverse event
was reported in more than 2 patients.
Figure 12. Brodmann area 25 circuitry. Schematic diagram and the main
(A) afferent and (B) efferent from and to Brodmann area 25. Acb,
nucleus accumbens; ACC, anterior cingulate cortex; amygdala (AB,
accessory basal nucleus; Bl, basolateral nucleus; Co, cortical nucleus; I,
intercalated nucleus; L, lateral nucleus; Me, medial nucleus); BST, bed
nucleus of the stria terminalis; Cd, caudate nucleus; CnF, cuneiform
nucleus; DB, diagonal band of Broca; EC, entorhinal cortex;
hypothalamus (DH, dorsal hypothalamus; DMH, dorsomedial
hypothalamus; LH, lateral hypothalamus; PH, posterior hypothalamus;
Mpre, medial preoptic area; TM, tuberomammillary nucleus; VMH,
ventromedial hypothalamus); Ia, agranular insular cortex; LC, locus
coeruleus; LS, lateral septal nucleus; OFC, orbitofrontal cortex; PAG,
periaqueductal gray; PB, parabrachial nucleus; PHC, parahippocampal
cortex; PPN, pedunculopontine nucleus; SI, subst ntia innominata; TP,
temporal pole; thalamus (AM, anteromedial nucleus; MD, mediodorsal
nucleus; MDpc, parvicellular portion of the mediodorsal nucleus; PT,
parataenial nucleus; Re, nucleus reuniens; CL, central lateral nucleus;
lim, nucleus limitans; PF, parafascicular nucleus; PV, paraventricular
nucleus); VTA, ventral tegmental area. (Reproduced with permission
from Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM:
The subcallosal cingulate gyrus in the context of major depression. Biol
Psychiatry 69:301-308, 2011.)
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Other studies have investigated the NAc,
a somewhat overlapping third target for de-
pression. In the initial report, three patients
entered a double-bli ded trial a d wer
stimulated with leads placed in the NAc
shell region, core region, ventral internal
capsule, and medial internal capsule (103).
These patients’ depressive symptoms, as-
sessed by HDRS, decreased significantly
within 1 week of stimulation and returned
after stimulation was discontinued for
1 week. Although the patients’ depressive
symptoms did not respond immediately,
the patients showed almost immediate
(within 60 seconds) changes in motivation
and interest when stimulation was initially
activated. In this study, no adverse events
were reported. The same group later re-
ported on 10 patients with bilaterally im-
plantedDBS electrodes in theNAc (12). The
adverse events most reported in these pa-
tients were parameter-related erythema
(n ! 4), anxiety (n ! 3), sweating (n ! 3),
surgery-related dysphagia (n ! 3), eye
swelling (n! 6), and pain (n! 3). Adverse
events deemed unrelated to DBS included
gastritis (n ! 4) and leg fracture (n ! 2).
During the follow-up period, one patient
completed suicide and one made a suicide
attempt. Notably, both of these patients
were noncompliant with either medication
or stimulation adjustment around the time
of their attempts. This study demonstrated
significant efficacy, with stable decreases in
HDRS scores, 50% of patients meeting re-
sponse criterion by stud endpoi t, and
three patients achieving remission for a
1-month period.
Additional targets have been considered
but have not been studied in blinded trials.
These include the lateral habenula; one pa-
tient remitted with stimulation and relapsed
repeatedly when stimulation was discontin-
ued with consistent resumption of response
on restimulation (100). The inferior thalamic
peduncle has also shown promise as a target
in a single published case report (51). In addi-
tion to reporting symptomatic response, this
study found that depending on which con-
tacts were activated, stimulation could either
induce or relieve anxiety.
CONCLUSIONS AND FUTURE PROSPECTS
Wepresently faceachall nge toreconcilecur-
rent systemic views of psychiatric disorder
pathophysiology with the efficacy of anatom-
ically localized treatments. These localized
treatments may act to interrupt the circuit to
reduce symptoms. Furthermore, understand-
ing of broader implications of these localized
treatments continues to grow, suggesting ef-
fects at a distance that may also contribute to
efficacy. For example, although initially
DBSwas thought toact similarly to functional
ablation, further evidence suggests that DBS
also acts by antidromic activation, and that
responses depend on both GABAergic and
glutamatergic transmission (79).
Also, we are challenged by the lack of
specificity in our diagnoses. For example,
diagnosis of MDD requires five of nine cri-
teria to be present in a 2-week period (Ta-
ble 1) (4). Clearly there are many possible
permutations that can i clude five of nine
possible symptoms. Though each permuta-
tion is not likely biologically different, it is
likely that there are several subtypes with
different presentations and etiologies. This
suggests that different targets may be ap-
propriate to optimally treat different dis-
ease subtypes.
The complexity of function and dysfunc-
tion also suggests that emotion and behav-
ior are not localized to discrete centers,
but rely on communication between multi-
ple neuronal circuits. As neurosurgical ap-
proaches to psychiatric illness become
more refined, procedures and electrical
fields directly affect progressivelymore lim-
ited amounts of tissue. This incongruity is
the paradox of psychiatric surgery; how can
precisely localized stimulation modify a
disorder that is based on widespread cir-
cuitry changes? It appears likely that local
stimulation propagates up- or downstream
throughout the circuit, resulting in signal
amplification. Alternatively, the incomplete
efficacy of current treatmentsmay relate not
only to diagnostic imprecision, but also due
to the spatially restricted effects of focal
treatments on larger circuits. It is conceiv-
able that multiple stereotactic targets and
combinations of neuromodulatory strate-
giesmay be required to optimally tune these
circuits. To better understand the implica-
tions of multiple parameters, larger studies
are needed to specifically target individual
parameters. Also, investigation of closed
loop systems may provide enhanced effi-
cacybyproviding stimulationwhenneeded,
rather than chronically. Responsive neuro-
stimulation systems have been studied and
the available data suggests efficacy in treat-
ing epilepsy (84). Similar systems are in de-
velopment for psychiatric indications, and
are being particularly considered for
Tourette, where activity at the time of urge is
likely to play an important role (74, 92).
Scheduled stimulation devices or even simply
having patients turn off stimulation at night
can provide advantages in extending battery
life or improving insomnia, and intermittent
stimulationmayalso limit tachyphylaxis.This
approach has been attempted in patients re-
ceivingDBS for OCD (36).
Understanding of psychiatric illness
grew immensely during the twentieth cen-
tury, and this increased understanding en-
abled the development of our current treat-
ments from more crude approaches. Still,
even when contemporary therapeutic
guidelines are followed, many patients re-
main severely impaired by illness that fails
to respond to conventional treatments in-
cluding medication and psychotherapy.
Figure 13. DBS electrode in Brodmann area 25. Postoperative magnetic resonance image (MRI). T2-
weighted (A) sagittal and (B) coronal MRI images of a deep-brain stimulation electrode in Brodmann
area 25. (Reproduced with permission from Mayberg H, Lozano AM, Voon V, McNeely HE,
Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant
depression. Neuron 45:651-660, 2005.)
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Disrup+ve	  developments	  in	  Medicine	  
Pa+entsLikeMe	  
PrevenQon	  eﬀorts,	  genomics-­‐guided	   More	  direct	  acQon	  on	  the	  brain	  itself	  
Figure 1 Sagittal and transverse computed tomography (CT) images of the brain and skull ofMA.We
show here sagittal and transverse sections taken from CT scans. Imaging was performed before (A) and
after (B) MA received deep brain stimulation surgery for his treatment refractory OCD. Two deep brain
stimulator probes can be seen to be in place from a bifrontal approach (B), with tips of the probes located
in the region of the hypothalamus. Leads traverse through the left scalp soft tissues. Streak artifact from
the leads somewhat obscures visualization of the adjacent bifrontal and left parietal parenchyma. We did
not observe any intracranial hemorrhage, mass eVect or midline shift or extra-axial fluid collection. Brain
parenchyma was normal in volume and contour.
DBS implant has contributed to any of these issues. Attempts to add fluoxetine at 80 mg
by mouth daily for two months to augment any eYcacy from the DBS and ERP were
unsuccessful, mainly due to no discernible benefit and prominent sexual side eVects. MA
still receives an injection of 37.5 mg risperidone every two weeks for his past history of
O’Rawe et al. (2013), PeerJ, DOI 10.7717/peerj.177 8/26
Complexity	  
•  There	  are	  ~25-­‐100	  TRILLION	  cells	  in	  each	  
human	  body,	  with	  ~6	  billion	  nucleoQdes	  per	  
cell.	  
•  There	  is	  extensive	  modiﬁcaQon	  of	  DNA,	  RNA	  
and	  proteins	  both	  spaQally	  and	  temporally.	  
•  There	  are	  higher	  level	  mechanisms	  of	  somaQc	  
mosaicism,	  heterosis,	  and	  likely	  ancestral	  
inheritance.	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  ediQon	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	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E.	  coli	  adapQng	  to	  low	  glucose	  condiQons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
"Finally,	  novel	  funcQons	  olen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuniQes.	  This	  three-­‐step	  process	  —	  in	  which	  
potenQaQon	  makes	  a	  trait	  possible,	  actualizaQon	  makes	  the	  trait	  manifest,	  and	  
reﬁnement	  makes	  it	  eﬀecQve	  —	  is	  probably	  typical	  of	  many	  new	  funcQons.”	  -­‐	  
Lemski	  
Genomic	  analysis	  of	  a	  key	  innovaQon	  in	  an	  experimental	  Escherichia	  coli	  populaQon.	  
Blount	  ZD,	  Barrick	  JE,	  Davidson	  CJ,	  Lenski	  RE.	  
Nature.	  2012	  Sep	  19.	  doi:	  10.1038/nature11514	  
	  
Waddington	  claimed	  that	  canals	  form	  in	  the	  landscape	  during	  
evolu+on,	  and	  that	  this	  is	  useful	  for	  understanding	  the	  unique	  
quali+es	  of	  biological	  robustness.	  
The	  canalisaQon	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturbaQons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  liPle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturbaQons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  liPle	  robustness	  beyond,	  is	  a	  paPern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctuaQng	  environment.	  

Down	  Syndrome	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
Genotype	  ≠	  Phenotype	  
Environment	  maPers!	  
Ancestry	  maPers!	  
Genomic	  background	  maPers!	  
Longitudinal	  course	  maPers!	  
	  
We	  can	  only	  begin	  to	  really	  understand	  this	  if	  we	  uQlize	  
the	  power	  of	  intense	  networking	  via	  internet-­‐enabled	  
archiving	  and	  distribuQon	  of	  data.	  
Take	  Home	  Message	  
Source:	  hcp://www.thenakedscien+sts.com/HTML/features/ar+cle/jamilcolumn1.htm/	  
Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
prePy	  much	  ALL	  mutaQons	  in	  humans,	  as	  we	  
have	  not	  systemaQcally	  sequenced	  or	  
karyotyped	  any	  geneQc	  alteraQon	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people,	  nor	  categorized	  into	  ethnic	  classes,	  
i.e.	  clans.	  



